SCI PHARMTECH, INC.

2022-2023 Sustainability Report

SCI PHARMTECH, INC.
旭富製藥科技股份有限公司

Contents

About the Report

Reporting Scope and Boundaries

Welcome to the Sustainability Report issued by SCI Pharmtech Inc. (hereafter referred to as SCI Pharmtech or SCI and Principles), the information and data disclosed in this report cover the period from January 1, 2022 to December 31, 2023. In terms of reporting boundary, the economic performance data is presented as the consolidated financial report, other social and economic aspects are based on information from all operation branches in Taiwan excluding the subsidiary Yushan Pharmaceuticals Incorporated.

Reporting Guidelines

This Sustainability Report has been prepared in alignment with the "Regulations Governing the Preparation and Filing of Sustainability Reports by Listed Companies." The report's structure adheres to the GRI Universal Standards 2021, issued by the Global Reporting Initiative (GRI). Further, it incorporates relevant disclosures guided by the Sustainability Accounting Standards Board (SASB) Chemical Industry Standards and the Task Force on Climate-related Financial Disclosures (TCFD) recommendations.

Report Quality Management

Compilation: The President's Office is responsible for overall planning of this report, while the data, strategic objectives, and performance indicators disclosed in the report are provided by the responsible business units, which are then integrated, compiled, proofread and revised by the President's Office.

Review: The completed report is reconfirmed by each department for completeness and correctness of its contents, and it is signed off by the top supervisor of the relevant department for approval.

Finalization: The complete manuscript is submitted to the President for review and finalization before public distribution.

External Verifications and Certifications

The financial data of SCI Pharmtech is compiled in consolidated financial reports verified by KPMG in accordance with International Financial Reporting Standards (IFRS), and are calculated in New Taiwan Dollars. In addition, the company has acquired ISO 9001: 2015 Quality Management System, ISO 14001: 2015 Environmental Management System, ISO 45001: 2018 Occupational Safety and Health Management System third-party certifications.

Publication Frequence

This is the 5th Sustainability Report (formerly known as the Corporate Social Responsibility Report) publicly issued by SCI Pharmtech Inc. The report was published in August 2024, with the previous publication date being September 2022. SCI formerly periodically publishes a Sustainability Report every 2 years, starting from 2025,SCI shall adjust to annual publication, with the next report expected to be released in August 2025.

Publication Channels

In an effort to conserve resources, this report is primarily published online (available on the company website). Stakeholders are welcome to view and download the report from the website. In the event of any errors, corrections, or data updates to the report, the electronic version available on the company website shall prevail.

Contact Information

If you have any questions or suggestions about the contents of this report, please feel free to contact us.

SCI Pharmtech, Inc.

Address: No. 61, Ln. 309, Haihu N. Rd., Luzhu District, Taoyuan City 33856, Taiwan

Tel: +886-3-354-3133#118

Fax: +886-3-354-3483

Website: http://www.sci-pharmtech.com.tw

Contact Window: Ms. Nelly Chen, Special Assistant to President

E-mail: nelly.chen@sci-pharmtech.com.tw

MESSAGE FROM THE CHAIRPERSON

In late 2020, SCI Pharmtech experienced an unexpected explosion that challenged our operations and values. However, with unwavering resolve and proactive measures, we not only restored our facilities but also transformed them into a more sustainable environment.

Challenges and Resilience

The 2020 incident was deeply saddening, yet it also ignited our resilience. Over the past three years, SCI Pharmtech has been diligently working to rebuild our facilities. We overcame numerous obstacles and, in 2022, began a phased resumption of operations, carefully balancing ongoing construction with production. Throughout this process, we upheld our commitment to our employees and their families by ensuring job security, even during construction. This demonstrates our steadfastness in the face of adversity. I extend my deepest gratitude to every employee who stood by us during this period. Their dedication has enabled the company to persevere and move forward.

Automation and Expansion

To mitigate risks and enhance competitiveness, SCI Pharmtech has constructed a new plant in the Guanyin Industrial Park, equipped with state-of-the-art automation technology. In addition to reducing labor requirements, this expansion is projected to increase our production capacity by 60% once trial operations commence in 2025, laying a solid foundation for our sustainable growth.

Green Commitment

SCI Pharmtech recognizes the critical importance of environmental protection alongside economic growth. To this end, we have partnered with Veolia Group to establish Framosa Co., Ltd., dedicated to solvent recycling and promoting green processes. This initiative represents a tangible step towards our sustainability goals and will become a key focus area for our future business.

Commitment to Environment, Safety, and Quality

We take pride in the quality of our products. Through the implementation of ISO 9000 and GMP quality management systems, along with Drug Master File (DMF) disclosures, we ensure our products meet the highest standards. Furthermore, our certifications in ISO 14001 and ISO 45001 underscore our dedication to employee well-being and environmental responsibility. By conducting annual internal and external audits, we continuously raise our standards, guaranteeing both safety and sustainability in our operations.

Looking Ahead

While navigating past challenges, SCI Pharmtech has remained steadfast in its commitment to sustainability at every step. We have not only implemented sound management practices during our recovery but have also made significant strides in expansion and innovation. We express our sincere gratitude to our shareholders, partners, employees, and the broader community for their support. Together, we will create a brighter future.

Chairperson
Dr. Wei-Chyun Wong

MESSAGE FROM THE PRESIDENT

The years 2022 and 2023 were a period of both challenges and opportunities for SCI Pharmtech. As the President, I am pleased to share our efforts and achievements during this time.

Overcoming Adversity and Restoring SCI Pharmtech's Glory

First and foremost, we are immensely proud of the successful reconstruction of our Taoyuan plant. The 3 years from 2020 to 2023 were most challenging for SCI Pharmtech, the fire incident dealt us a significant blow, but it also fueled our determination to overcome adversity. During the reconstruction, we have learned from the past and implemented newer processing methods and equipment, enhancing the overall safety and production efficiency of our plant.

With the physical reconstruction of our facilities complete, the Chairperson and I have also made adjustments to our organizational structure. We believe we have built a formidable team, and I share this encouragement with my colleagues:

Those who serve, embrace your tasks with courage, and strive for what is rightfully yours.

Those in power, bow in dedication, and fulfill your noble duty.

Those who lead, transform complexity into clarity, and maintain order even in chaos.

Those who steer, navigate with steady progress, and harmonize with the natural flow.

I look forward to working together with everyone on the management team and all employees to rebuild SCI Pharmtech's glory!

Capacity Expansion and Automation, Driving Economic Growth Amidst Challenges

As we progressively rebuilt and resumed operations in different zones, we swiftly obtained TFDA approval and restarted production. In 2023, sales of our main products gradually recovered. We anticipate further increases in sales volume in the coming year, particularly with the full resumption of production capacity at our Taoyuan plant, which will contribute to increased sales value.

In addition to strengthening operational resilience by diversifying production locations and expanding into the CDMO (Contract Development and Manufacturing Organization) business, we have introduced automated warehousing equipment and are constructing a new plant in the Guanyin Industrial Park. We expect that once the Guanyin plant becomes operational in 2025, it will increase SCI Pharmtech's production capacity by 60%, laying a solid foundation for our sustainable development.

Dual Focus on Environment and Safety, Actively Exploring a Green Development Path

SCI Pharmtech has partnered with Veolia Group to establish Framosa Co., Ltd. (FRAMOSA), leveraging both companies' core technical capabilities to develop a circular economy within the pharmaceutical industry.

Currently, SCI Pharmtech holds multiple international certifications, including ISO 9001, ISO 14001, ISO 45001, and ISO 14067. Through these standards and management systems, we continuously improve our management practices, striving to achieve the highest standards in environmental protection, occupational health, and safety.

Joining Hands for the Future, Creating a New Chapter of Excellence

With the completion of post-disaster recovery, SCI Pharmtech is turning a new page. In addition to focusing on technological innovation and product quality improvement, we will continue to expand our ESG efforts, aiming to become an industry leader. We sincerely thank our shareholders, partners, employees, and the wider community for their support. Your trust and encouragement are our greatest motivation to keep moving forward.

President
Dr. Wen-Chih Chou

ESG Implementation Philosophy

CSR Commitment

SCI Pharmtech was established in 1987, the core values of the company are “Talent”, “Teamwork”, and “Honesty and Integrity”. The company’s business practices are regulated by relevant measures including the integrity management code, ethical code of conduct, and work rules, the company clearly defines rules for rewards and punishments and employee performance evaluation based on these measures. Since its establishment more than 36 year ago, SCI Pharmtech has developed into a professional manufacturer of intermediates and APIs (Active Pharmaceutical Ingredients, APIs), and continues to strive towards the goal of "the highest quality API manufacturing company in the world". We are looking forward to becoming a world-class leader in the specific niche for APIs in the market.

Corporate Vision

For the health of human being, we contribute.

Corporate Values

Sustainability

Credibility

Innovation

ESG Implementation Structure

Sustainability Development Committee

To actively promote corporate sustainability initiatives and implement actions related to energy conservation and carbon reduction, employee care, business development, and social welfare, SCI Pharmtech established the "Corporate Social Responsibility Promotion Committee" in 2013, and in response to regulatory changes, the committee has been renamed the "Sustainability Development Committee." The Sustainability Development Committee is chaired by Chairperson Dr. Wei-Chyun Wong, under the committee, there is an Executive Team responsible for supervising the implementation and effectiveness of various sustainability projects by each team. There are four subcommittee teams: Operation Development, Sustainable Environment, Social Welfare, and Corporate Governance. (The Sustainable Environment Team further includes an Energy Conservation and Carbon Reduction Team.)

SCI Pharmtech Sustainability Development Committee Organizational Chart



Responsibilities of the Sustainability Development Committee Teams

Team	Executive Team	Operation Development Team	Sustainable Environment Team	Energy Conservation and Carbon Reduction Team	Social Welfare Team	Corporate Governance Team
Respon-sibilities	Supervise ESG-related activities of each team and be responsible for data collection, editing and publication of the sustainability report.	Conduct market development, business strategy evaluation, operation performance, and continuous management.	Implement mechanisms for environmental protection, and formulate and carry out improvement plans to prevent violation of environmental laws and regulations	Disclose and manage energy and resource consumption in accordance with policies, promote energy and resource conservation mechanisms and take GHG inventory.	Protect and enhance the rights and benefits of employees, plan community welfare activities relevant to the industry and regularly review results and make improvements.	Promote continuous improvement of the corporate governance mechanism, assist the board of directors in fulfilling its responsibilities, and improve the internal control and risk management system.
Issues of Concern	• Economic Performance • Operation Integrity • Legal Compliance • Innovation and R&D • Information Security • Risk Management, • Environmental Protection • Labor Employer Relations • Customer Health and Safety • Occupational Safety and Health	• Economic Performance • Operation Integrity • Supply Chain Management • Innovation and R&D • Customer Satisfaction • Information Protection • Customer Health and Safety	• Supply Chain Management • Environmental Protection • Wastewater and Waste • Energy Management and GHG Emissions • Environmental Policy and Management System • Green Products		• Labor Relations • Customer Health and Safety • Occupational Safety and Health • Training and Education • Social Engagement	• Economic Performance • Corporate governance • Operation Integrity • Legal Compliance • Risk Management
Stake-holders	Employees, Customers, Suppliers, Stockholders, Government, Community	Employees, Customers, Suppliers, Stockholders	Employees, Customers, Suppliers, Stockholders, Government, Community		Employees, Customers, Suppliers, Community	Employees, Customers, Stockholders, Government

Stakeholder Identification and Materiality Assessment

Stakeholder Identification and Materiality Assessment

SCI Pharmtech believes that businesses should actively pursue sustainable development alongside their core operations. Through responsible corporate citizenship, we aim to contribute to the national economy, enhance the quality of life for our employees, communities, and society as a whole, and foster a competitive advantage rooted in sustainability. We integrate environmental, social, and governance factors into our management policies and operational activities. Our commitment to sustainable development is guided by four key principles: Strengthening Corporate Governance, Promoting a Sustainable Environment, Upholding Social Welfare, Enhancing ESG Disclosure.

Strengthening Corporate Governance

- The SCI Pharmtech Board of Directors should fulfill its duty of care as a good manager to supervise the company's implementation of sustainable development, regularly review its effectiveness, and make continuous improvements to ensure the implementation of sustainable development policies.
- The Board will authorize senior management to address economic, environmental, and social issues arising from business operations. Management will report on these matters to the Board, with clear and specific operational procedures and designated personnel in place.
- The company website will feature a dedicated stakeholder section, facilitating communication and understanding of stakeholder expectations and needs. The Board will ensure that material sustainability topics of concern to stakeholders are appropriately addressed.

Responsibilities of the Board

1. Establish a sustainability mission or vision and formulate sustainability policies, systems, and relevant management guidelines.
2. Integrate sustainability into the company's operations and development strategies, and approve concrete sustainability action plans.
3. Ensure the timely and accurate disclosure of sustainability-related information.

Promoting a Sustainable Environment

- SCI Pharmtech adheres to environmental regulations and international standards, demonstrating a commitment to protecting the natural environment. We have established an environmental management system and strive to improve energy efficiency and reduce environmental impact throughout our operations and internal management.
- SCI Pharmtech has a dedicated environmental management unit responsible for formulating, implementing, and maintaining our environmental management system. We endeavor to minimize adverse effects on human health and the environment by adopting the best available pollution prevention and control measures.
- To assess potential risks and opportunities associated with climate change, we are progressively implementing GHG inventory and energy and resource reduction initiatives. The acquisition of carbon credits is also incorporated into our carbon reduction strategy planning.

Environmental Management Mechanism

1. Gather and evaluate comprehensive and timely information on the environmental impacts of our operations.
2. Establish measurable environmental sustainability goals and regularly review their progress and relevance.
3. Develop and implement concrete action plans and regularly assess their effectiveness.

Upholding Social Welfare

- SCI Pharmtech upholds international human rights conventions and regulations, providing a safe, healthy, and career-enhancing work environment for our employees. We implement fair employee welfare measures and establish effective communication channels.
- SCI Pharmtech takes responsibility for our products and services, emphasizing marketing ethics. We ensure product information transparency and safety and have established customer rights policies to prevent any harm to customers from our products or services.
- We are dedicated to minimizing various impacts on consumers and society, including the environmental and social effects of our procurement practices on supplier communities. We also assess and manage risks that could disrupt our operations.
- We evaluate the impact of our operations on local communities and prioritize hiring local talent to enhance community identity. We actively contribute to community development through business activities, in-kind donations, corporate volunteerism, and other professional services for the public good.

Enhancing ESG Disclosure

- To enhance corporate transparency and comply with relevant regulations, SCI Pharmtech fully discloses sustainability-related information. We continuously monitor the development and changes in domestic and international sustainability standards and review and improve our established sustainability systems to enhance our ESG performance.

Sustainability Development Related Information

1. Sustainability development policies, systems, and related management guidelines, as well as specific implementation plans.
2. Plans, goals, measures, performance, future improvement directions, and targets formulated by the company for ESG aspects of sustainable development.
3. Risks and impacts of ESG-related plans on the company's operations and finances.
4. Stakeholders and their areas of concern.
5. Information on suppliers' management and performance related to environmental and social issues.

Stakeholder Engagement

Our company recognizes the significance of fostering robust relationships with our diverse stakeholders. We adopt tailored communication strategies for different stakeholder groups, including one-way information dissemination, two-way dialogue, one-to-many, and many-to-one engagement approaches, to ensure effective communication. For in-depth information, please refer to the "Stakeholder Concerns and Communication" section. Each department actively engages with stakeholders through day-to-day business interactions, regular surveys, and in-depth interviews. Because the concerns of stakeholders vary based on the nature of their relationship with our business, therefore we utilize a variety of communication channels to gain a comprehensive understanding of their needs and expectations. This valuable input is carefully considered in adjusting our operational management strategies and providing timely and appropriate responses to stakeholder concerns.

Stakeholder Concerns and Communication

Stakeholders	Topics of Concern	Communication Channels and Response Methods	Frequency
Employees	• Legal Compliance • Labor Relations • Salary and Benefits • Occupational Safety and Health • Post-Disaster Recovery	1. Email announcements and bulletin board posts 2. HR services and health consultations 3. Communication through meetings 4. Supervisor/employee opinion mailboxes for communication 5. Complaint (Whistleblowing) process 6. Employee training	Ad-hoc Available anytime 1. HR services provided by the administration department. 2. Health consultations provided by external doctors and in-house medical staff. 3. Annual health checkups. Quarterly labor-management meetings and occupational safety and health committee meetings. Available anytime Available anytime 1. Semi-annual fire safety training for all employees. 2. Departmental professional training held periodically. In 2022, internal training totaled 18,223 participants, with 30 external participants; the same for 2023.
Customers	• Green Products • Customer Health and Safety • Customer Privacy • Post-Disaster Recovery	1. Customer satisfaction surveys 2. Production and sales meetings 3. Customer audits 4. Responding to customer concerns via email 5. Participation in exhibitions	Customer satisfaction surveys conducted annually. In both 2022 and 2023, the average satisfaction score was 4.6 out of 5. Held weekly (after the 2021 fire incident, these meetings were integrated into supervisor meetings). Conducted on an ad-hoc basis. In 2022-2023, 17 online customer audits were completed with no major deficiencies. Available anytime 1. CPHI in Shanghai and Europe 2. DCAT in the United States
Suppliers	• Supply Chain Management • Occupational Safety and Health • Legal Compliance • Post-Disaster Recovery	1. Contact via phone and email 2. Questionnaires 3. On-site audits	Ad-hoc Supplier questionnaires conducted periodically. Performed annually, from 2022 to 2023, the Quality Assurance Department audited five suppliers.

Stakeholder Identification and Materiality Assessment

Stakeholders	Topics of Concern	Communication Channels and Response Methods	Frequency
 Shareholders/ Investors	• Post-Disaster Recovery • Integrity Management • Economic Performance • Industry Development	1. Shareholders' meeting 2. Participation in investor conferences 3. Responding to investor inquiries via phone and email 4. Uploading financial reports to the public information platform and company website quarterly. 5. Dissemination of material information via the Market Observation Post System and company website	Annual general shareholders' meetings Four conferences organized by securities firms in 2022-2023. Ad-hoc responses to investor inquiries via phone, email, and website Post-disaster recovery updates are posted weekly on the official website until September 2023. Uploading financial reports to the public information platform and company website quarterly. Material Information was proactively disclosed on an ad-hoc basis via the Market Observation Post System and the company website, with a total of 32 material announcements released between 2022 and 2023.
 Society	• Post-Disaster Recovery • Wastewater and Waste Management • Energy Management and GHG Emissions • Social Participation	1. Participate in the Haihu Kengkou Industrial Zone Manufacturers' Association 2. Engage in community activities 3. Sponsor public welfare activities 4. Sponsor various educational activities organized by non-profit organizations 5. Donate to non-profit organizations or institutions	The Haihu Kengkou Industrial Zone Manufacturers' Association holds an annual general meeting, which SCI Pharmtech attends on an ad-hoc basis. • Irregularly participate in community activities, sponsor temple rituals and donate to temple funds. • Cooperate with the national army in military exercises by providing venues. • Conduct joint fire drills with the Shanjiao Fire Squad. • Communicate and coordinate with the community through notaries and spokespersons on an ad-hoc basis. • Hold ad-hoc compensation coordination meetings with local residents. Make ad-hoc donations to public welfare activities. Joined the Republic of China Criminal Investigation and Prevention Association to support the development of public welfare undertakings in the police force. Make ad-hoc donations to non-profit organizations. Donated NT$150,000 to the Chang Chao-Ting Memorial Foundation to support research and publications in science, culture, and talent development. Ad-hoc sponsorship. Sponsored the Bio Asia Taiwan exhibition with NT$30,000 to showcase the achievements of Taiwan's biotechnology industry and attract global biotechnology energy and talent to converge in Taiwan.
 Government/ Regulatory Agencies	• Legal Compliance • Integrity Management • Energy Management and Greenhouse Gas Emissions • Customer Health and Safety • Wastewater and Waste Management • Post-Disaster Recovery	1. Official announcements and correspondence from regulatory authorities 2. Regulatory briefings or seminars held by regulatory authorities 3. Communication with regulatory authorities through phone calls, letters, emails, and visits	Responds to official announcements and correspondence from regulatory authorities on an ongoing basis. Participated in regulatory briefings or seminars held by regulatory authorities as needed, with a total of 39 attendees in 2022-2023. Maintains open communication with regulatory authorities through various channels, including phone calls, letters, emails, and visits.

Materiality Assessment and Disclosure

In terms of impact management of material topics, the Board of Directors serves as the highest governing body, bearing the responsibility of supervision and decision-making. SCI Pharmtech has additionally established a Risk Management Committee and an Audit Committee to prevent and improve potential or actual risks. The President's Office, referencing international ESG trends, GRI standards, SASB chemical industry standards, international rating agencies' rating requirements, and the Financial Supervisory Commission's requirements for listed companies' corporate governance evaluations, selected a total of 14 possible topics and conducted impact assessments and rankings for these topics. To address the significant changes in the company's operations caused by the fire incident, interviews were conducted in 2022 with various department heads and external experts and scholars. Together, they assessed the level of concern for stakeholder issues. Continuing from the previous reporting period's stakeholder concerns and impact levels, a cross-analysis was performed to create SCI Pharmtech materiality matrix for 2022 to 2023.

Material Topic Positive/Negative Impact Assessment Results



Material Topics and Their Impact Scope and Involvement

●Direct Impact ○Contributory Impact ▲Commercial Impact

Material Topics	Importance to SCI Pharmtech	GRI Standards	Stakeholder					
			Em-ployee	Cus-tom-er	Sup-plier	Stake-holder/ Inves-tor	Community/ Non-profit Or-ganization	Gov-ern-ment
Disaster Recovery	After the major fire incident at the end of 2020, which resulted in casualties, production line shutdown, and affected upstream and downstream supply chains and surrounding communities, severely impacting the company's operations, we are now fully committed to post-disaster recovery, hoping to resume normal operations as soon as possible and protect the rights and interests of all stakeholders.	Self-defined	●	●	▲	●	●	○
Occu-pational Safety and Health	The pharmaceutical industry is a crucial, cross-disciplinary, and highly inte-grated science, involving hazardous raw materials and processes in chemis-try and engineering. To protect employees' safety and rights, and maintain normal operations, SCI Pharmtech will continue to strengthen occupational safety management.	GRI 403-9 Work-related injuries	●		○	○	○	○
Economic Perfor-mance	Economic performance is the driving force of corporate growth. In 2020, SCI Pharmtech's consolidated operating revenue reached NT$2.689 billion, the highest in history. However, a major disaster occurred at the end of the year, resulting in almost complete shutdown in 2021. By renting factories and equipment from peers, we were able to fulfill orders and maintain short-term operations.	GRI 201-1 Direct eco-nomic value generated and distributed	●	▲	○	●		○
Customer Health and Safety	'Contributing to human health' is SCI Pharmtech's vision and the core value of the pharmaceutical industry. Therefore, we have implemented the ISO 9001 quality management system, adhered to GDP and GMP management regulations, and passed multiple international inspections to ensure the health and safety of end consumers.	Self-defined	○	●	●		○	○

/ Material Topics and Their Impact Scope and Involvement

●Direct Impact ○Contributory Impact ▲Commercial Impact

Material Topics	Importance to SCI Pharmtech	GRI Standards	Stakeholder					
			Employee	Customer	Supplier	Stakeholder/ Investor	Community/ Non-profit Organization	Government
Wastewater and Waste Management	Pharmaceutical wastewater often contains residual antibiotics and organic solvents, and has a high concentration of suspended solids, making it difficult to treat. To reduce environmental impact, SCI Pharmtech and French company Veolia Group formed a joint venture, Framosa, to facilitate the recycling of solvents used in drug and raw material production, setting an example for circular economy practices.	GRI 303-3 Water withdrawal GRI 306-3 Waste generated GRI 306-4 Waste diverted from disposal GRI 306-5 Waste directed to disposa	○				●	○
Energy Management and GHG Emissions	The impact of climate change and extreme weather events is becoming increasingly significant. To mitigate the environmental and operational consequences, SCI Pharmtech utilizes clean energy equipment, continuously promotes environmental awareness among employees, strives to comply with environmental regulations, and develops relevant standard operating procedures and methods.	GRI 302-1 Energy consumption within the organization GRI 302-3 Energy intensity GRI 305-1 Direct (scope 1) GHG emissions GRI 305-2 Energy indirect (scope 2) GHG emissions GRI 305-4 GHG emissions intensity			▲		●	○
Integrity Management	To establish a corporate culture of ethical business practices, promote the company's sound development, and build a solid operational framework, SCI Pharmtech implements legal compliance measures, strictly prohibits and prevents unethical behavior, regularly reviews the effectiveness of corporate governance, and continuously improves to ensure the implementation of ethical business policies.	GRI 205-3 Confirmed incidents of corruption and actions taken	○	▲	▲	●	○	○
Labor Relations	A positive labor relationship is the foundation of stable business operations. SCI Pharmtech values employee rights, provides a safe and healthy work environment, and assists employees in maintaining physical and mental health and work-life balance, aiming to foster a more harmonious and stable labor-management relationship.	GRI 401-1 New employee hires and employee turnover	●	▲	▲		○	○

Material Topics and Sdgs Correspondence Table

Topic No.	Topics	Corresponding SDGs	Target	2022~2023 Performances
1	Disaster Recovery	8, 12	Full plant operation resumption in 2024	Hardware reconstruction completed in September 2023 and entered the testing phase
2	Economic Performance	8, 12	Zero losses during the reconstruction phase	• Net profit NT$308.78 million in 2022 • Net profit NT$294.72 million in 2023
3	Integrity Management	12	Zero corruption cases	Zero corruption cases
4	Legal Compliance	12	Zero fines	Fine amount NT$208,000
5	Energy Management and GHG Emissions	12, 13	Planning for comprehensive carbon footprint assessment	• Set annual phased targets for carbon footprint assessment. • Obtained ISO 14067 external verification for 1 product.

/ Material Topics and Sdgs Correspondence Table

Topic No.	Topics	Corresponding SDGs						Target	2022~2023 Performances
		3 GOOD HEALTH AND WELL-BEING	6 CLEAN WATER AND SANITATION	8 DECENT WORK AND ECONOMIC GROWTH	12 RESPONSIBLE CONSUMPTION AND PRODUCTION	13 CLIMATE ACTION	14 LIFE BELOW WATER		
6	Wastewater and Waste Management		●		●		●	• Promote waste reduction processes. • 100% proper disposal rate for waste. • Effluent concentration meets standards.	• Increased the recovery rate of solvents and catalysts. • 100% proper disposal rate for waste. • 1 case of effluent exceeding standards.
7	Occupational Safety and Health	●			●			Comprehensive harm index (FSI)：0	2022 FSI：0.89 2023 FSI：0
8	Customer Health and Safety	●			●			Establish product PNEC	Complete PNEC re-ports for Dulox. HCl, Propafenone.HCl, Thio-pental, PEB.Na, NAVA
9	Labor Relations			●				Total turnover rate ≦10%	Total turnover rate 7.48%

Material Topic Boundary Descriptions

Topic Number	Topics	Descriptions	Corresponding Chapter
1	Energy Management and GHG Emissions	With the tightening of domestic regulations and the forthcoming EU CBAM and Taiwan carbon fees, greenhouse gas emissions and energy management are no longer just environmental impacts but also bring financial impacts. Regular greenhouse gas emissions and energy audits, and how to effectively reduce energy consumption and greenhouse gas emissions, have become important issues for the company to move towards sustainable operations and strengthen operational resilience.	03 Green Operations and Circular Innovation
2	Wastewater and Waste Management	The production process generates hazardous waste. Proper removal and treatment, and establishing waste reduction strategies, can mitigate pollution to the Earth's environment.	03 Green Operations and Circular Innovation
3	Disaster Recovery	From the moment the cordon was lifted on December 28, 2020, SCI Pharmtech colleagues joined hands to overcome obstacles and rebuild. The chairperson spearheaded the reconstruction plan, while various departments concurrently carried out insurance claims processing, site cleanup methods, plant and equipment repair assessments, communication with government officials and customers, evaluation of commissioned production, shipment of remaining products, and review of industrial safety matters, all with the aim of resuming normal operations as soon as possible.	03 Green Operations and Circular Innovation
4	Economic Performance	After the fire incident, in a difficult environment with limited production capacity, SCI Pharmtech is still committed to delivering profitable results.	01 About SCI
5	Occupational Safety and Health	The production process and factory environment have potential occupational safety and health risks. If not properly managed, it may cause casualties and other hazards. Ensuring workplace safety, establishing a safe, healthy, and comfortable working environment, and continuously reducing occupational accident rates are the top priorities for safe operations.	05 Occupational Safety and Health
6	Customer Health and Safety	Comply with customer PSCI audit requirements, establish product PNEC and monitor API concentration in effluent.	03 Green Operations and Circular Innovation
7	Labor Relations	If employee welfare is not valued and no communication channels are provided for employees, it may lead to labor disputes, which in turn will affect the company's operations and cause financial losses.	04 Employee-Friendly Workplace
8	Integrity Management	Ensuring legal compliance and the implementation of internal and external supervision and control, establishing a legal identification system and risk assessment mechanism, is one of the elements of sound corporate governance.	02 Corporate Governance
9	Legal Compliance		

01
About SCI

About SCI

SCI PHARMTECH, INC.
旭富製藥科技股份有限公司

SCI Pharmtech was originally established in 1987 by the Swiss Siegfried Group and natural persons from Taiwan and the United States. In 2001 the company was acquired by Mercuries & Associates Holding, Ltd., and was listed on the Taiwan Stock Exchange in 2004 with the stock code 4119. The principal business activities of the company are the research and development, manufacturing, and sales of active pharmaceutical ingredients (APIs), API intermediates, and special and fine chemicals. The company is also an agent for various domestic and foreign pharmaceutical manufacturers in Taiwan, which provide price quotes, participate in commercial bids, and assist in research and development of various related products. Our headquarters is located at No. 61, Lane 309, Haihu North Road, Luzhu District, Taoyuan City. We are an API company that complies with US Food and Drug Administration (FDA) and current international GMP standards. The company also actively maintains a good partnership with industry guilds and associations by sharing industry information and promoting research and development to enhance the competitiveness and sustainability of the pharmaceutical industry.Presently, the company participates in the Taiwan Pharmaceutical Manufacturer's Association (TPMA) and the Haihu Industrial Park Manufacturer's Association.

Operational Performance

The operating revenue for 2022 was NT$899,738,000, with a gross profit margin of 32% and operating profit of NT$118,970,000. Similar to the previous year, due to the aftermath of the fire, there were more non-operating gains and losses in 2022. The net profit for the current period was NT$308,780,000, with basic earnings per share of NT$3.24. Despite the challenging environment of limited production capacity, SCI Pharmtech's core business still delivered a profitable performance. In the most difficult two years, we were meticulous and resourceful, ensuring that the company did not incur any losses.

The operating revenue for 2023 was NT$1,204,159,000, with a gross profit margin of 29% and operating profit of NT$160,300,000. In the current period, due to insurance claims, there was a relatively large amount of non-operating income. The net profit after tax was NT$294,721,000, with basic earnings per share of NT$2.7. With the gradual recovery of production capacity, revenue grew and operating net profit increased, but the gross profit of some products was reduced.

/ SCI Pharmtech Financial Overview

	2019	2020	2021	2022	2023	Unit
Capital	794,853	794,853	953,824	953,824	1,195,087	Thousand NTD
Operating Revenue	2,355,747	2,689,222	864,217	899,783	1,204,159	Thousand NTD
Gross Profit	935,770	1,274,328	208,098	291,179	350,323	Thousand NTD
Income Tax	140,059	95,091	9,810	79,040	69,469	Thousand NTD
Net Income (Loss)	571,101	360,124	55,696	308,780	294,721	Thousand NTD
Earning Per Share	7.19	3.78	0.58	3.24	2.70	NTD
Net Value Per Share (After Distribution)	39.51					NTD
Employee Salaries and Benefits	355,441	341,904	191,753	238,135	288,260	Thousand NTD
Stock Dividends	0	158,970,620	0	119,227,970	0	NTD
Cash Dividends	461,014,798	39,742,655	0	23,845,593	149,385,793	NTD

Note: This table also includes the financial information of SCI Pharmtech subsidiary company Yushan Pharmaceutical Inc.

Operations and Value Chain

The pharmaceutical industry is categorized into upstream, midstream, and downstream sectors. SCI Pharmtech operates within the midstream and upstream segments of the pharmaceutical industry, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs), API intermediates, and specialty chemicals. The company's business activities also include providing quotation, bidding, and distribution services for domestic and international manufacturers, as well as engaging in research and development related to these products. SCI Pharmtech's products are marketed in dozens of countries, primarily in Europe and the United States. Sales of APIs and API intermediates constitute approximately 87% of the company's total revenue, supplying a wide range of pharmaceutical companies globally.



The midstream and upstream sectors encompass raw materials and API processing. In the case of Western medicine, raw materials include natural products and general chemicals, primarily synthesized through chemical or semi-synthetic methods. The API industry predominantly falls under organic chemistry, with production methods varying based on the source of the materials.

The downstream sector consists of API and formulation industries. This stage involves combining APIs with pharmaceutical excipients, disintegrants, binders, lubricants, and emulsifiers to create convenient dosage forms.

Subsequently pharmaceutical distribution channels are formed. Prescription drugs, over-the-counter drugs, and finished medicines produced by pharmaceutical manufacturers are supplied to consumers through hospitals, clinics, and pharmacies.

SCI Pharmtech's main products in the past five years have been APIs, accounting for more than 50% of revenue, reaching a new high of 72.98% in 2020. However, due to a fire at the end of 2020, the company adjusted its production capacity in 2021, focusing on APIs and API intermediates, and operating revenue dropped sharply to NT$864.21 million. In 2022 and 2023, the company actively resumed work in different zones, and operating revenue grew by about 40% in two years to NT$1.204 billion.

/ SCI Pharmtech's Main Product Revenue and Proportion in Recent Five Years (Unit: NTD Thousand)

Year		2019		2020		2021		2022		2023	
		Revenue	Proportion	Revenue	Proportion	Revenue	Proportion	Revenue	Proportion	Revenue	Proportion
Product	API	1,546,270	65.64%	1,962,647	72.98%	396,602	45.89%	450,223	50.04%	718,312	59.65%
	API Intermediates	627,962	26.66%	597,496	22.22%	451,915	52.29%	433,362	48.17%	471,644	39.17%
	Others	181,515	7.70%	129,079	4.80%	15,700	1.82%	16,153	1.79%	14,203	1.18%
	Total	**2,355,747**	**100%**	**2,689,222**	**100%**	**864,217**	**100%**	**899,738**	**100%**	**1,204,159**	**100%**



/ 2022 Production Volume

API
216.9
Tons per Order

Intermediates
173.9
Tons per Order

/ 2023 Production Volume

API
267.5
Tons per Order

Intermediates
190.6
Tons per Order

APIs are divided into new drugs and generic drugs. The APIs produced by SCI Pharmtech are mainly generic APIs. APIs are the most important therapeutic ingredients in medicines, and their quality directly affects the quality, efficacy, and safety of formulations, which are closely related to the health and lives of people. Intermediates are products generated during the complex process of producing APIs. They are diverse and have a wide range of applications. The intermediates produced and sold by the company are mainly used for the synthesis of APIs, but they can also be used in the manufacture of fine chemicals. In addition, specialty chemicals are products manufactured on behalf of customers and are targeted at specific customers. The company uses sophisticated equipment and strict pharmaceutical regulatory requirements to carry out process scale-up and mass production on behalf of customers with high-quality requirements. Currently, the main focus is on electronic chemicals.

/ SCI Main Products and Applications

API

Main Product Name	Main Application
VA	Antiepileptic, Anticonvulsant
Probucol	Lipid-lower
Divalproate Sodium	Antiepileptic, Anticonvulsant
Propafenone Hydrochloride	Arrhythmia
Duloxetine Hydrochloride	Antidepressant
Allopurinol	Gout
Clindamycin palmitate HCl	Antibiotic
Articaine Hydrochloride	Anesthesia
HOCLQ-Sulfate	Malaria, Rheumatoid Arthritis, Lupus
Brinzolamide	Glaucoma
Sodium Valproate	Antiepileptic, Anticonvulsant
Pentobarbital Sodium	Anesthetic
Methylphenidate HCl	Anti-hyperactivity
Biso-FA	Hypertension, Angina
Thiopental acid	Anesthetic
Loxoprofen Sodium Hydrate	Antipyretic, Analgesic
Atomoxetine HCl	ADHD
Cannabidiol	Rare Childhood Epilepsy, Multiple Sclerosis

Intermediates

Main Product Name	Main Application
Pent-2	Anesthetic
PGA	Anti-Parkinson's Disease
NBE	Surgical Sedatives, Anesthetics
5-HMT	Anti-HIV/AIDS
BOV	Corticosteroids
(S)-MMAA	Antidepressant
HOCLQ	Antimalarial
Prop-3	Arrhythmia
Thiazole acid	Antineoplastic
Olivetol	Antiepileptic
PMDOL	Antiepileptic

Customers and Markets

SCI Pharmtech's products are mainly sold overseas, accounting for more than 90% of sales. The main exports are to major pharmaceutical companies in Europe, America, and Japan, and the quality is highly recognized by customers. In 2023, exports to Europe accounted for 52.82%, America accounted for 15.24%, Asia accounted for 20.48%, and domestic sales accounted for 7.99%. The difference compared to 2022 is not significant.

SCI Pharmtech's production lines were completely destroyed in the fire at the end of 2020, so the key operating factors in 2022 and 2023 were "when will production capacity be restored" and market competition factors. As of March 2024, all production lines have been repaired.

After three years of hard work, we have finally completed the reconstruction of the Taoyaun plant, and have peacefully and smoothly handled all the compensation for losses to neighboring factories. The haze of the fire has dissipated, although we may not yet feel the warmth of the sun, we are no longer in the cold wind. The factory facilities have gone from being devastated after the disaster to being as good as new today. The bitterness and pain along the way are unforgettable. We will keep the lessons in mind and start again in the Year of the Dragon. In 2023, SCI Pharmtech operated with less than half of its production capacity, and its revenue was NT$1.2 billion, about half of the pre-disaster level. To fully recover its past performance, it is undeniable that there is still a long way to go, but all employees will work together and move forward!



Main Regions of Product Sales (Unit: Thousand NTD)

Year / Sales Regions		2019		2020		2021		2022		2023	
		Revenue	Proportion	Revenue	Proportion	Revenue	Proportion	Revenue	Proportion	Revenue	Proportion
Export	Europe	1,271,195	53.96%	1,422,867	52.91%	467,009	54.04%	426,034	47.35%	636,052	52.82%
	Americas	341,430	14.49%	479,583	17.83%	119,785	13.86%	127,441	14.16%	183,510	15.24%
	Asia	502,512	21.33%	455,464	16.94%	202,435	23.42%	205,548	22.85%	246,601	20.48%
	Other	19,555	0.84%	106,839	3.97%	16,409	1.90%	31,395	3.49%	41,758	3.47%
	Total Export	2,134,692	90.62%	2,464,753	91.65%	805,638	93.22%	790,418	87.85%	1,107,921	92.01%
Domestic		221,055	9.38%	224,469	8.35%	58,579	6.78%	109,320	12.15%	96,238	7.99%
Total		2,355,747	100%	2,689,222	100%	864,217	100%	899,738	100%	1,204,159	100%

02
Corporate Governance

Corporate Governance Structure

SCI Pharmtech's Board of Directors serves as the highest governing body and the core of major business decision-making. Its primary responsibilities include appointing and overseeing the company's management team, reviewing the company's operating performance, preventing conflicts of interest, and ensuring compliance with various laws and regulations. To enhance corporate governance effectiveness, the company selects members of the Board of Directors in accordance with the Company Act and the " Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies." The selection process considers factors such as operational judgment and management ability, accounting and financial analysis skills, crisis management capabilities, leadership and decision-making abilities, industry knowledge, and understanding of international markets, ensuring a well-rounded composition of the board.

Board Diversity and Independence

SCI Pharmtech's Board of Directors consists of 7 directors with a term of 3 years, from June 21, 2022 to June 20, 2025. This includes 3 independent directors, representing 43% of the board seats. This composition aims to strengthen the board's independence and diversity while enhancing its strategic guidance capabilities.

Functional Committees

In order to fulfill corporate governance principles, strengthen risk management, and protect the rights and interests of investors and other stakeholders, the company promptly publishes important board resolutions on the Market Observation Post System of the Taiwan Stock Exchange. Information such as directors' remuneration, board operations, and the implementation of conflict of interest avoidance procedures is also available for real-time inquiry by domestic and foreign investors. The company has established a Remuneration Committee and an Audit Committee, both composed of independent directors.

Board Training and Collective Learning

The Board of Directors adheres to the " Directions for the Implementation of Continuing Education for Directors and Supervisors of TWSE Listed and TPEx Listed Companies " and arranges for directors to participate in external training. In 2023, the total training hours for the company's directors amounted to 66 hours.

Board Performance Evaluation

In accordance with the " Rules for Performance Evaluation of Board of Directors " passed in 2019, the company conducts regular performance evaluations of the Board of Directors (including functional committees) and individual directors each year using appropriate methods.

The Board of Directors meets at least once a quarter, and in 2023, a total of 7 board meetings were held, with an actual average attendance rate of 95.92%. The Chairperson of the Board is Dr. Wei-Chyun Wong, whose main responsibilities are to improve ESG and implement the operation of the Board of Directors.

/ Professional and Diverse Board Members

Title	Name	Gender	Major Education/Experience	Age Range	Actual Attendance	Actual Attendance Rate (%)
Chairperson	Dr. Wei-Chyun Wong	Male	• Ph.D. in Chemistry from the University of Pennsylvania • Researcher at Industrial Technology Research Institute • President of SCI Pharmtech	61~70	7	100%
Director	Shiang-Li Chen	Male	• MBA from Georgetown University • Chairperson of Mercuries & Associates Holding Ltd	51~60	6	85.7%
Director	Mercuries & Associates Holding Ltd. Representative: Yen-Ju Chen	Female	• Master's from Northwestern University • Manager at McKinsey & Company	51~60	7	100%
Director	Mercuries & Associates Holding Ltd. Representative: Dr. Wen-Chih Chou	Male	• Ph.D. in Chemistry from National Taiwan University • Researcher at Development Center for Biotechnology • R&D Manager at SCI Pharmtech	51~60	6	85.7%
Independent Director	Te-cheng Tu	Male	• MBA from the University of Houston • President of President International Development Corp.	61~70	7	100%
Independent Director	Chia-Chun Jay Chen	Male	• Ph.D. in Chemistry from Harvard University • Professor and Distinguished Professor at National Taiwan Normal University • Associate Professor at National Chung Cheng University	51~60	7	100%
Independent Director	Vincent Wang	Male	• Dual Master's in Finance and Entrepreneurial Management from The Wharton School, University of Pennsylvania • Director of EasyCard Corporation • Director of Taiwan Sugar Corporation • Supervisor of Taiwan Venture Capital Association	41~50	7	100%

Integrity Management and Insider Trading Prevention

SCI Pharmtech's President's Office is responsible for promoting ethical business conduct within the company. The President oversees this initiative, and the Corporate Governance Officer reports annually to the Board of Directors on the previous year's implementation status. The Audit Office regularly checks compliance with these regulations.

To effectively enhance the company's overall operational efficiency, SCI Pharmtech has established an Audit Office directly under the Board of Directors in accordance with the Financial Supervisory Commission's " Regulations Governing Establishment of Internal Control Systems by Public Companies." The Audit Office employs independent and full-time internal auditors whose primary responsibilities include understanding and evaluating the implementation of internal control systems, measuring operational efficiency, and providing timely improvement suggestions. This ensures the continued effective execution of internal control systems and auditing operations, assisting the Board of Directors and management in fulfilling their responsibilities. The Audit Supervisor attends board meetings to report on auditing activities and submits monthly audit reports to independent directors for review. In the event of any major illegal activities or significant risks to the company, the Audit Supervisor immediately submits a report and notifies the independent directors.

In terms of internal audit operations, the Audit Office conducts on-site inspections or document reviews based on the annual audit plan approved by the Board of Directors, taking risks into consideration. This is complemented by ad-hoc audits for special purposes and ad-hoc participation in audits of international management systems such as ISO 9001 Quality Management, ISO 14001 Environmental Management, and ISO 45001 Occupational Safety and Health Management. Furthermore, the Audit Office assists various departments in conducting self-inspections at least once a year, providing timely suggestions for improvement. This allows the Board of Directors and managers to review and identify deficiencies in internal control systems, assess the effectiveness and efficiency of operations, and reasonably ensure the continued effective implementation of operational performance, legal compliance, and financial reporting, as well as providing a basis for reviewing and revising internal control systems.

SCI Pharmtech's 2023 Material Topic: "Integrity Management" - Response and Management Approach Elements and Evaluation

Integrity Management

Corresponding GRI Indicator

GRI 205-3 Confirmed incidents of corruption and actions taken

Policies and Commitments

Treat all stakeholders with honesty and integrity, and strive to enhance the transparency of corporate operations. Internalize honesty and integrity as the company's core values, and maintain a zero-tolerance attitude towards dishonest behavior.

Goals and Targets

Goals

- Promote and coordinate training and awareness programs on integrity policies.
- Improve the whistleblowing system to ensure its effectiveness.
- Prepare and properly preserve documented information related to integrity management policies, compliance statements, commitment implementation, and implementation status.
- Regularly analyze and assess the risk of dishonest behavior within the scope of business operations, and formulate preventive measures accordingly, including establishing standard operating procedures and codes of conduct for relevant work tasks.
- Plan the internal organizational structure, staffing, and responsibilities, and implement a system of checks and balances for business activities with higher risks of dishonest behavior.
- Assist the Board of Directors and management in reviewing and evaluating the effectiveness of preventive measures established for integrity management, and regularly assess and report on the compliance of relevant business processes.
- Stay abreast of domestic and international developments in Integrity Management regulations, and encourage directors, managers, and employees to make suggestions for reviewing and improving the company's Integrity Management policies and measures.

SCI Pharmtech's 2023 Material Topic: "Integrity Management" - Response and Management Approach Elements and Evaluation

Integrity Management

Goals and Targets

Goals

- Integrate integrity and ethical values into the company's business strategy, and formulate relevant anti-fraud measures to ensure integrity management in compliance with laws and regulations.

Responsibilities and Resources

- The President's Office is responsible for promoting corporate Integrity Management, with oversight by the President. The Corporate Governance Officer reports to the Board of Directors annually on the previous year's implementation status. The Audit Office regularly checks compliance with these regulations.
- Complaint channels are established to allow employees and relevant personnel to report any improper business conduct, and the company designates management to personally handle such reports.

Evaluation Mechanisms and Results

- In 2023, the Audit Office conducted an audit on the implementation of integrity management and found no instances of dishonest behavior.
- There were no incidents of dishonest behavior or any complaints reported in 2022 and 2023.
- The most recent integrity management implementation status was reported to the Board of Directors on March 12, 2024. The Corporate Governance Officer reported on the 2023 integrity management implementation status, and no fraud or dishonest behavior occurred.
- All directors and senior management at the manager level and above have signed the Integrity Management Declaration.

- The Company revised its Corporate Governance Best Practices Mechanism on March 18, 2022, at the Board of Directors meeting. It added stock trading control measures for company insiders upon learning of the company's financial reports or related performance content, including (but not limited to) that directors shall not trade their shares during the closed period of 30 days before the announcement of annual financial reports and 15 days before the announcement of quarterly financial reports. The company notifies directors and all employees of the aforementioned stock trading control measures quarterly via email.
- To promote and advocate ethical conduct and prevent insider trading, the company holds regular training sessions annually. Starting in 2024, online training on listed company regulations will be conducted for 250 employees via the electronic system MasterControl Training Task at January of each year. The content includes the integrity management code, internal material information handling procedures, self-regulatory guidelines for merger and acquisition information disclosure, corporate governance best practices, and sustainable development guidelines. Relevant regulations are also available on the company's intranet and website for employees to access at any time. The advantage of using this system for management is that it keeps a record of each employee's training and test results.
- In 2023, a total of 11 individuals participated in external training sessions on integrity management, corporate governance, and other related regulations, for a total of 108 training hours.

Policy and Complaint Channels

SCI Pharmtech complies with government regulations on internal control and the company's integrity management code. In addition to requiring the Board of Directors and management to implement integrity management, the company has also established an internal control system and assigned audit personnel to perform investigative work in accordance with their professional responsibilities. This involves heightened vigilance regarding potential fraud, errors, waste, and conflicts of interest. If any such issues are verified, they are immediately reported to the relevant supervisors for investigation and handling. Since its establishment, the company has not experienced any incidents of corruption or bribery. From 2022 to 2023, no complaints were received reporting any illegal activities related to company operations or employees violating ethical integrity.

Since August 2013, SCI Pharmtech has required suppliers to sign a "Corporate Social Responsibility Commitment Letter" to ensure their adherence to professional ethics, prohibition of child labor or forced labor, prohibition of discrimination and punitive measures, compliance with health and safety regulations, and respect for employees' personal rights and benefits. If a supplier engages in any conduct that violates corporate social responsibility, it is considered a breach of contract, and the company will immediately terminate or cancel all contracts and orders with that supplier and revoke their supplier status.

The company has established reporting channels to encourage internal personnel to report any improper conduct that violates the principles of integrity. Strict and effective measures are taken to protect the identity and report content of those who report in good faith or participate in investigations. The company also properly tracks and handles all reported incidents, assigning the Finance and Administration Division to conduct thorough investigations and then report to the President for further action.

SCI Pharmtech Anti-Corruption Reporting Process



Education and Training

To promote and advocate ethical conduct and prevent insider trading, the company holds regular training sessions annually. Starting in 2024, online training on listed company regulations will be conducted for all employees via the electronic system MasterControl Training Task at January of each year. The content includes the integrity management code, internal material information handling procedures, self-regulatory guidelines for merger and acquisition information disclosure, corporate governance best practices, and sustainable development guidelines. Relevant regulations are also available on the company's intranet and website for employees to access at any time. The advantage of using this system for management is that it keeps a record of each employee's training and test results. In 2023, a total of 11 individuals participated in external training sessions on integrity management, corporate governance, and other related regulations, with a total of 108 training hours.

Remuneration Policy

SCI Pharmtech has a Remuneration Committee composed of three independent directors. Its main responsibilities include assisting the Board of Directors in evaluating the link between the remuneration levels of the company's directors and managers and the company's operating performance, determining the bonus allocation ratio, and providing recommendations on manager remuneration and the company's overall remuneration policy based on the industry's competitive environment, the company's operating performance, and benchmark market conditions. In addition, the company regularly participates in salary surveys conducted by industry or consulting firms to review the relevance of its salary and benefits measures to the market, with the aim of developing an incentive-based remuneration system. Employee and director remuneration allocation proposals are submitted to the shareholders' meeting for reporting and are disclosed in the company's annual report. The Remuneration Committee held five meetings in 2023, with an actual average attendance rate of 100% for all members.

2023 Remuneration Committee Meeting Attendance

Title	Name	Actual Attendance	Attendance by Proxy	Actual Attendance Rate (%)
Independent Director	Te-cheng Tu	3	0	100%
Independent Director	Chia-Chun Jay Chen	3	0	100%
Independent Director	Vincent Wang	3	0	100%

If the company has profits in each fiscal year, it should allocate employee and director remuneration. Employee remuneration should not be less than 3%, and director remuneration should not be more than 2%; however, if the company still has accumulated losses, it should reserve the amount to cover the losses in advance. The estimated amount of employee and director remuneration payable is based on the articles of incorporation and the relevant remuneration regulations. It is calculated by multiplying the company's pre-tax net profit for each period, before deducting employee and director remuneration, by the allocation ratio stipulated in the company's articles of incorporation, and is reported as operating costs or operating expenses for that period. If the board of directors decides to distribute employee remuneration in the form of shares, the number of shares for stock remuneration is calculated based on the closing price of common shares on the day before the board resolution.

Distribution of employee and director remuneration in 2022

Employee Remuneration
NT$
26,091,471

Director Remuneration
NT$
4,250,000

Distribution of employee and director remuneration in 2023

Employee Remuneration
NT$
24,407,466

Director Remuneration
NT$
3,936,000

Legal Compliance

SCI Pharmtech has always been committed to integrity, dedicated to establishing open and smooth communication channels with employees, and respecting and protecting their legal rights and interests. All rules and regulations are formulated in accordance with the Labor Standards Act, the Act of Gender Equality in Employment, and other relevant laws to safeguard employees' legal rights. Regarding the appointment, dismissal, and remuneration management of employees, SCI Pharmtech adheres to the internal control system management measures to ensure the basic rights and interests of employees. To ensure that every employee is treated fairly and humanely, we have formulated the "Measures for the Prevention, Complaint, and Punishment of Sexual Harassment" to protect the rights and interests of all employees. In terms of employee recruitment, the company's "Work Rules" clearly stipulate that child labor is prohibited. SCI Pharmtech provides equal employment opportunities for all and does not discriminate based on race, gender, disability, religion, constellation, blood type, or other characteristics. In 2022 and 2023, there were no incidents of discrimination, complaints about labor practices that violated human rights, prohibition of employees' freedom of association, forced labor, use of child labor, or infringement of indigenous peoples' rights.

In terms of products and services, SCI Pharmtech's marketing and labeling comply with relevant laws and regulations and international standards. All products are accompanied by Safety Data Sheets (SDS) prepared in accordance with domestic and foreign laws and regulations. The company has also established an "Environmental, Safety, and Health Policy" to ensure product compliance in terms of safety, environment, and health. The company's products fully comply with international norms, legal requirements, and customer needs in various countries and engage in industry competition based on principles of fairness, openness, and justice. In 2022 and 2023, there were no incidents of products violating health and safety regulations, product labeling regulations, market communication regulations, or antitrust regulations.

In terms of environmental safety and health, SCI Pharmtech not only complies with domestic regulations based on industry characteristics but also actively aligns with international standards. The company has obtained ISO 14001 certification for our environmental management system and ISO 45001/CNS 45001 certification for our occupational safety and health management system. We have also implemented the ISO 14064-1 Greenhouse Gas Inventory Project and continues to operate in accordance with the PDCA system framework. In 2022 and 2023, there was one incident of violation of environmental regulations and one incident of violation of occupational safety and health regulations. The company took immediate corrective actions and reported the results to the governing authorities. In the future, we will continue to strengthen employee training and the implementation of relevant protective measures to prevent similar incidents from happening again.

Penalty Date	Violated Law	Penalty Amount (NTD)	Reason for Violation
2022/06/30	Water Pollution Control Act	108,000	Effluent exceeding standards
2023/01/31	Occupational Safety and Health Act	100,000	Failure to install protective covers or other facilities at the equipment hoisting openings on the 2nd floor of Area 11B, and failure to ensure that workers entering the area wear safety helmets.

Note: The table is disclosed based on the actual penalty date. Penalty date range: January 1, 2022 to December 31, 2023.

Risk Management

SCI Pharmtech's risk management policy, in line with the company's operational guidelines, establishes a risk management mechanism for risk identification, measurement, monitoring, and control within an acceptable range of risk, the objective is to achieve a reasonable balance between risk and return. The Board of Directors serves as the highest authority for risk management, responsible for approving, reviewing, and supervising the company's risk policies and ensuring the operation of the management framework and risk control functions. The Audit Committee oversees the company's risk management operational mechanisms, responsible for reviewing risk management policies, procedures, and frameworks to ensure that the risk management mechanism can adequately address the risks faced by the company, it also designates personnel to report to the Board of Directors on the implementation of risk management at least once a year. The President's Office is primarily responsible for planning business strategies, supervising and implementing their execution, and achieving operational effectiveness and efficiency to reduce strategic and operational risks. The Audit Office evaluates significant risk items as a reference for selecting operational tasks in the audit plan and formulates and revises relevant control measures and procedures for potential risks.

SCI Pharmtech has established an Audit Committee composed of three independent directors, its main responsibilities include supervising the company's affairs, such as reviewing the company's business and financial status, auditing accounting books and documents, supervising employee performance, investigating illegal and derelict acts, reviewing budgets and final accounts, reviewing proposals for profit distribution or loss compensation, and exercising other powers granted by law. The Audit Committee held five meetings in 2023, with an actual average attendance rate of 100%.

2023 Audit Committee Meeting Attendance

Title	Name	Actual Attendance	Attendance by Proxy	Actual Attendance Rate (%)
Independent Director	Te-cheng Tu	5	0	100.0%
Independent Director	Chia-Chun Jay Chen	5	0	100.0%
Independent Director	Vincent Wang	5	0	100.0%

SCI Pharmtech's corporate mission is to create sustainable products and services. We regard risk management as a key operational issue to enhance the overall organization's risk tolerance and achieve the goal of uninterrupted operation. The company regularly reports on the operation of risk management to the Audit Committee and the Board of Directors annually. The 2023 report was completed on December 18th at the Audit Committee and Board of Directors meetings.

Risk Category	Responsible Unit	Description
Market	Business Administration Division	The overall demand for pharmaceuticals is closely related to population growth. In the past, development has maintained a steady growth pace, and sales are less affected by the overall economic environment. For individual products, whether it is a patented drug manufactured on behalf of a patented drug manufacturer or a generic drug whose patent has expired, they are all approved by health authorities in various countries. Basically, the product life cycle is long, and the market risk is low. APIs and intermediates need to undergo strict customer certification, and APIs also need to pass GMP inspections by the Ministry of Health and Welfare, the US FDA, and the EU EDQM. Therefore, the cost and threshold for customers to switch suppliers are high, and customers pay more attention to product quality and supplier reputation. Therefore, unless under special circumstances, customers will not arbitrarily change suppliers, so the risk of customer churn is not high. In view of the above, the impact of market risk on the company's profit and loss is limited. To enhance market competitiveness, in addition to strengthening the sales team, the company will continue to develop new products in the future. The goal in 2023 is to reduce the revenue share of a single product item to 15%. It will also continue to develop new customers, with the goal of reducing the revenue share of a single customer to 10% in 2023.

Risk Category	Responsible Unit	Description
 R&D	R&D Department	In the drug research and development stage, SCI Pharmtech strengthens the prevention of hazards to laboratory personnel using unknown chemicals. It has specially set up equipment such as negative pressure rooms and glove boxes for isolation operations to protect the health and safety of laboratory personnel.
 Supply Chain Management	Business Administration Division	As a manufacturer of intermediates and APIs, SCI Pharmtech has always diversified its raw material procurement as much as possible, avoiding concentration in specific regions, and maintaining the supply of the same raw material from different countries under acceptable circumstances to achieve risk diversification. Therefore, currently, SCI Pharmtech's raw material suppliers are located all over the world, and we continue to develop new suppliers to ensure the stability of the supply chain. If faced with material shortages and supply interruptions, the company will establish excess inventory for raw materials as much as possible and quickly establish other suppliers to diversify the risk of supply chain disruptions. In addition, we also value mutual trust and mutual assistance with suppliers. When suppliers experience material shortages, we also actively help search for and provide information, making suppliers regard SCI Pharmtech as a high-quality partner and giving us full support for a win-win situation.

Risk Category	Responsible Unit	Description
 Financial	Finance and Administration Division	**Exchange rate risk:** To address exchange rate risk, the company closely monitors exchange rate changes and judges the appropriate time to buy and sell foreign currencies based on the development of the international political and economic situation and exchange rate trends. We also use methods such as forward foreign exchange to avoid exchange rate risk and appropriately reflects unfavorable exchange rate changes to customers when quoting product prices. **Credit risk:** The company strictly implements customer credit investigation operations in accordance with internal control procedures. Credit sales amounts are controlled within the credit limit granted to individual customers. For new customers, the company requires advance payment or letter of credit transactions to reduce credit risk. The company will continue to rigorously conduct customer credit investigations, and for customers with concerns, we will adopt prepayment transactions and, when necessary, sell or insure accounts receivable to avoid credit risk. **Liquidity risk:** The company pays close attention to changes in liquidity financial indicators. In November 2023, in response to the capital needs for the construction of the Guanyin plant, the company raised NT$960 million through a cash capital increase. We also have sufficient bank credit lines for capital allocation. In addition, the company has always focused on its core business operations and does not engage in high-risk, high-leverage investment activities. To effectively control special matters arising from actual business needs, the company has formulated internal management measures and operating procedures based on sound financial and operational practices in accordance with the relevant regulations of the Securities and Futures Institute. Currently, there are no instances of lending funds to others, and all derivative transactions are for hedging purposes. However, in response to the actual operating capital needs of the company's affiliates, banks require shareholders to provide guarantees according to their capital contribution ratios to ensure that the creditor's rights are guaranteed. In the future, the company will also strictly abide by the relevant transaction handling procedures of the competent authorities and the company. In addition to prudent assessment and execution, we will further strengthen our control mechanisms.

Risk Category	Responsible Unit	Description
Legal	President's Office Finance and Administration Division Quality Assurance Department	The patented drugs produced by the company for the original factory and the generic drugs manufactured after the patent has expired have no concerns about infringing product patents. As for process patents, the company carefully investigates and evaluates before research and development or production to avoid any legal issues related to patent infringement. In addition, the company adheres to the principle of acting in accordance with the law and strictly complies with domestic and foreign government laws and orders. Each department assigns personnel to review the impact of the formulation and amendment of laws and regulations on the company and its response. Therefore, it is assessed that there are no other potential legal risks arising from operations. The company has not had any litigation since its establishment, and it is estimated that the risk of occurrence in the future is also low, with limited impact on profit and loss. Management will continue to maintain close communication and consultation with lawyers to avoid any potential legal risks.

Risk Category	Responsible Unit	Description
Strategic and Operational	President's Office Finance and Administration Division Quality Assurance Department	In 2021, the company established Framosa Company in a joint venture with Veolia, hoping to reduce the company's consumption of chemical solvents and the amount of out-sourced processing, and to win solvent processing contracts from peers to generate economies of scale, strengthen operational competitiveness, and comply with the global trend of ESG. In addition, the second plant area, Guanyin Plant, was also built in the same year. The Guanyin Plant is expected to invest NT$2.44 billion. This part of the investment in fixed assets will generate strategic and operational risks. However, considering that the expanded production capacity can be effectively utilized in the future, there is no risk of impacting profit and loss. Strategic and operational risks are inherent risks in business operations. The company will reduce these risks through careful pre-assessment by management and fully leveraging the functions of the Board of Directors. In terms of quality risks, the company ensures that products are produced in accordance with GMP and customer standards, as well as production schedules and relevant SOPs, to optimize production efficiency. It also complies with the regulations of health authorities in various countries to avoid risks such as delayed shipments or production disruptions, and to reduce quality-related and customer complaint risks. If customer audits and inspections by health authorities reveal deficiencies, in addition to affecting business quality, rework or scrapping may be necessary. In response, the company will continue to implement quality policies and GMP manufacturing to ensure the effective operation of the ISO 9001 system.

Quality Management

Patent Portfolio

SCI Pharmtech's R&D Department is responsible for new product development, process improvement of existing products, and applying for process patents. It continues to expand its R&D workforce every year to meet customer needs and cooperate with business development. In 2022, SCI Pharmtech invested nearly NT$39.65 million in R&D expenses, an increase of 30.65% compared to 2021. In 2023, it invested nearly NT$49.09 million in R&D expenses, an increase of 23.8% compared to 2022. Based on its excellent international customer relationships in the past, SCI Pharmtech has a steady stream of R&D projects with a high probability of commercialization and contributing to revenue. Cannabidiol, glaucoma, and Alzheimer's disease APIs are examples of products successfully developed by SCI Pharmtech, so its operations have maintained growth momentum in recent years. In the future, the company will continue to invest R&D resources and focus on "developing niche product processes" and "scaling up and commercializing new drugs under development" as key R&D projects.

SCI Pharmtech R&D Expenses in the Past Five Years (Unit: Thousand NTD)



Developing Specialty Drugs

Domestic chemical pharmaceutical business models are mainly divided into two categories. Some companies export large quantities of bulk APIs such as vitamins, antibiotics, and antipyretic analgesics to Europe, America, and Japan every year. Other companies choose to enter the more profitable specialty API market. Due to the wide variety of chemical formulations and pharmaceutical projects, the thresholds and added value from generic drugs to patented drugs vary. Chemical specialty drugs require a large investment in R&D personnel and funds to acquire intangible assets such as professional know-how and intellectual property rights. Through new product mass production and later international alliances, these intangible assets are transformed into tangible assets, determining the unlimited value of the company's future.

Therefore, SCI Pharmtech is actively investing in the chemical specialty drug market. Following the development of the "cannabidiol" (CBD) API, SCI Pharmtech has also developed the "buprenorphine" drug addiction treatment agent and completed process verification and scale-up, it is currently applying for drug approval. As the problem of drug abuse becomes increasingly serious, the development of such products enables SCI Pharmtech to contribute to society.

In addition, SCI Pharmtech also focuses on products with high processing difficulty, such as asymmetric hydrogenation and ultra-low temperature reactions, continuously optimizing processes to increase yield and reduce waste, further distancing itself from competitors. At the same time, SCI Pharmtech has also strengthened GMP management and introduced systems such as SAP, MasterControl, and LIMS, differentiating itself from Chinese and Indian pharmaceutical companies.

Customer Health and Safety

SCI Pharmtech 2023 Material Topic "Customer Health and Safety" Response and Management Approach

Material Topic	Customer Health and Safety
Corresponding GRI Indicator	Custom topic
Policies and Commitments	Provide customers around the world with products manufactured in accordance with GMP, and continuously improve the quality management system and comply with current government regulations and international standards to achieve customer satisfaction and promote and improve the health and safety of end consumers.
Goals and Targets	**Short Term Goals** Start production and process validation in the repaired areas, and gradually apply for and pass the suspended drug licenses and GMP operational audits. **Medium to Long Term Goals** Quality compliance, supply capacity, distribution, customer service, price, and product liability is up to global standards, and pass the impact assessment on the environment and society.
Responsibilities and Resources	The company invests significant manpower in process, quality control, and quality assurance, and has 50 professional quality control and quality assurance personnel, including 7 analytical process development personnel. Analytical methods and equipment have also been validated.

Material Topic	Customer Health and Safety
Evaluation Mechanisms and Results	• All drug licenses for APIs in major regions such as the EU, the US, and Japan continue to be maintained and remain valid. • Passed the ISO 9001 quality management system renewal audit again at the end of 2023. • Follows the Good Distribution Practice (GDP) to implement quality management in the pharmaceutical supply chain. • APIs whose drug licenses and GMP certificates were previously suspended by the Taiwan Food and Drug Administration have gradually started production and process validation in the restored areas, and have obtained GMP certificates. Drug licenses continue to be valid. • Passed multiple US FDA inspections since 2005; passed EU EDQM and Japan PMDA inspections. • Submitted Drug Master Files (DMF) to the Food and Drug Administration's registration center in accordance with the Food and Drug Administration's regulations "Technical Review Form for Raw Material Master Files" and "Precautions for Applying for Raw Material Master File Review" to ensure the safety and quality of APIs. • A Certificate of Analysis (COA) is attached to each shipment, disclosing the product's ingredient and raw material performance analysis report to ensure raw material safety and drug safety assessmen

Quality Assurance

SCI Pharmtech's GMP and ISO quality systems remained unchanged despite the major fire at the end of 2020, and pharmaceutical regulatory operations continued uninterrupted. All drug licenses for APIs in major regions such as the EU, the US, and Japan continue to be maintained and remain valid. The ISO 9001 quality system was audited again by a third-party certification body at the end of 2023, and the certificate remains valid. Damaged production line facilities and equipment have been rebuilt. Manufacturing equipment, air conditioning systems, nitrogen systems, and computer systems are all equivalent to pre-disaster levels, and relevant verification and validation work has been completed.

In addition, the Taiwan Food and Drug Administration is promoting Good Distribution Practice (GDP) and has announced that by the end of 2022, the product distribution operations of all API manufacturers must be evaluated to meet regulatory requirements. SCI Pharmtech already has considerable experience in GMP operations, and based on this foundation, it has also completed the construction of its distribution and supply chain management and passed the Taiwan Food and Drug Administration's inspection in May 2022.

Implementing the ISO 9001 Quality Management System

SCI Pharmtech, as part of the pharmaceutical biotechnology industry, upholds the ISO 9001 quality policy of "providing customers around the world with products that comply with GMP/ISO 9001 and ensuring customer satisfaction." We continue to invest in quality system improvements and follows current regulations and international regulatory trends. The company's product quality complies with the health authorities and safety regulations of various countries, and it first passed ISO 9001 quality management system certification in 2001 and has continued to operate the system effectively. At the same time, the company also uses advanced analytical instruments to maintain high quality, including GC, HS-GC, HPLC, UPLC, IC, UV, IR, DSC, TGA, Laser Particle size analyzer, ICP-MS, and LC-MS/MS analytical instruments.

To protect the health of end users, SCI Pharmtech actively invests in research and development, providing high-quality and stable APIs and intermediates to the highest standards. When products are still in the laboratory stage, the R&D Department implements the quality system, listing the health and safety-related matters that require special attention in each reaction step. After mastering the data, operational personnel are trained before production to ensure correct and safe production.

ISO 9001 Quality Management System Certificate

Compliance with GDP Management

To maintain patient medication safety and ensure the quality of drugs after they leave the factory, SCI Pharmtech follows the "Good Distribution Practice" (GDP) that the Food and Drug Administration has been promoting since 2011. The Food and Drug Administration first targeted Western medicine distributors and pharmaceutical manufacturers with drug licenses, requiring them to obtain GDP permits before engaging in drug distribution operations from January 1, 2019. Subsequently, it required Western medicine preparation distributors that require cold chain storage and transportation to complete the implementation of GDP by December 31, 2021, gradually completing quality management of the drug supply chain.

Improper storage or transportation of APIs may lead to deterioration, which in turn may adversely affect drug production operations and human health. Therefore, we implement distribution record management and GDP for API distributors. We continue to improve various operations such as procurement, supply, storage, import, and export of SCI Pharmtech APIs and refer to the "Guidelines on the Principles of Good Distribution Practice of Active Substances for Medicinal Products for Human Use" published by the PIC/S organization to formulate relevant guidelines for our API manufacturing and distribution companies to implement GDP.

Based on the public interest of safeguarding the national drug safety and ensuring the integrity of the drug supply chain, SCI Pharmtech's drug trading complies with the Pharmaceutical Affairs Act and relevant regulations to confirm the legality of the source and flow of drugs and maintain complete distribution records of drug sales (including product name, content, dosage form, batch number, recipient's name, address, shipment date, and quantity) for subsequent traceability. To strengthen drug quality control, implementing drug GDP is an important direction for sound quality management of the drug supply chain. SCI Pharmtech implements domestic drug distribution quality to improve the drug quality management system, allowing the public to use drugs with greater peace of mind.

GMP Good Manufacturing Practice

Good Manufacturing Practice (GMP) is a set of regulations that requires everything from the quality of raw material sources to product purity, manufacturing processes and their monitoring, instruments used in the process, plant design, and product purity analysis to comply with this standard. To obtain GMP certification level of drug quality assurance standards, it is necessary to apply to the health authority and undergo verification and confirmation by the health authority.

APIs whose drug licenses and GMP certificates were previously suspended by the Taiwan Food and Drug Administration have gradually started production and process validation in the restored areas. After the follow-up GMP evaluation conducted by the Taiwan Food and Drug Administration in May 2022, as of 2023, 14 APIs have obtained GMP certificates. Applications for this GMP evaluation will continue based on the production items.

SCI Pharmtech GMP Approved Items

衛 生 福 利 部
MINISTRY OF HEALTH AND WELFARE

CERTIFICATE OF GOOD MANUFACTURING PRACTICE

Issue Date: August 30, 2023

Issued following an inspection in accordance with Article 57 of the Pharmaceutical Affairs Law and relevant Regulations of the Republic of China (Taiwan).

The competent authority of the Republic of China confirms the following:
The manufacturer: SCI Pharmtech, Inc.
Site address: No.61, Ln. 309, Haihu N. Rd., Luzhu Dist., Taoyuan City 33856, Taiwan
Manufacturer's license number: (C)0014016

is the manufacturer of medicinal products for human use that has been inspected with the following Active Pharmaceutical Ingredients: Articaine Hydrochloride, Atomoxetine Hydrochloride, Brinzolamide, Divalproex Sodium, Duloxetine Hydrochloride, Hydroxychloroquine Sulfate, Loxoprofen Sodium Hydrate, Methylphenidate Hydrochloride, Pentobarbital Sodium, Probucol, Propafenone Hydrochloride, Sodium Valproate, Thiopental, Valproic Acid.

From the knowledge gained during GMP inspection performed on May 11-13, 2022, it is considered that the manufacturer complies with the Pharmaceutical Inspection Convention/Co-operation Scheme Guide to Good Manufacturing Practice (PIC/S GMP) Part II (=GMP of WHO/ICH Q7) and Good Distribution Practice (PIC/S GDP) for medicinal products.

This certificate is valid until January 8, 2026.
This certificate may be revoked at anytime as warranted.

Signed by

Shou-Mei Wu

Shou-Mei Wu, Ph.D.
Director-General
Food and Drug Administration
(http://www.fda.gov.tw/TC/index.aspx)

Under the delegated authority of
Jui-Yuan Hsueh, M.D., LL.M.
Minister
Ministry of Health and Welfare
Republic of China (Taiwan)

08838

1. Atomoxetine Hydrochloride(TFDA Registration No.059045)
2. Articaine Hydrochloride(TFDA Registration No.058626)
3. Bisoprolol Fumarate(TFDA Registration No.048989)
4. Brinzolamide(TFDA Registration No.058824)
5. Divalproex Sodium(TFDA Registration No.048274)
6. Duloxetine Hydrochloride(TFDA Registration No.056630)
7. Hydroxychloroquine Sulfate(TFDA Registration No.058143)
8. Loxoprofen Sodium Hydrate(TFDA Registration No.056704)
9. Methylphenidate Hydrochloride(TFDA Registration No.057214)
10. Pentobarbital Sodium(TFDA Registration No.039735)
11. Probucol(TFDA Registration No.036473)
12. Propafenone Hydrochloride(TFDA Registration No.055424)
13. Sodium Valproate(TFDA Registration No.047587)
14. Thiopental(TFDA Registration No.056637)
15. Valproic Acid(TFDA Registration No.033996)

GMP Current Good Manufacturing Practice

If a product is exported to the United States, it needs to apply to the U.S. Food and Drug Administration (FDA). After accepting the application, the FDA will send specialists to Taiwan for on-site assessment and verification. To enhance the quality of pharmaceuticals used by the public and expand the export of domestic products, the Ministry of Health and Welfare, following the full implementation of the "Good Manufacturing Practice" (GMP) by domestic pharmaceutical factories 10 years ago, announced the "Current Good Manufacturing Practice" (cGMP) with higher standards in May 1999. On October 21, 1999, it announced the "Implementation Table for Pharmaceutical Validation Operations" again, specifying the implementation schedule and requiring drug manufacturers to complete the validation of support systems, instruments, equipment analysis methods, and at least one key manufacturing process by July 1, 2000.

SCI Pharmtech's employees receive formal cGMP training when they join the company. Based on strict product control and adherence to cGMP standards, the APIs, intermediates, and other products manufactured by SCI Pharmtech are all produced under the principle of compliance with regulations and laws. SCI Pharmtech's products have passed the reviews of the Taiwan Food and Drug Administration, the U.S. Food and Drug Administration, the European EDQM, and health authorities in other countries. The company has established a comprehensive GMP inspection mechanism for APIs and API review cooperation to promote the safety and quality of public medication.

Passing U.S. FDA Inspection



11/01/2019
Dr. Weichyun Wong, PhD, President
SCI Pharmtech Inc.
Luzhu Dist. 309 No. 61 Ln.; Haihu N. Rd. Taoyuan City,

Dear Dr. Wong Weichyun, PhD:

The U.S. Food and Drug Administration (FDA) conducted an inspection at SCI Pharmtech Inc., FEI 3004065859, located at Luzhu Dist. 309, No. 61 Ln.; Haihu N. Rd., Taoyuan City, , from 09/02/2019 to 09/05/2019. FDA has determined that the inspection classification of this facility is "no action indicated" ("NAI"). Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of NAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by the appropriate CDER or CVM review office. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact Dell Moller via telephone at 614-227-5780 Ext. 1108 or email at Dell.Moller@FDA.HHS.GOV.[br]
Sincerely,

Dell Moller
Supervisory Investigator
300 River Place, Suite 5900 Detroit, MI 48207-4291 Telephone: (313) 393-8100 Fax: (313) 393-8139/8140

FDA U.S. FOOD & DRUG ADMINISTRATION

1

Passing EU EDQM Inspection

Certification of Substances Department

ATTESTATION OF INSPECTION

Inspected site	SCI PHARMTECH, INC. No. 61, Ln. 309, Haihu N. Rd. Luzhu District Taiwan 33856 Taoyuan City
Holder of the Certificate of Suitability	SCI PHARMTECH, INC. No. 61, Ln. 309, Haihu N. Rd. Luzhu District Taiwan 33856 Taoyuan City
References of CEP dossier	CEP 2009-030 / Pentoberbital Sodium
Inspection dates	21/11/2016 to 23/11/2016
Inspector / Name of organisation	Dr KLAES Maria, NATIONAL ORGANISATION FOR MEDICINES EOF, Greece Dr PARASCHOS Sotirios, EDQM, COUNCIL OF EUROPE
Scope of the inspection	The inspection focused on the compliance with the information provided in the above-mentioned application for a certificate of suitability, as well as the implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal Products in the European Union, Volume 4.
Conclusion	The company operates in accordance with the application submitted and the requirements of the Resolution AP-CSP (07) 1. This attestation is valid only in conjunction with a valid version of a CEP for the dossier mentioned above.

EDQM Inspection Reference number: INSP-2016-621-P01

Strasbourg, 2 June 2017

On behalf of the Director of EDQM

Passing Japan PMDA Inspection



認定番号 AG10600027
Number of accreditation

医薬品 外国製造業者認定証
Accreditation certificate of foreign drug manufacturer

氏名又は名称 Name (Name of corporation) SCI Pharmtech, Inc.

製造所の名称 Name of the manufacturing establishment SCI Pharmtech, Inc.

製造所の所在地 Location of the manufacturing establishment No. 61, Ln. 309, Haihu N. Rd., Luzhu Dist., Taoyuan City 33856, Taiwan

認定の区分 Accreditation categories 医薬品 一般(Non-sterile Drugs)

医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第13条の3の規定により認定された医薬品外国製造業者であることを証明する。
It is certified that the above manufacturer is certificated foreign drug manufacturer pursuant to Article 13-3 of the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals,Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics.

令和 4 年 7 月 19 日
2022 Year Month Day

厚生労働大臣 後藤 茂之
Minister of Health, Labour and Welfare Goto Shigeyuki

有効期間 Valid period From 令和 4 年 11 月 16 日 から 2022 Year Month Day
until 令和 9 年 11 月 15 日 まで 2027 Year Month Day

5130408020310

Marketing and Labeling

Standard Operating Procedures

"QA-024 Development, Review and Use of Shipping Labels"
"WH-002 Finished Product Warehousing and Shipping Procedures"

Packaging

The warehouse department should apply to the Occupational Safety Department for SDS, chemical hazard labels, and dangerous goods transport labels before shipment packaging. It should also apply to the Quality Assurance Department for shipping labels and shipping transport labels to be affixed to the outer packaging of finished products. Product packaging must also take protective measures to prevent product deterioration or collision according to its characteristics.

Labeling

API shipping labels should be submitted to the TFDA for application and approval before they can be used for shipping labels. The label information includes CAS no., SCI code no., Lot no., net weight, gross weight, manufacturing date, re-inspection date, and license number. The relevant label information content is agreed upon between the Sales Department and the customer.

Shipping

The Occupational Safety Department provides the Safety Data Sheet (SDS) to the transport personnel and customers for subsequent proper handling. Before shipment, the product does not leave the plant until it has been fully inspected by the Quality Assurance Department and photographed and documented.

Customer Satisfaction Survey

To establish long-term cooperative relationships with customers, SCI Pharmtech's sales unit uses email, telephone, meetings, and visits to respond to customer needs as quickly as possible, it also regularly or irregularly cooperates with customer audits to enable them to fully understand the company's operational status. Through continuous contact, customer and agent visits, or participation in exhibitions, the company collects market information, such as prices and their trends, Drug Master File (DMF) holders, potential customers, competitors, and regulatory requirements. It also introduces new products and plans to customers and keeps them informed of development progress to help them meet regulatory requirements.

SCI Pharmtech asks its sales unit to conduct a customer satisfaction survey every year. The survey includes nine scoring items: Quality, Label/Packaging, Lead time, Delivery, Services, Documentation, Safety, Competitiveness, and Repeated Order. Each item is scored on a scale of 1 to 5, and customers are asked to rate them. Based on customer suggestions, improvements are made to enhance customer satisfaction.

The company attaches great importance to customer feedback and is committed to properly coordinating customer complaint handling and satisfying customer evaluations of existing and new products.

The customer satisfaction survey scores for the past five years are shown in the table below. Customer feedback has remained in the highest scoring range.

SCI Pharmtech Customer Satisfaction Survey Results for the Past 5 Years

Note: The sampling target is customers with a transaction amount of NT$1.5 million or more.

Protecting Customer Privacy

We comply with the Trade Secrets Act and the Personal Data Protection Act, and refer to the ISO 27001 Information Security Management System (ISMS) standard to formulate internal management measures "IT-008.07 Document Management Protection," and create a sound information security management system. In addition to establishing a sound information security protection mechanism, we can also provide customers with safer and more stable services. In recent years, we have also paid attention to the EU General Data Protection Regulation (GDPR) and domestic personal data protection regulations, and implemented information security management and confidentiality mechanisms for various documents. From 2022 to 2023, there were no incidents of infringement of customer privacy or complaints due to loss of customer data.

Customer Information Security Control Items

- Personal information such as name, ID card or passport, address, and telephone number, as well as sensitive information that can directly or indirectly identify individuals, shall not be used or processed by the company without the authorization of the data subject.
- Due to the company's business involving the collection of sensitive data, data protection personnel have been appointed.
- Employees receive personal data protection training and email reminders.

Supply Chain Management

Pharmaceutical Supply Chain

API manufacturers and pharmaceutical companies have a supplier-customer relationship. In API contract manufacturing, SCI Pharmtech prioritizes quality, delivery time, product stability, and intellectual property protection. We build long-term trust and ensure stable supply to our customers. There were no significant changes in our supply chain from 2022 to 2023. However, the fire incident led to a temporary shutdown of our production lines in 2022, and to maintain short-term operations, we leased facilities and equipment from industry peers for off-site production and outsourced the manufacturing of cancer APIs required for our clients' clinical trials, mitigating the impact of supply disruptions on our customers.

SCI Pharmtech operates in the midstream of the pharmaceutical industry supply chain, providing APIs to pharmaceutical companies worldwide. The development of an API from initial development to market launch typically takes 2-3 years. We procure raw materials from fermentation companies, biotech firms, and chemical plants, and then manufacture high-quality APIs through chemical synthesis, extraction, crystallization, and purification. Only after successfully registering a Drug Master File (DMF) with the US FDA are we qualified to produce the API. Subsequently, if European and American generic drug manufacturers decide to use our API, we must also pass the PIC/s GMP certification system before we can truly become their API supplier.

Upstream

The upstream sector encompasses raw materials for pharmaceuticals, including natural substances, general chemicals, intermediates and active pharmaceutical ingredients (APIs) produced through semi-synthesis, as well as materials or APIs derived from plants, minerals, animal organs, microbial strains, and related tissues and cells.

Mid-stream

The midstream sector is the API industry, primarily comprising organic chemical industries. APIs are typically synthesized through biological or chemical methods, with chemical synthesis being the predominant approach due to its convenience, speed, and cost-effectiveness. Production methods vary depending on the source of raw materials.

Downstream

The downstream sector is the pharmaceutical formulation industry. It involves processing APIs with excipients, disintegrants, binders, lubricants, emulsifiers, and other pharmaceutical excipients into convenient dosage forms such as tablets, capsules, and ointments. Formulations can also be administered through injections, categorized as aqueous injections or powder injections based on their content properties.

Procurement Practices

Local sourcing and local supply are the procurement principles of SCI Pharmtech. However, most local raw material suppliers in Taiwan are petrochemical plants, which can only meet the needs for basic solvents. The raw materials used in the products are mostly fine chemicals, with most raw materials purchased from China and a small number ordered from Japan, India, Europe, and the United States. From 2022 to 2023, as production lines gradually recovered, the company's product lines have gradually resumed production. With the replenishment of basic solvent inventory and the increase in local supply sources, the local procurement ratio in 2023 has reached 44.13%, significantly higher than in 2021-2022 and higher than the local procurement ratio of 26.24% in 2022. In recent years, the company has been committed to energy conservation and carbon reduction in the supply chain, to shorten the transportation distance of raw materials and reduce greenhouse gas emissions, the source of goods has been shifted from Europe and the United States to neighboring countries such as China, India, Japan, and South Korea. In addition, solvent suppliers are mostly supplied by domestic manufacturers, while fine chemicals, equipment, and major equipment parts are still supplied from abroad.

Percentage of Local Purchases from 2020 to 2023



To ensure a stable and reliable source of raw materials, SCI Pharmtech maintains good cooperative relationships with major suppliers and continues to develop new suppliers. In order to promote the concept of sustainable operation to the supply chain, the company also requires the inclusion of relevant clauses in contracts, such as integrity, transparency, and responsibility in business ethics, human rights, and ethical policy norms. In addition to taking into account the quality, delivery time, and price of suppliers' products, the company also expects suppliers to fulfill their corporate social responsibilities in terms of ethics, labor rights, environment, health and safety, and management systems, and to implement risk management and business continuity plans.

Supplier Evaluation

To ensure that suppliers are capable of complying with SCI Pharmtech's supplier management measures, all new suppliers must pass QCDS (Quality, Cost, Delivery, Service) evaluation, environmental standards evaluation, and social standards evaluation before they can become approved suppliers (Approved Vendor List, AVL). New raw material suppliers must first provide samples for testing and then complete a questionnaire. The questionnaire covers information related to quality, environment, and animals. Suppliers are also required to sign a human rights and ethics policy to confirm their understanding of the requirements. The procurement unit then provides supplier information to various departments within the factory for joint evaluation. Finally, the Quality Assurance department summarizes whether an on-site audit of the factory is necessary. Only after completion of these steps are suppliers included in the list of qualified suppliers.

/ QCDS (Quality, Cost, Delivery, Service) Evaluation


SCI PHARMTECH, INC.
旭富製藥科技股份有限公司

供 應 商 評 核 表

評核期：

供應商名稱：Changchun Watson Fine Chemical Co., Limited	供應商代號：
交期 30%：	
☐ 30% 交貨符合預期	
☐ 20~29% 交期大致符合預期，偶有況容扣不影響成劑生產：_____%	
☐ 10~19% 交期大致符合預期，偶有況容且影響成劑生產：_____%	
☐ 9~1% 交期常態性延容並影響成劑生產：_____%	
☐ 0% 說明：	
價格 20%：	
☐ 20% 報價低於市場價	
☐ 10~19% 價格與市場相符，計價敘述又確標之形：_____%	
☐ 9~1% 價格高於市場且無議標空間：_____%	
☐ 0% 說明：	
異常處理 15%：依不合格品退貨、異常處理之時效及結果，市場缺貨之調度，專案調節之協助等等予以評分	
異常表處理：	
☐ 15% 如具有符合之處理述述	
☐ 14~10% 異常表處理態度良好且報高配合度佳：_____%	
☐ 9~1% 異常表處理態度☐一般；☐消極，☐超過時限：_____%	
☐ 0% 說明：	
配合度 15%：連絡時效、新品提供表說明、報價之時效及合理性，公司政策之配合等	
☐ 15% 供應商配合度良好；	
☐ 10~5% 供應商配合度☐佳；☐一般；☐超過時限：_____%	
☐ 4~2% 供應商配合度☐消極；☐差，☐超過時效：_____%	
☐ 0% 無配合意：說明：	
品質與環安系統及其他國際認證 20 %：	
☐ 5% ISO9001	
☐ 5% ISO14001	
☐ 10~0% _____%；超過兩個以上之認證仍評 10%	
☐ CRS；☐ ISO45001；☐ ISO50001；☐ cGMP；☐ 其他_____	
合 計： %	供應商結果判定： ☐ 核供應商


SCI PHARMTECH, INC.
旭富製藥科技

年度原物料供應商評核彙總表

PS

一、評定標準：

1. 交期 30%：以交易次數之準時度為計分標準。
2. 價格 30%：以該原物料之同業快速查出合理報價及與本公司交易議價空間，等因素權狀況評定。
3. 品質表現 15%：a.以合格檢驗不合格之原料進行計。
   b.異常處理通知後之處理時效及結果評定。
   c.市場缺貨時調貨能力之評估。
   d.客訴回報之協助處理能力。
4. 配合度 15%：a.樣本 sample 送樣之時效及配合。
   b.品質上之提供及解說。
   c.協調、溝通時效之配合與合理性。
   d.外場本公司設備之配合與調度。
   e.其他新倫理等之狀況評估。
5. 品質與環安系統之認證與執行 20%：依據其品質與環安系統之認證與否。

二、評核結果判定：

1. A 級：80 分以上為合格供應商。
2. B 級：70-80 分為為合格供應商，持續觀察中。
3. C 級：70 分以下為不合格供應商，次年度不可列其採購原料料，但特殊情況並經採購主管簽核同意者例外。

三、評核期間：每年第一季針對上年度執行評核，以作為當年度採購之依據。

採購主管：_____ 採購人員：_____


SCI PHARMTECH, INC.
旭富製藥科技股份有限公司

人權及道德政策
Human Right & Ethics Policy

(以下稱本公司)支持並遵守《聯合國世界人權宣言（UDHR）》(國際人權法典)、《國際勞工組織一工作基本原則與權利宣言》等國際公認之基本人權原則。
_____ (referred as the Company) supports and adheres to the fundamental principles of human rights recognized internationally, such as the Universal Declaration of Human Rights (UDHR), the International Bill of Human Rights, and the International Labor Organization's Declaration on Fundamental Principles and Rights at Work.

本公司訂定人權政策以保障與勞工，遵守相關以維護人權：
The Company has formulated a human rights policy to safeguard the rights and interests of current employees and also expects to comply with the following principles to uphold human rights:

- 遵循勞動基準法及相關適用法令，以保障員工權益。
  Adhere to The Labor Standards Act and applicable laws and regulations to protect employees' rights.
- 提供安全、健康與零騷擾的工作環境。
  Provide a safe, healthy, and harassment-free working environment.
- 以平等權用為原則，不因種族、國籍、年齡、性別、婚姻狀態、政治立場、宗教信仰等差別待遇或歧視，並保障原住民、移女、移工、弱勢人員與被派人士等弱勢團體或邊緣化團體的勞動權利。
  Follow the principle of equal employment, and not discriminate or treat individuals differently based on race, nationality, age, gender, marital status, political views, religion, etc., and protect the labor rights of vulnerable or marginalized groups, such as indigenous people, women, migrant workers, contract employees, and physically challenged individuals.
- 禁止強迫勞動、僱用童工。
  Prohibition of forced labor and child labor.
- 尊重隱私權與員工自由結社及行動自由之權利。
  Respect employees' right to privacy, freedom of association and freedom of movement.
- 支持並協助員工維持身心健康及工作生活平衡。
  Support and assist employees in maintaining physical and mental health and work life balance.
- 建立暢通勞資溝通管道，提供申訴機制。
  Establish smooth labor-management communication channels and provide complaint mechanisms.

Page 1 / 2


SCI PHARMTECH, INC.
旭富製藥科技股份有限公司

- 定期檢視及評估相關人權制度及作為。
  Regularly review and evaluate systems and actions relevant to human rights.

本公司履守最高的道德標準，包括：
The Company upholds the highest standards of ethics including:

- 採取零容忍政策來禁止任何形式的賄賂、貪污、賄款勒索和回扣。
  Having a zero-tolerance policy to prohibit any and all forms of bribery, corruption, extortion and embezzlement.
- 不接收好、提供、許諾、給予文物或國際公共的好文物不當收益。
  Bribes or other means of obtaining undue or improper advantage are not to be promised, offered, authorized, given, or accepted.
- 所有的業務來往應具適用度，並準確地記錄在賬簿和商業紀錄上，不得偽造紀錄或虛報任何賬目的狀況或情況。
  All business dealings should be transparently performed and accurately reflected on the Participant's business books and records. Falsification of records or misrepresentation of conditions or practices in the supply chain are unacceptable.
- 尊重知識產權，須以保護知識產權的方法傳遞技術和知識；並必須以保護智慧財產權的方式。
  Intellectual property rights are to be respected, transfer of technology and know how is to be done in a manner that protects intellectual property rights, and customer and supplier information is to be safeguarded.
- 廣告和競爭 應履守公平交易、廣告和競爭標準。
  Standards of fair business, advertising, and competition are to be upheld.
- 本公司制定溝通程序及制度來保護供應商和員工檢舉者，並確保其身份的機密性和匿名性。
  Establishing communication process and programs that ensure the confidentiality, anonymity and protection of supplier and employee whistleblowers are to be maintained.
- 承諾和確保個人資料的隱私合理期望(包括但不限於客戶、消費者和員工)的個人資料及隱私。
  Committing to protecting the reasonable privacy expectations of personal information of everyone they do business with, including suppliers, customers, consumers, and employees.

Supplier:

_____
Company stamp/ Official seal

Page 2 / 2

Supplier Audit

In addition to screening suppliers through supplier evaluations, the company conducts on-site audits of existing suppliers every five years. The Quality Assurance department regularly conducts audits of major raw material suppliers on-site, focusing on environmental protection, personnel training, and quality control. At the same time, it strengthens communication and exchanges with key suppliers to ensure that all requirements are effectively implemented.

Before the audit, an annual social responsibility survey is conducted with suppliers through a social responsibility questionnaire. During the audit, the company's Quality Assurance department identifies key suppliers for review this year based on the survey results and conducts on-site audits of these key suppliers. After the audit, suppliers are required to provide a Corrective Action Plan (CAP) and the company follows up on their subsequent improvement status.



SCI SCI PHARMTECH, INC. 旭富製藥科技

Part II: Related environment, health and safety program
(環安衛相關事項)

No	Article 項目	yes 是	no 否
1	Do you currently comply with the applicable local and national EHS legislation? 貴公司是否遵守當地或國家環安衛法令?		
2	Does your company / site have any EHS, Occupational Health or Environmental related litigation pending at present? 貴公司是否有任何關於環安衛、職業健康或環保懸而未決之案件?		
3	Do you execute safe and healthy management system? 貴公司是否執行安全及衛生管理系統?		
4	If not, does your company have an EHS organization / function (including EHS policy / manual / procedures) in place? 假如沒有，貴公司是否備有環安衛組織 / 功能 (包括環安衛政策 / 手冊 / 程序)?		
5	Do you execute the safe and health training for your employees? 貴公司是否對員工進行安全及衛生之訓練?		
6	Do you execute safe and health management system audit regularly? 貴公司是否定期執行安全及衛生管理系統稽核?		
7	Which kind of fire protection do you have on the site? 貴公司備有何種防火措施?		
	7.1 Site owned fire brigade / first aid team available 備有消防組 / 急救護理組		
	7.2 Public fire brigade available within 15 minutes 公有消防隊可在有效 15 分鐘到達		
	7.3 Fire evacuation drills regularly performed 定期舉行防火疏散訓練		
	7.4 Automatic or manual fire alarm systems installed 備有自動或手動火災警報系統		
8	Is personal protection utensils (safety shoes, safety goggles, ear plugs, gloves, etc.) readily available during working on your site? 在貴公司之所有工作場所，是否備有以下之個人防護器具 (安全鞋、安全眼鏡、耳塞、手套等)		

Information Security

Information Security Management Policy

In order to preserve overall information security, SCI Pharmtech reinforces the security management of various information assets to ensure its confidentiality, integrity, and availability, to avoid internal or external intentional or accidental threats and damages, resulting in the risk of tampering, disclosure, destruction or loss of business information. The company formulates special information security management policies for all employees (including external departments using information resources, service providers, outsourced manufacturers and other authorized users) to follow, so as to establish a reliable information and communication system, to improve information security and service quality of the R&D, production, and marketing of intermediates, APIs, and specialty chemicals.

The information security risk management of the company is coordinated by the Information Office under the President's office, the Auditing Office draws up relevant procedures for management and conducts regular internal audits. In case of changes in the organization, businesses, government regulations or the environment, etc., appropriate revisions shall be made and submitted to the President for approval to ensure the effectiveness of information security practices.

In order to ensure that each information system is free from any interference, destruction, intrusion or any improper behavior, SCI Pharmtech prevents internal and external threats through proper system planning, procedure specification and administrative management to achieve the purpose of sustainably maintaining the security of the information system. If an information security incident occurs that causes the information system to fail or affect operation efficiency, the department supervisor and the Information Office personnel will be promptly notified, and the affected information system or equipment will be immediately deactivated, and the current situation of the system will be retained for the IT personnel to review. The Information Office will also regularly evaluate the possibility of loss caused by information security risks, and purchase appropriate insurance if necessary to reduce the cost of losses.

The company carries out annual reviews and discussions on internal and external information security-related issues, stakeholder requirements, and other organizations' information security operation activities, and requires senior executives to actively participate in information security management and operation activities to provide support for the information security management system to ensure that all information security incidents or suspected security weaknesses are reported in accordance with appropriate reporting mechanisms, and are properly investigated and dealt with.Our specific management plans and objectives are as follows:

Basic internal information security risk protection measures within the company

1. The Information Office applies for intrusion protection services from Chunghwa Telecom on the Hinet network side to prevent internet viruses and intrusion attacks.
2. Builds a firewall to further block intrusion and virus attacks on the company's internal network.
3. Implements SAP ERP and Master Control, and enables the laboratory information management system in 2021 to achieve the goal of GMP management on data integrity.
4. The Information Office holds information security trainings and promotion activities to improve employee information security awareness and reduce the possibility of internal human error.

User side information security risk protection measures

1. Automatically delivers Windows Update to clients through the Windows Update Services Server, patching its vulnerabilities and prevent viruses and hackers from exploiting vulnerabilities.
2. In addition to installing Sysmantec enterprise antivirus software, the company also installs Palo Alto Tarps Advanced Endpoint Protection for enhanced protection.

Information security management goals

1. Strengthen internal control to prevent unauthorized access and ensure the confidentiality of the company's business-related information.
2. Guarantee the availability of the company's business-related information equipment, and provide the needs of business operations such as R&D, production and marketing.
3. Ensure that information will not be disclosed to unauthorized third parties during the transmission process or due to unintentional behaviors, so as to ensure the correctness and completeness of the company's business-related information, and improve operational efficiency and quality.
4. To have no information security incidents every year.
5. Perform an important system backup data restoration drill at least once a year.
6. Ensure that important and sensitive information is not leaked and is properly backed up, and internal audit is conducted once a year.

Digitized Management

2018	SAP® System	SCI Pharmtech officially introduced the SAP®/ system in 2018, this system can manage business, financial and accounting information in a timely manner, integrate the GMP-related equipment maintenance system, the warehouse management system, and the product quality control system, and improve data integrity and ensure that the computer runs in compliance with regulations.
2019	Master Control Electronic Sign-off	In response to the fact that the majority of drug certifications have adopted electronic system applications, SCI Pharmtech implemented the Master Control electronic audit system (electronic sign-off) in 2019 to manage the edit and compilation of documents.
2019	Environmental Safety Cloud System	In view of rapid changes in regulations and increasingly strict requirements, SCI Pharmtech introduced the Environmental Safety Cloud System - Enterprise Environmental Safety and Health Risk Control Platform in 2019, which can update the latest regulations, measures, and standards in real time. Compared with using the excel sheet before using the new service, information management after the simplified process saved about 70% of the operation time.
2021	LabWare LIMS	In order to improve data integrity, reduce human error and improve work efficiency, SCI Pharmtech officially launched LabWare Laboratory Information Management System (LIMS) in June 2021. The management system can not only comply with GAMP, ISO and other norms and standards, but also effectively integrate and manage laboratory samples, personnel, instruments, standards and other laboratory activities, and quickly search inspection batch numbers, instrument calibration and other laboratory activities, it is also one of the important elements for the company to become paperless.

03
Green Operations and Circular Innovation

Responsible Chemical Management

Before mass production of a product, the chemical management procedure assesses high-risk and hazardous substances for substitutes and reduced usage. The Occupational Safety and Environmental Protection unit jointly conducts environmental hygiene hazard and safety assessments of the production process, aiming to reduce the use of potentially hazardous substances to humans or the environment and lower risks during production.

To ensure that SCI Pharmtech can continuously identify various hazards that may arise from materials, machinery and equipment, the operating environment, and personnel behavior, and to continuously improve and reduce risks, the company has established the "Hazard Identification and Risk Assessment Operating Procedure (SA-037)." This procedure serves as a reference for occupational safety and health goals and management plans. The Occupational Safety and Health Committee is responsible for confirming and integrating assessment results and improvement items, as well as reviewing and approving unacceptable risks. The Occupational Safety Office participates in and assists with safety and health hazard assessments, provides relevant technical data, and confirms unacceptable risk items.

PSM Technical Guidance and Risk Assessment

In 2022, SCI Pharmtech commissioned the Safety and Health Technology Center to provide guidance on Process Safety Management (PSM) techniques to enhance safety during new product development and reduce risks before mass production. In 2023, the Buprenorphine product completed hazard identification and risk assessment. Through PSM technology in the experimental stage, unsafe factors were identified, and engineering improvements, controls, substitutions, and monitoring were implemented to prevent accidents.

Regular and Ad-hoc Assessments

SCI Pharmtech conducts regular safety and health risk assessments every two years. Ad-hoc assessments are conducted when units have process changes, new equipment, changes in raw materials, or changes in operating environment conditions. For example, before the production of new products, an assessment of on-site trial operation is conducted. When changes involve process chemicals, process equipment, process technology, or operating procedures, they are handled in accordance with "Change Control (SCI-020)."

Hazard Identification and Risk Assessment Process

The scope of hazard identification and risk assessment includes the operating environment of the manufacturing process, personnel routine and non-routine operating methods and procedures, existing safety equipment and management measures, and investigation results and reviews of past accidents. Each unit is required to fill out the "Hazard Identification and Risk Assessment Form (FSA589)" in accordance with regulations. The form includes the nature of the work, hazard factors, accident categories, existing protection/control measures, and risk level assessment. Accident categories are divided into five major categories: physical, chemical, biological, ergonomic, and other. The risk level assessment is conducted according to the "Risk Level Scoring Criteria and Response Strategies," analyzing the risk level from the frequency of work exposure, the probability of occurrence, and the severity of consequences.

Risks classified as levels 1, 2, and 3 are unacceptable risks. Each department needs to review factors such as regulatory compliance, stakeholder concern, degree of control, technology acquisition, investment amount, and impact on operations or business based on the assessment results, and formulate response strategies. These strategies include safety and health management programs, operational controls, emergency response measures, education and training, or wearing protective equipment. The results are compiled into an "Unacceptable Risk Control Table (FSA590)," which is submitted to the management representative for review and then to the President for approval. This serves as a reference for relevant units to formulate annual goals and management plans.

Risk Matrix

Severity of consequence / Risk Probability / Risk Grades	A	B	C	D	E	F
60~100	1	1	2	3	4	5
40~59	1	2	2	3	4	5
30~39	1	2	3	3	5	6
20~29	1	2	3	4	5	6
10~19	2	3	3	4	6	6
0~9	2	3	4	5	6	6

/ Hazard Identification and Risk Assessment Process Flowchart



/ Chemical Management Mechanism

High-Risk/Hazardous Substance Assessment and Substitution

- Conduct substitution and quantity reduction evaluations before product mass production.
- Ensure occupational safety by evaluating the hazards and safety of production processes and the environment.

Hazard Identification and Risk Assessment Procedures

- Risk review by the Occupational Safety and Health Committee.
- Evaluate occupational safety and health hazards.

Periodic and Non-Periodic Evaluations

- Conduct occupational safety and health risk assessments every two years.
- Perform ad-hoc assessments when there are changes in procedures or conditions.

Process Safety Management (PSM)

Engage professional organizations to assist in evaluating process safety technologies and enhance the safety of new product developments.

Risk Grading Assessment

- Utilize tools like the "Hazard Identification and Risk Grading Table (FSA589)" for risk level analysis.
- Departments review risk assessment results and prioritize management levels.
- Develop response measures, including management plans and operational protocols.

Management Audits and Approvals

- Management representatives conduct reviews and report to the President for approval.
- Departments set annual management goals and improvement plans for reference.

Toxic Substance Control

Currently, there are 50 types of toxic chemical substances operated in SCI Pharmtech's laboratory. In accordance with the "Toxic and Concerned Chemical Substances Control Act," operation records are filled out daily and reported regularly. There are 5 types of precursor chemicals operated in the laboratory, which are strictly controlled and not sold to individuals of unknown origin or manufacturers with non-compliant business items to prevent them from being used for drug production and violating the law.

Newly Added Toxic Chemical Substances in 2022-2023

1. Methyl tert-butyl ether - 90-95%
2. Hydrazine - 50-55%

Special Controlled Products

In 2021, the company's manufactured products included 2 controlled drugs. Through systematic sales management, no illegal activities have occurred so far, and we will continue to manage them cautiously and legally.

Production and Sales Control of Controlled Drugs

Before Production: Apply for manufacturing permit	After Production: Apply for export permit
Submit the estimated output and import permit from the competent authority of the exporting country (indicating the purpose and usage).	Provide the original import permit document and report the production quantity to the authorities after export.

Controlled Drugs Produced by SCI Pharmtech

Pentobarbital Sodium	A central nervous system drug used for sedation and hypnosis. In countries where euthanasia is legal, it is also used for assisted suicide and even as an injection for lethal injection. It is a controlled drug in most countries, and in Taiwan, it is a Class 3 controlled drug. Production and sales require prior application and approval, and the quantity is also controlled.
Methylphenidate	A "central nervous system stimulant" that can increase brain excitement, alertness, and reduce feelings of physical fatigue, keeping the patient's brain in a awake state. This drug can be used to treat "narcolepsy" in adults and "attention deficit hyperactivity disorder (ADHD)" in children. Long-term and high-dose use of this drug may lead to addiction or dependence. It is commonly known as "children's amphetamine" and is a psychiatric drug.

Environmental Management Approach

Environmental Protection Policy

SCI Pharmtech has formulated the "Environmental Protection and Occupational Safety and Health Policy." The Occupational Safety and Environmental Protection unit is responsible for drafting, planning, supervising, and promoting safety and health management matters. Environmental protection is the primary goal of the environmental management system, and implementing relevant environmental protection measures is the company's established management objective. Good environmental protection practices can achieve the highest respect and protection for human life, the ecosystem, and facilities. The company also promotes a responsible care system, continuously improves to meet the requirements of various standards, and ensures that all activities within the plant fully comply with and follow relevant regulations. These practices should be consistently maintained to effectively sustain the operations of various activities within the plant. SCI Pharmtech has implemented the ISO 14001 environmental management system, obtained third-party verification, and developed an effective environmental management system. Daily environmental management operations are carried out in accordance with the ISO 14001 standard to ensure that plant operations meet environmental requirements. The chemical industry has a significant impact on the environment, and SCI Pharmtech sets management indicators and targets for major issues related to the environment.

Environmental Protection and Occupational Safety and Health Policy



SCI PHARMTECH, INC.
旭富製藥科技股份有限公司

Environmental and Safety Policy

In Nineteen-eighty-seven, SCI PHARMTECH, INC has completed establishment to serve industries worldwide. Our main business is manufacturing active pharmaceutical ingredients and specialty chemicals to be supplied to pharmaceutical or chemical plants. The major equipment we use includes reactors, distillation units, kettles, millers, dryers, etc. The generated wastes with environmental impact are volatile organic compounds (VOC's), wastewater, waste solvents, general industrial waste, etc. The major occupational health and safety (hereafter safety) risks are accidents caused by equipment, hazardous chemicals, flammable chemicals, human errors, power failure, etc.

We are an environmental conscious manufacturer and commit ourselves to general environmental protection and employees safety - in addition to supply quality products. We place environmental protection and employees safety on our high priority list. We have installed waste handling equipment to reduce/eliminate VOC's and wastewater. Additionally, we contract certified waste management companies to dispose, recover, or incinerate our waste solvents or general industrial waste. To reduce accidents to the minimum, we have implemented preventive maintenance and know-hazards training program. We require our employees to follow written standard operation procedures strictly; the operators are required to wear/use appropriate personal protective garment/equipment at all time. As a responsible care company, we oblige ourselves to the following:

1. The line supervisors are responsible to enforce the environmental and safety policies. They review environmental and safety practices periodically; they enforce the policies by a "Plan-Doing-Check-Action" management cycle.
2. We educated our employees about environmental and safety policies on a continuous basis to ensure that all employees are following these policies faithfully.
3. We strive to comply with environmental and safety regulations; we have developed numerous standard operation procedures and measures to protect our employees, public interests, and environment.
4. We strive to eliminate pollutions and hazards, and constantly improve our practices.
5. We proclaim our policies and control measures to our employees, suppliers, contractors, neighbors, environmental groups, and more.
6. We furnish our customers with safety information regarding transportation, use, and disposal of our products.

We continuously review our objectives and practices to ensure our established environmental and safety goals are achieved. We are determined to enforce them faithfully to protect our environment, employees, and public interests. The politics are documented and are available for public review.

Environmental Regulations Compliance

From 2022 to 2023, SCI Pharmtech had 1 environmental violation, with a total fine of NT$108,000, mainly for violating the Water Pollution Control Act. The company has fully reviewed and strengthened education and training, improved the operation process, and there are no significant abnormal environmental violations. The company will continue to strive towards the goal of zero violations in the future.

Environmental Violations from 2022 to 2023

Violation Category	Number of Cases	Amount (NTD)
Waste Pollution	-	0
Air Pollution	-	0
Water Pollution	1	108,000
Toxic Substance Pollution	-	0
Total	1	108,000

Investment In Environmental Management Costs

Environmental protection is a critical issue that SCI Pharmtech values significantly. Major themes related to this include regulatory compliance and pollution prevention. Both the investment in environmental costs and various management indicators reflect our efforts in this area.

Environmental Costs and Proportion of Total Production Value in Recent Years



Environmental Management Performance

For each management item, we refer to the GRI and SASB standards, as well as local regulations and customer requirements, to formulate the following management indicators:

Item	SDGs Indicators	Target	2022-2023 Performance
1		Reduce the accumulation of outdoor waste, distill and recycle organic waste liquid/concentrate for classified organic wastewater treatment	Resale of by-products in 2023: MeOH: 680 barrels, EtOH: 141 barrels, ACT: 117 barrels, IPA: 29 barrels, TOL: 48 barrels, THF: 31 barrels, EA: 37 barrels, DEK: 48 barrels, Hexane: 17 barrels PF.HCl, VA, PEB product production and waste removal in progress, other inventory 0
2		Reduce VOC emissions leading to ozone pollution, implement air quality deterioration prevention plan	Taoyuan City Government Environmental Protection Bureau did not issue an air quality deterioration forecast
3		New chemical substance registration and existing chemical substance operation permit management, establish an internal new chemical substance and existing chemical substance registration mechanism and reporting	1. Completed annual manufacturing or import declarations 2. Registered 2 new chemical substance extensions 3. Registered 3 existing chemical substances 4. Standard registration of 5 first stage existing chemical substances
4		Increase the treatment rate of solvents after process use, distillation and recovery of solvents after process use	Solvent recovery rate by distillation in 2023 was 97.9% Sales processing rate in 2023 was 90.4%

Item	SDGs Indicators	Target	2022-2023 Performance
5		Soil and groundwater pollution prevention and control in the factory area, groundwater pollution remediation/ improvement of existing underground wastewater collection and transmission facilities	Pollution improvement measures have been completed and self-verification has been completed. The Environmental Protection Bureau has completed on-site sampling and evidence collection on November 1, 2023, and the site has been removed from the control list.
6		Reduce the accumulation of outdoor waste, add new treatment processes for strong acids (pH<2) or strong bases (pH>11) in the process or wastewater treatment plant	2023: PEB-wet-W1 (C-0202) cleared 182.72 tons W1-DEMBM-C (C-0299) cleared 0 tons W1-DEMBM-C cleared 0 tons EB-wet-W1 inventory 4 barrels
7		Reduce air pollution emissions from the process area	A plant area completed installation and testing of 4 sets of oxidation-reduction scrubbers
			B plant area completed installation and testing of 3 sets of oxidation-reduction scrubbers
8		Meet customer PSCI audit requirements, establish product PNEC and monitor API concentration in effluent	Completed PNEC reports for Duloxetine.HCL, Propafenone.HCL, Thiopental, PEB.Na, NAVA.

Item	SDGs Indicators	Target	2022-2023 Performance
9		Reduce the accumulation of nickel catalyst (Ra-Ni) in the factory area and establish proper disposal channels	Inventory 0 kg, all (11370 kg) handed over to Hong Jing Metal Corporation for disposal on March 23, 2023
10		Prevent waste leakage outside the factory, set up overflow ditches in the waste temporary storage area	Construction and acceptance completed in September 2023
11	  	Enhance the plant's emergency response capabilities and resources for toxic disasters/establish a professional emergency response personnel training system and registration for future reference in accordance with laws and regulations	1. Obtained professional emergency response personnel training for 2 expert level, 1 technical level, and 5 operation level personnel 2. Professional emergency response personnel for operation sites and joint defense organizations have been registered 3. Establishment of emergency response capabilities and resources is underway

Item	SDGs Indicators	Target	2022-2023 Performance
12		Greenhouse gas inventory and energy use	In response to the carbon tariffs imposed by European and American customers, the carbon tax levied by the Environmental Protection Administration, FSC supervision, and cooperation with the Group’s inventory, the company has launched internal and external verification operations for ISO 14064 organizational greenhouse gas and ISO 14067 product carbon footprint inventory since 2022. Obtained ISO 14067 product carbon footprint certification for 1 product in March 2023.

Climate Change Response and Adaptation

In response to global climate change trends, SCI Pharmtech conducts TCFD climate-related risk and opportunity financial impact assessments and continues to develop short-, medium-, and long-term greenhouse gas reduction targets and actions. The Board of Directors has established a Sustainable Development Committee, under which the President's Office, as the executive team, is responsible for identifying, assessing, and managing climate change-related risks and opportunities.

Identification of Climate Change Risks and Opportunities

In response to the increasing risks posed by climate change, SCI Pharmtech refers to relevant climate change information and the TCFD framework to identify short, medium, and long-term climate change risks and opportunities. These are ranked according to the degree of impact and the likelihood of impact, resulting in a risk matrix, and corresponding response measures are developed. The top three items in the 2023 risk matrix are: carbon fees and carbon border taxes as policy and regulatory risks, customer demands for carbon reduction and the development of a circular economy, and cost expenditures for developing low-carbon technologies for replacement, SCI Pharmtech has formulated appropriate management response measures for these risks. In the future, SCI Pharmtech will continue to strengthen the assessment and review of the potential impact of climate risks on the company from various aspects. In addition to adopting adaptation strategies to mitigate the impact of climate risks, the company will also actively seize opportunities for improving production efficiency and developing innovative products from the opportunity list.

Climate Risk Identification Process

Establish Risk Inventory

Based on the TCFD-recommended risk inventory, identify the risks that climate change poses to the company's operations, employees, customers, suppliers, products and services, and reputation.

Identify and Rank Risks

Assess the risks based on their likelihood of occurrence and the degree of impact, and create a risk matrix.

Confirm Key Risks

Review the key risks based on the ranking results, and identify three types of risks, for a total of four major risks.

Financially Quantify Key Risks

For the most important policy and regulatory risks, set scenarios and conduct financial quantification analysis.

The organization conducts climate-related risk identification by describing the short, medium, and long-term climate-related risks and opportunities it has identified, then ranks these risks in a risk matrix according to their severity and probability of occurrence to determine the most important climate-related risk issues. Finally, response strategies and potential opportunities are developed for each risk issue.

/ TCFD Risk Matrix



List of Climate Risk and Opportunity Issues and Financial Impacts

Risk/Opportunity Issue List

Issue No.	Issue	Risk Category	Issue Description	Impact Level
1	Proposed Carbon Fee	Policy and Legal	To address climate change, the government will levy a carbon fee.	High
2	Imposition of "Water Consumption Fee"	Policy and Legal	The government announced the amendment to the Water Act in February 2023, and will impose a "water consumption fee" on those who consume large amounts of water resources.	Medium
3	Carbon Border Adjustment Mechanism Imposed by Europe and the US	Policy and Legal	The European Union will start imposing a carbon border tax from 2026.	High
4	Customer Demand for Carbon Reduction	Market	Customers' green awareness is increasing, and the demand for low-carbon products continues to grow. Therefore, considering the product life cycle and product value chain, high-carbon products will have an impact on the company.	High
5	Company Reputation	Reputation	In recent years, with the ESG trend, investment institutions and financial institutions often focus on ESG performance when evaluating investments and loans. Failure to meet ESG sustainability requirements will negatively impact the company's reputation.	Medium
6	Flooding	Acute Physical Risk	In response to the impact of strong winds or typhoons caused by climate anomalies, the plant needs to stop production to avoid process hazards. Heavy rainfall/flood impacts leading to plant shutdown due to flooding will pose a risk of revenue loss.	Low
7	Water Shortage	Chronic Physical Risk	In response to water shortages or droughts caused by climate anomalies, there will be a risk of revenue loss.	Medium
8	Circular Economy	Technology	Invest in Framosa Company to leverage in-process purification technology and develop process solvent recovery technology for the pharmaceutical industry.	High
9	Reuse	Resource Efficiency	Recycle materials through purification and other methods to reduce production costs and increase internal recycling of products.	Medium
10	Low-Carbon Fuel or Renewable Energy	Resource Efficiency	Evaluate the installation of renewable energy systems such as solar power to reduce overall carbon emissions.	Medium

Financial Impact of Opportunity Issues

SCI Pharmtech plans to introduce the risk assessment mechanism recommended by the TCFD. In the future, it will evaluate the financial impact and feasibility of transition caused by increasingly stringent regulations and policies, extreme weather event risks, supply chain stability, and other analytical factors, assessing production, legal compliance, and changes in market demand.

Scope of Impact Legend: ▲Up Stream ●Operation ▼Down Stream

Issue No.	Issue	Risk Category	Scope of Impact	Impact Level	Issue Description	Potential Financial Impact	Management Strategy (Eliminate/Reduce/Accept Risk)
1	Proposed Carbon Fee	Policy and Legal	▲	High	The Legislative Yuan passed the third reading of the amendment to the "Greenhouse Gas Reduction and Management Act" to the "Climate Change Response Act" in January 2023, which will impose a carbon fee and stipulate preferential carbon fee rates and emission reduction quotas for deducting carbon fee emissions.	Currently, SCI Pharmtech is not yet included in the list of carbon emitters subject to carbon fee collection. The company's greenhouse gas emissions in 2023 is about 11,000 tons (Category 1 and Category 2), after the expansion of the EPA control list in the future, SCI Pharmtech may be included. Based the assumption of NT$300 per ton of emissions, it is estimated that about NT$3.3 million in carbon fees will need to be paid, which will increase expenses.	1. Conduct an annual greenhouse gas inventory to identify emission hotspots. 2. Promote energy-saving improvements and energy transition to reduce greenhouse gas emissions. 3. Develop carbon reduction targets and strategies. 4. Promote energy-saving technologies and strive for subsidies for carbon reduction projects. 5. Implement internal carbon pricing as an important indicator for performance evaluation, product operation, and investment evaluation to maintain competitiveness.
2	Imposition of "Water Consumption Fee"	Policy and Legal	●	Medium	The government announced the amendment to the Water Act in February 2023, and will impose a "water consumption fee" on those who consume large amounts of water resources.	Excess water volume and rate during the dry season are calculated at NT$3/$m^3$, with a 50% reduction before the end of 2025.	Increase the company's water recycling rate.

Issue No.	Issue	Risk Category	Scope of Impact	Impact Level	Issue Description	Potential Financial Impact	Management Strategy (Eliminate/Reduce/Accept Risk)
3	Carbon Border Adjustment Mechanism Imposed by Europe and the US	Policy and Legal	▼	High	The European Union announced the Carbon Border Adjustment Mechanism (CBAM) on July 14, 2021. High-carbon emission products such as cement, steel, electronics, plastics, and petrochemicals imported into Europe must declare their carbon emissions and pay a carbon tariff, which is expected to be officially implemented in 2027 and expanded to all categories of products in 2030. The collection method will be based on the difference in the "efficiency benchmark" of carbon emissions during the production process to pay the carbon border tax.	The company's main products that will be affected by future exports to the EU are organic chemicals, which will increase costs and be detrimental to product competitiveness. Our export value to the EU in 2023 was NT$636 million. Assuming a 10% increase in cost, the cost would increase by NT$63.6 million.	1. Continue to promote energy conservation and carbon reduction, energy transition, and circular economy to reduce carbon emissions per unit of product. 2. The domestic carbon fee can be used to reduce foreign carbon border taxes.
4	Customer Demand for Carbon Reduction	Market	●	High	Some EU customers have set a goal of halving carbon emissions by 2030 and will further require suppliers to participate in carbon reduction plans in the future.		1. Promote calculation of product carbon footprints to identify carbon emission hotspots in the life cycle of each product. 2. Promote carbon reduction plans for multiple material suppliers to increase competitiveness through supply chain carbon reduction.
5	Company Reputation	Reputation	●	Medium	As ESG is gradually gaining attention, financial institutions will take a company's ESG performance into consideration when evaluating investments and loans. The Ministry of Finance requires all public banks to sign a commitment not to provide loans for coal-fired power, and eight private companies, including Taipei Fubon Bank, have also pledged to join.	If SCI Pharmtech's actions in response to climate change fail to meet the requirements of financial institutions, it will negatively impact the company's reputation. If financial institutions increase lending rates as a result, interest expenses may increase.	1. Actively participate in the Carbon Disclosure Project (CDP), TCFD initiative, and Science Based Targets initiative (SBTi) in the future to fully demonstrate the company’s determination to promote ESG and its carbon reduction achievements, and strive for interest rate reductions. 2. Continue to observe the development schedule of renewable energy and relevant government regulations, and evaluate appropriate energy transition paths.

Issue No.	Issue	Risk Category	Scope of Impact	Impact Level	Issue Description	Potential Financial Impact	Management Strategy (Eliminate/Reduce/Accept Risk)
6	Flooding	Acute Physical Risk	●	Low	Heavy rainfall/flood impacts caused by climate anomalies, leading to plant shutdown due to flooding, will cause revenue loss.	Based on the 2023 revenue of about NT$1.2 billion, assuming a one-day shutdown due to heavy rainfall and flooding, the loss will be NT$4.86 million.	1. Regularly monitor and manage the plant's energy consumption and water usage every month. 2. Install additional water pumps to prevent flooding in the plant.
7	Water Shortage	Chronic Physical Risk	▲	Medium	Consider responding to the impact of water shortages caused by climate anomalies. In the case of limited water use, if it is not possible to cope, each process will be reduced in production. In the event of a severe water shortage, it will cause a reduction or shutdown of process production.	Based on the estimation that when plant area water supply reduces by 10%, the company's production capacity will be reduced to 80%; assuming that a 10% water restriction may occur for 4 months in the future, it will affect the company's revenue by NT$186 million.	1. Promote emergency water-saving measures. 2. The future new Guanyin plant plans to have an in-plant wastewater treatment plant to recycle water, which can be used as one of the water sources during the dry season.
8	Circular Economy	Technology	●	High	Leverage in-process purification technology to develop process solvent recovery technology for the pharmaceutical industry.	Jointly invested in Framosa Company with Veolia. The estimated solvent recovery rate is about 85%, and the annual solvent recovery volume is estimated to reach 23,000 tons in the future.	Established Framosa Company to increase the recovery rate of organic solvents in the pharmaceutical industry, which not only helps to reduce environmental pollution during the pharmaceutical production process, but also helps to save resources and energy consumption.
9	Reuse	Resource Efficiency	▼	Medium	Considering the product life cycle and product value chain, the company develops low-carbon products and carries out development from raw material recycling and process improvement. In addition to treating and recycling by-products generated in the process, it further recycles materials, which on the one hand reduces production costs and also promotes sustainable resource utilization.	For environmental sustainability, expand the introduction of a circular economy, increase the solvent recovery rate, and expand waste reduction to reduce raw material procurement and waste disposal costs.	Recycle by-products back into the process after purification, effectively reducing raw material usage and product carbon emissions.
10	Low-carbon Fuel or Renewable Energy	Resource Efficiency	●	Medium	The amendment to the "Renewable Energy Development Act" was officially passed in April 2019. Listed companies are required to install renewable energy equipment or energy storage system amounting to 10% of the company's contract capacity, or purchase renewable energy certificates, otherwise they must pay a fee.	Currently, SCI Pharmtech is not yet a listed company. After the expansion of the control list in the future, the estimated benefit of installing solar panels is about NT$2,300/kWp.	Invest in the construction of renewable energy, with an initial plan to install about 500kW of solar photovoltaic power.

Greenhouse Gas and Energy Management

SCI Pharmtech 2023 Material Topic "Energy Management and Greenhouse Gas Emissions" Response and Management Approach Elements and Evaluation

Material Topic	Energy Management and Greenhouse Gas Emissions
Corresponding GRI Indicators	• GRI 302-1 Energy consumption within the organization • GRI 302-3 Energy intensity • GRI 305-1 Direct (Scope 1) GHG emissions • GRI 305-2 Energy indirect (Scope 2) GHG emissions • GRI 305-4 GHG emissions intensity
Policies and Commitments	• SCI Pharmtech is committed to improving the utilization efficiency of various equipment and continuously improving product manufacturing processes to reduce the impact of the company's operations on the natural environment.
Goals and Targets	• SCI Pharmtech has been promoting various product carbon footprint projects since 2022. One product has passed ISO 14067:2018 verification, and it is expected to obtain ISO 14064-1:2018 verification in 2024. • Through carbon footprint and greenhouse gas inventory, SCI Pharmtech reviews emission hotspots, with the goal of reducing annual greenhouse gas emissions by 1%, striving to improve the utilization efficiency of various equipment, continuously improve product manufacturing processes, and reduce the impact of the company's operations on the natural environment.
Responsibilities and Resources	• The Environmental Protection Department and the Occupational Safety Office are responsible for the promotion and implementation of environmental protection, safety, and health related tasks. An Environmental Management Promotion Committee has been established to formulate the company's overall environmental safety and health policies and proposals, and the Labor Safety and Health Committee meets quarterly for discussion.
Evaluation Mechanisms and Results	• In 2022 and 2023, some production areas resumed operation. The total greenhouse gas emissions were 6,289 and 10,570 tons of CO_2e, respectively. The emissions from the resumed production areas in 2023 were about 63% of the emissions before the fire accident in 2020 (16,682 tons of CO_2e). • The plant uses automatic devices to turn on or off lighting, water dispensers, and automatic doors on a regular basis. • The air conditioner is turned on only when the room temperature exceeds 28 degrees Celsius, and it is set to turn off automatically. The air conditioning exhaust project in the office building has been improved.

Energy Management

Excessive energy use is a major contributor to climate change, as burning fossil fuels releases large amounts of greenhouse gases (GHG), leading to temperature increases. Therefore, efficient energy use is crucial to mitigating climate anomalies. Currently, our primary energy consumption is still mainly electricity and natural gas. In 2020, SCI Pharmtech's production value reached a new high of NT$19.0973 billion, with an energy intensity of 0.96 GJ/NT$10,000. Due to the fire at the end of 2020, many production lines were shut down, and energy consumption decreased significantly. The annual production value was only NT$282.44 million, and the energy intensity was 0.42 GJ/NT$10,000. From 2022 to 2023, with the resumption of work in different zones, energy consumption gradually increased, and the energy intensity in 2023 rebounded to 0.84 GJ/NT$10,000.

SCI Pharmtech's Energy Consumption in Recent Years

Energy	Energy Type	Unit	2019	2020	2021	2022	2023
Category 1	Diesel	Liter (L)	36,400	34,800	15,600	3,500	18,300
		Gigajoule (GJ)	1,279.91	1,223.65	548.53	123.07	643.47
	Natural Gas	Cubic Meter M³	3,215,920	3,266,457	4,547	667,439	1,213,235
		Gigajoule (GJ)	107,694.73	109,387.11	152.27	22,351.20	42,660.20
Category 2	Electricity	kWh	20,235,978	20,013,597	3,126,800	9,699,200	16,022,800
		Gigajoule (GJ)	72,849.52	72,048.95	11,256.48	34,917.12	57,682.08
Total Energy Consumption		Gigajoule (GJ)	181,824.16	182,659.71	11,957.28	57,391.39	100,985.75
Annual Production Value		Per NT$10,000	235,565	268,922	86,422	89,974	120,416
Energy Intensity		GJ／NT$10,000	0.77	0.68	0.14	0.64	0.84

Note:
1. 1kWh=0.0036GJ
2. Natural gas fixed source conversion standard at 8,000 Kcal/ m³
3. Energy intensity = annual production value ÷ total energy consumption

SCI Pharmtech's Energy Saving Measures in Recent Years

Process Optimization	Constructed an anaerobic tank, which can reduce the operating hours of the blower by about 50%.
Replacement and Renewal	Replaced the metal halide lamps used inside the warehouse with LED lights.
	Replaced and updated old chillers to improve efficiency and reduce energy consumption.
	Improved the air conditioning exhaust system in the office building to save electricity consumption.

Behavioral Adjustment	The air conditioner starts only when the room temperature reaches 28°C, and it has a timer for automatic shutdown.
	Plant lighting, water dispensers, automatic doors and other equipment and facilities are equipped with timers.
	Established a paperless work environment and promoted the reuse of recycled paper.

Greenhouse Gas Management

To address the risks posed by global climate change, relevant regulations and agreements are becoming increasingly stringent, such as carbon emission taxes or trade restrictions imposed by governments on imported products, forcing companies to reduce carbon emissions, promote energy transition, and implement mandatory emission reduction measures. To comply with relevant legal requirements, SCI Pharmtech will need to increase costs for technological upgrades or equipment renewal in the future. The company will continue to pay attention to relevant domestic and international regulations, while also imposing self-requirements to keep up with future industry trends and respond to regulatory changes in a timely manner to reduce risks and seek opportunities.

To address the global trend of carbon reduction and fulfill its corporate social responsibility, SCI Pharmtech is committed to the following: 1. Accurately monitor greenhouse gas emissions. 2. Propose greenhouse gas reduction plans. 3. Implement greenhouse gas reduction efforts. 4. Actively increase the proportion of green energy used.

To mitigate the risk impact of climate change, SCI Pharmtech's Board of Directors has approved the planning and timeline for greenhouse gas inventory and third-party verification, with the goal of completing third-party verification by 2026. Since 2022, various product carbon footprint projects have been successively carried out. One product has passed ISO 14067:2018 verification, and it is expected to obtain ISO 14064-1:2018 verification in 2024. Through carbon footprint and greenhouse gas inventory, the company reviews emission hotspots, with the goal of reducing annual greenhouse gas emissions by 1%, strives to improve the utilization efficiency of various equipment, continuously improves product manufacturing processes, and reduces the impact of the company's operations on the natural environment.

SCI Pharmtech's carbon dioxide emissions in 2020 were approximately 16,282 tons of CO_2e. However, due to the fire accident at the end of that year, normal production was not possible in 2021, so carbon dioxide emissions were significantly reduced to only 1,644 tons of CO_2e.

In 2022 and 2023, some production areas resumed operation, and the greenhouse gas emissions and intensity were as follows:

- 2022: Emissions 6,289 tons of CO_2e, intensity 7.0 tons of CO_2e/NT$ million. (Scope 1: 1,352 tons of CO_2e; Scope 2: 4,937 tons of CO_2e)
- 2023: Emissions 10,570 tons of CO_2e, intensity 8.8 tons of CO_2e/NT$ million. (Scope 1: 2,416 tons of CO_2e; Scope 2: 8,154 tons of CO_2e)

Greenhouse gas emissions from the resumed production areas in 2023 were about 63% of the emissions before the fire incident in 2020 (emissions in 2020 were 16,805 tons of CO_2e).

SCI Pharmtech's Greenhouse Gas Emissions in the Past 5 Years



Note:

1. The conversion factors for various fuels in Scope 1 refer to the Environmental Protection Administration's "Greenhouse Gas Emission Factor Management Table 6.0.4."
2. The conversion factor for Scope 2 is calculated based on the electricity emission factor announced by the Energy Administration, Ministry of Economic Affairs, for that year.

Air Pollution Control

According to the " Emergency Control Regulations for the Serious Deterioration of Air Quality," air quality deterioration warning levels are divided into two main categories pre-alert and deterioration, and five levels of seriousness based on the degree of pollution. Each level is determined based on whether the concentration of air pollutants such as suspended particles, fine suspended particles, sulfur dioxide, nitrogen dioxide, carbon monoxide, and ozone exceeds the standard.

Among them, ozone is a secondary pollutant, and its precursors are volatile organic compounds (VOCs) and nitrogen oxides. Therefore, the company has formulated corresponding VOCs reduction plans according to the different levels of pollution.

Air Quality Pollution Levels and SCI Pharmtech's Corresponding VOCs Reduction Plan

	Pollution Level	VOCs Reduction
Pre-Alert	Level 2 Pre-alert	>8%
	Level 1 Pre-alert	>10%
Deterioration	Level 3 Deterioration	>10%
	Level 2 Deterioration	>20%
	Level 1 Deterioration	>40%

In addition, volatile organic compounds (VOCs) generated from the process often become odorous due to process emissions or poor collection and treatment efficiency, and industrial VOCs odorous gases are particularly noticed by society. To effectively reduce VOC emissions, SCI Pharmtech has installed new structured oxidation-reduction scrubbers. These scrubbers utilize structured packing media in both the packing and demister layers. This media is woven from monofilament fibers with a specific structure, designed to promote liquid phase decomposition and maximize surface area for mass transfer. The advantages of structured packing media include maximized specific surface area, smooth drainage, and reduced consumable usage. This air pollution treatment system uses the principle of wet scrubbing and adds long-acting oxidants to catalyze and neutralize pollution sources in the process. A total of 3 units of 80CMM and 2 units of 50CMM are installed for process exhaust, and 1 unit of 500CMM and 1 unit of 350CMM are installed for environmental exhaust in Plant A and Plant B. Through the newly built air pollution control equipment, the company can effectively reduce air pollution emissions and improve the environment in the process area.

Other Major Gas Emission Statistics (Unit: Metric Tons)

Gas Emission Items	2019		2020		2021		2022		2023	
	Quantity	Percentage	Quantity	Percentage	Quantity	Percentage	Quantity	Percentage	Quantity	Percentage
Nitrogen Oxides (NOx)	3	4.7%	2.8	5.1%	-	-	0.3	12.2%	0.5	7%
Sulfur Oxides (SOx)	0	0%	0	0	-	-	0	0%	0	0%
Volatile Organic Compounds (VOCs)	61	95.2%	52.1	94.6%	-	-	2	82.5%	6.8	92.2%
Particulate Matter (PM)	0.06	0.1%	0.2	0.3%	-	-	0.1	5.3%	0.06	0.8%
Total	64.06	100%	55.1	100%	-	-	2.4	100%	7.36	100%

Note: Data testing on particulate matter (PM) and nitrogen oxides (NOx) emitted from natural gas combustion in boilers in 2021 was suspended due to the fire at the end of 2020.

Water and Waste Management

SCI Pharmtech 2023 Material Topic "Wastewater and Waste Management" Response and Management Approach Elements and Evaluation

Material Topic	Wastewater and Waste Management
Corresponding GRI Indicators	GRI 303-1 Interactions with water as a shared resource
	GRI 303-2 Management of water discharge-related impacts
	GRI 303-5 Water consumption
	GRI 306-1 Waste generation and significant waste-related impacts
	GRI 306-2 Management of significant waste-related impacts
	GRI 306-3 Waste generated
	GRI 306-4 Waste diverted from disposal
	GRI 306-5 Waste directed to disposal
Policies and Commitments	Although the treatment of wastewater and waste in the pharmaceutical industry is not easy, in order to fulfill corporate responsibility and reduce environmental impact, we have established Framosa through a joint venture with the French Veolia Group to address solvent recovery and other environmental issues, hoping to become a model of circular economy in the pharmaceutical industry.
Goals and Targets	Short-term goals • Increase the recyclability and reusability of raw materials or products. • Reduce the discharge of pollutants, toxic substances, and waste, and properly dispose of waste.
	Medium- and long-term goals • Reduce resource and energy consumption of products and services. • Maximize the sustainable use of renewable resources.

Material Topic	Wastewater and Waste Management
Responsibilities and Resources	Joined hands with the French Veolia Group to establish Framosa Company, focusing on "innovative circular economy technologies." Veolia is responsible for designing and providing management solutions for various environmental issues, hoping to expand the current wastewater and waste treatment capacity and solve the problem of solvent recovery and treatment in the pharmaceutical manufacturing process.
Evaluation Mechanisms and Results	• In 2021, due to the impact of the fire incident, normal production was not possible, and the total water consumption was significantly reduced to 28,000 tons. In 2022 and 2023, some production areas resumed operation, and the total water consumption (tap water consumption + recycled water consumption) was 104,000 tons and 259,000 tons respectively, which was 18% to 48% of the full operation in 2020.
	• In 2022 and 2023, some production areas resumed operation, and the total weight of waste was 2,800 tons and 3,500 tons respectively.
	• SCI Pharmtech unfortunately suffered a fire incident on December 20, 2020, which resulted in several environmental and public safety violations. Although most of them were force majeure incidents, there were also areas where the company itself was negligent and could be improved. All fines have been paid in full, and the required training courses have been completed.

Water Resource Management

The company's current water source is tap water, which is divided into four main categories within the plant: cooling water, boiler water, process water, and domestic water. In 2022 and 2023, some production areas resumed operation, and the total water consumption (tap water consumption + recycled water consumption) was 104,000 and 259,000 tons respectively.

Regarding the recycled water policy, the cooling water and high- and low-pressure steam used for heating and cooling in the process have a recycling mechanism to reduce the amount of raw water used. The annual recycled water consumption accounts for about 35-40% of the total water consumption. In the future, the company will gradually replace underground pipelines with elevated pipelines, which will not only clarify the direction of water supply in the plant, but also prevent a large loss of water resources in case of leakage.

SCI Pharmtech's Water Consumption in the Past 5 Years

Year	2019	2020	2021	2022	2023
Water Consumption Note[1] (tons)	498,342	544,209	28,433	104,000	259,000
Production Value (per NT$10,000)	235,575	268,922	86,422	89,974	120,416
Water Intensity (tons/NT$10,000)	2.12	2.02	0.33	1.16	2.15
Intensity Annual Increase / Decrease Rate	--	-4.34%	-83.74%	251.33%	86.08%

Note 1: Includes recycled water consumption in addition to tap water, recycled water consumption accounts for about 35-40%.

Note 2: The data in 2021 dropped significantly due to the impact of the fire incident on production capacity.



Recycled Water Usage Policy

Production process includes a recycling mechanism, including the recovery of cooling water and high- and low-pressure steam (35% to 40% of total water usage).

Future Plans

Gradually replace underground pipelines with elevated pipelines

Wastewater Treatment System Reconstruction and Innovation

Process wastewater has always been a difficult issue for major pharmaceutical technology companies. To fulfill our management responsibilities, SCI Pharmtech has proposed an integrated solution by monitoring, testing, and analyzing process wastewater data. In 2018, SCI Pharmtech officially launched a large-scale UASB anaerobic tank built at a cost of over NT$30 million and connected it to the original SBR, successfully improving sewage treatment capacity. The pollutants in the effluent is only half of the standard discharge value specified in the Water Pollution Control Act. The daily wastewater treatment volume increased from 550 CMD before the connection to 800 CMD, an increase of 45.5%, and as a result, a 600 CMD SBR reactor was shut down.

After the fire incident, SCI Pharmtech rebuilt the wastewater treatment system in 2021 and established two sets of wastewater biological treatment processes (activated sludge biological tank and anaerobic biological treatment tank). Starting from the source of the production process, SCI Pharmtech carries out wastewater diversion and classifies wastewater according to concentration and sewage characteristics (whether it contains nitrogen or toxic substances) for classified treatment. In addition, a dedicated wastewater pipeline to the Houbicuo drainage mainline is also installed to prevent industrial wastewater from flowing into irrigation channels.

SCI Pharmtech's ability to meet effluent standards is not only the result of the efforts of environmental protection colleagues, but also relies on waste reduction in the production process and energy-saving design of engineering equipment (such as high and low vacuum pumps). The entire treatment process is based on the two sustainable development goals of reducing energy consumption and responsible production, and continues to strive for the coexistence and co-prosperity of the company, the environment, and society.

Wastewater Treatment Process and COD Concentration at Each Stage

Process	Wastewater to be Treated	UASB Treatment	SBR Process
COD Concentration	10,000 ppm	2,000～3,000 ppm	50 ppm

Wastewater Treatment Volume and Effluent Pollutant Statistics in the Past 5 Years (Unit: Metric Tons)

	2019	2020	2021	2022	2023
Wastewater Treatment Volume	114,986	122,905	9,251	47,036	82,943
Effluent Pollutant COD	4,772	5,156	677	2,427	2,708
Effluent Pollutant BOD	1,679	756	22	491	174
Effluent Pollutant SS	1,276	909	166	253	730

Note: The influent volume dropped significantly in 2021 due to the impact of the fire incident on production capacity.

Waste Management

For waste management, SCI Pharmtech carefully evaluates and confirms that process pollutants can be effectively prevented or controlled during the product research and development stage. Only after the impact is reduced to an acceptable range through risk management can the product enter the mass production stage. Hazardous waste (waste liquid with a flash point of less than 60°C) generated during the process is entrusted to a cleaning and disposal company for incineration and thermal treatment. In addition, non-hazardous waste (including non-hazardous organic waste liquid or waste solvent, general garbage, sludge mixture, organic sludge) is also entrusted to a cleaning and disposal company for incineration and thermal treatment, and physical treatment respectively.

For the disposal of various materials, the company ensures that they are recycled and reused through appropriate methods as much as possible to avoid discarding and wasting materials. For example, the company actively reduces solvent usage and increases the recovery rate of solvents and catalysts , or purifies waste solvents into fuel. Regardless of the disposal method adopted, it must not pose a threat to the health and safety of colleagues or the environment. The issue of responsible production also includes product line planning. The company prioritizes high-value and high-technical threshold products to maximize resource efficiency.

SCI Pharmtech's Core Principles of Waste Management

Legalization	The company manages waste in accordance with the Waste Disposal Act, such as entrusting qualified companies to dispose, regularly declare, and properly store waste.
Environmental Benefit	The company adopts the concept of source reduction and resource recycling, considering raw material reduction and process solvent recovery at the process development stage.
Cost-Effective Disposal	Establish sales customers, sell recycled solvents such as ethanol, increase the reuse value of waste, to achieve zero waste of resources.

/ Disposal Methods for Hazardous and Non-Hazardous Waste in the Past 5 Years

Waste Type	Disposal Status of Waste Types		Total Weight (Metric Tons)				
	Disposal Method	Treatment Site	2019	2020	2021	2022	2023
Hazardous Waste	Preparation for Reuse	On-Site	330.000	330.000	-	-	-
	Recycle and Reuse	Off-Site	37.800	508.700	190.000	285.050	301.915
	Landfill	NA	1,948.400	1,572.100	195.700	167.230	896.590
	Other Disposal Operations	Off-Site	-	-	147.800	41.410	68.150
Non-Hazardous Waste	Preparation for Reuse	Off-Site	18.600	18.200	8.600	-	-
	Recycle and Reuse	Off-Site	783.800	1,049.200	2,827.700	1,375.960	1,045.160
	Incineration (Excluding Energy Recovery)	Off-Site	103.500	88.800	39.300	79.990	593.180
	Landfill	Off-Site	783.500	1,026.300	569.100	482.900	318.270
	Other Disposal Operations	Off-Site	-	-	9.200	334.960	223.970
		Hazardous Waste Subtotal	2,316.200	2,410.800	533.500	493.690	1,266.655
		Non-Hazardous Waste Subtotal	1,689.400	2,182.500	3,453.900	2,273.810	2,180.580
		Total	4,005.600	4,593.300	3,987.400	2,767.500	3,447.235

Note:

1. Reuse: Reuse of products or components that were originally intended to become waste for the same purpose, through inspection, cleaning, or repair operations.
2. Recycle: Reprocessing of products or components that have become waste into new materials.
3. On-site: Self-processing of waste.
4. Off-site: Waste is outsourced for processing.
5. Recovery of palladium metal, propyl n-pentanol aqueous solution, and zinc hydroxide solid, etc.

Circular Economy

A Model of Taiwan-France Cooperation in Circular Economy: SCI and Veolia's Innovative Green Solutions

Amidst the global call for sustainable development and environmental protection, all industries are seeking innovative solutions to achieve efficient resource utilization and recycling. SCI Pharmtech and the French Veolia Group have joined hands to establish Framosa Company. This collaboration aims to promote innovative circular economy technologies, particularly in the pharmaceutical industry.

The establishment of Framosa is the culmination of the collaboration between these two companies. Veolia is responsible for designing and providing water, waste, and energy management solutions, while SCI Pharmtech focuses on the research and development, production, and sales of active pharmaceutical ingredients and intermediates. The two parties established this company with a 60% and 40% stake respectively, positioning it as a platform to promote an innovative circular economy.

Enhancing Environmental Performance in the Pharmaceutical Industry

The core objective of Framosa is to increase the recovery rate of organic solvents in the pharmaceutical industry, which is crucial for reducing the environmental impact of pharmaceutical production processes. Through design changes, Framosa plans to increase annual production capacity from 15,000 tons to 23,500 tons and raise the solvent recovery rate to 85%. This series of measures will not only help reduce environmental pollution during pharmaceutical production but also contribute to saving resources and energy.

This Taiwan-France cooperation project is a model for circular economy initiatives, demonstrating the importance and value of collaboration between different countries and industries. Through joint efforts, SCI Pharmtech and Veolia have provided sustainable development solutions for the pharmaceutical industry. As global environmental problems become increasingly serious, such cooperation is not only of great significance to individual industries but also has a profound impact on achieving global sustainable development goals.

Transformation and Progress at SCI



Framosa's Green Loan and Future Prospects

In 2023, Framosa Company received recognition from the independent assessment organization Sustainalytics, confirming that it complies with the 2023 Green Loan Principles and obtained green financing of NT$1.35 billion from Sumitomo Mitsui Banking Corporation. Green loans are one of the 12 key strategies in the domestic "Net-Zero Emissions Path by 2050," aiming to use funds to guide domestic economic investment towards sustainable development and implement the emphasis on climate change and net-zero carbon emissions. Framosa meets the ESG sustainable development indicators of environmental protection, social responsibility, and corporate governance, and has received government recognition. It is believed that it can contribute to domestic net-zero carbon emissions in the future.

Integrated Solutions Under the Circular Economy Mindset

In the government's actively promoted "Five Plus Two" industry innovation plan, the "biomedical industry" and "circular economy" are two key industries. Framosa focuses on "innovative circular economy technologies." SCI Pharmtech introduces advanced in-process purification contract manufacturing technology to effectively improve the capacity utilization rate of the API industry. Veolia is responsible for designing and providing management solutions for various environmental issues. In addition to optimizing wastewater treatment efficiency, this also helps to solve the problem of solvent recovery and treatment used in the pharmaceutical manufacturing process.

SCI Pharmtech has applied to establish a new API manufacturing plant in the Guanyin Industrial Park. The in-process products generated in the process will be entrusted to Framosa for GMP-compliant purification contract manufacturing. After the contracted manufacturing is completed, they will be returned to SCI Pharmtech as usable raw materials. It is estimated that the annual solvent recovery volume can reach 23,000 tons in the future, with a recovery rate of up to 85%. It is expected to reduce carbon emissions by 11,000 tons of carbon dioxide equivalent per year (equivalent to 28 Daan Forest Parks). At the same time, SCI Pharmtech has also commissioned Framosa to design and build a wastewater treatment plant. By adding a water recovery unit, each unit of water can be reused 2.5 times, reducing the overall water footprint by 39%. This will realize the vision of green manufacturing and carbon emission reduction, and strengthen the sustainable development of the value chain.

Post-Disaster Recovery and New Construction Integration

SCI Pharmtech's 2023 Material Topic "Post Disaster Recovery" - Response and Management Approach Elements and Evaluation

Material Topic	Post Disaster Recovery
Corresponding GRI Indicators	Custom topic
Policies and Commitments	Make every effort and sincerity to properly handle post-disaster matters and repairs, and fully invest in post-disaster recovery, hoping to resume normal operations as soon as possible and protect the rights and interests of all stakeholders.
Goals and Targets	Short term goals • Increase production capacity to 60% in 2022 • Resolve compensation issues in 2022 • Fully repair all production lines in 2023 Mid term goals • Improve production efficiency • Build Guanyin plant to increase overall production capacity long term goals • Maximize production capacity in conjunction with the Guanyin plant and achieve record revenue
Responsibilities and Resources	An emergency response team was established during the disaster, and all departments were mobilized after the disaster to resume basic operations in the plant.

Material Topic	Post Disaster Recovery
Evaluation Mechanisms and Results	• March 2021: Signed a contract with Everlight Chemical to commission the production of cancer APIs required for clinical trials. • Late March 2021: Officially started production of the intermediate product Pyrogallolaldehyde at the Cheng Fong plant. • August 2021: Obtained a construction license for the Guanyin No. 2 plant from the Taoyuan City Government Office of Building Administration. • December 2021: Completed process equipment and air conditioning system verification for the 03B process area, and completed the restoration project; completed pre-shipment safety inspection of the newly purchased hydrogenation reactor for the 05 process area and arranged for it to be positioned in the plant. • March 2022: Plant A 03B/02/08 area accepted the GMP assessment and on-site and document review by the Food and Drug Administration. • May 2023: The GMP compliance assessment of Plant A production areas 15 and 16 was completed after review and confirmation by the Taiwan Food and Drug Administration. • December 2023: Plant B has submitted an application and is awaiting the Food and Drug Administration to schedule a date for inspection. • A total of 34 on-site or remote audits by customers were completed in 2023. Many APIs and intermediates have been produced in the rebuilt plant area and completed process validation.

Taoyuan Plant Post Disaster Recovery

After the fire incident, the chairperson coordinated the reconstruction plan. The strategic direction was to quickly restore part of the production capacity in the plant area, continue product research and development, seek external production capacity support, and re-plan the development of the Guanyin plot. In consideration of short-term production line transfer, the company negotiated equipment rental with suitable manufacturers while completing technical and regulatory assessments. The damage to the new R&D building was relatively minor. In addition to carrying out repair work, the established construction project was still carried out according to schedule, allowing the research and development of new products to continue. Various departments simultaneously carried out insurance claims, plant cleanup methods, plant and equipment repair assessment, communication with authorities and customers, commissioned production assessment, shipment of remaining products, and review of occupational safety matters. They also held frequent meetings with department managers to review the work schedule of each unit and track the progress of implementation, continuously accumulating momentum for operation recovery, and maintaining customer relationships, quality management systems, and drug licenses. The overall average production capacity recovered by about 35% in 2022. After three years of hard work, the reconstruction of the Taoyuan plant was finally completed in early 2024, and all compensation for losses to neighboring factories was handled peacefully and smoothly, the impact of the fire has lessened. The factory facilities have gone from being devastated after the disaster to being as good as new today. The bitterness and pain along the way are unforgettable. We will keep the lessons in mind and start again in the Year of the Dragon!

SCI Pharmtech Post Disaster Recovery Progress

2020/12

- 12/20 Fire broke out
- 12/22 12/22 Fire extinguished
- 12/23 Occupational safety accident investigation launched
- 12/31 Application submitted to the Ministry of Labor to terminate labor contracts with foreign colleagues

2021/01

- 01/04 Inventory of damaged plant area launched
- 01/23 Cliff's funeral
- 01/30 Safety assessment of damaged buildings conducted

2021/02

- 02/19 Signed a contract with Cheng Fong Chemical to lease its plant and related equipment

2021/03

- Sampling for safety assessment of damaged buildings started
- 03/18 Signed a contract with Everlight Chemical to commission the production of cancer APIs needed for customer clinical trials
- Officially started production of the intermediate product Pyrogallol aldehyde at the Cheng Fong plant in late March

2021/04

- Laboratory Information Management System (LIMS) officially launched for simulation testing
- Implemented the first phase of pipeline installation, supplying the R&D laboratory and pilot plant
- End of April first phase of demolition plan: production areas 03/05/06/07/08/10 not included in the building safety assessment

Green Operations and Circular Innovation

2021/05

Early May — Held a pre-production trial run and risk assessment meeting with Everlight Chemical

2021/06

Early June — Completed the architectural planning submission and applied for a construction permit for Guanyin Plant 2

Second phase of plant area demolition plan: production areas 01/01B/02/04/08/12/15/16/20/21/22/23/24/25

2021/07

Completed the construction of the second distillation production equipment

2021/08

The Taoyuan City Government Economic Development Bureau convened a "Meeting on Application of Resumption of Work", representatives from the city government's fire department, environmental protection bureau, labor inspection office, and building management office, together with SCI Pharmtech representatives, discussed the regulatory requirements and document procedures for resuming work.

Obtained a construction license for the Guanyin No. 2 plant from the Taoyuan City Government Office of Building Management.

2021/09

09/30 — Held a groundbreaking ceremony for the Guanyin plant and completed the city government's construction kickoff report

2021/10

Officially received the resumption of work notice for Plant A from the Taoyuan City Government Labor Inspection Office, approving the resumption of work from October 14th

2021/11

Conducted a joint inspection

2021/12

Completed equipment verification of process equipment and facilities and air conditioning systems in the 03B process area, and completed the restoration project

Completed pre-shipment safety inspections of the newly purchased hydrogenation reactor for the 05 process area and arranged for it to be positioned in the plant

2022/03

Planned to apply to the Food and Drug Administration for GMP assessment of Plant A 03B/02/08 area in March, and undergo on-site and document review

2022/05

Completed piping and power wiring for process equipment and distillation systems in production area 16 of Plant A, and started equipment leak testing and performance confirmation

2022/09

Continued equipment validation in the 05 process area and planned to complete it in early October

2022/10

Planned to complete the installation of the control system and arrange pre-trial operation testing and equipment validation

2022/11

Continued to push for resumption of production in Plant A. Some production equipment and ancillary peripheral equipment have been gradually positioned in the plant, and the preparation and placement of process pipelines have begun.

2022/12

Aim to complete the restoration of Plant B by the end of the year and restore 90% of production capacity

2023/01

Continued the restoration project in Plant A and started trial operation and performance confirmation of equipment to ensure the normal operation of all equipment

2023/02

Completed piping construction drawings for the 22A process area and started related installation work. The renovation progress of Plant B is also continuing.

2023/03

Completed the installation of the centrifuge in the 21 process area and carried out instrumentation wiring. The power distribution work for the public facilities' ice water system is also in progress.

2023/04

The process equipment project in the 21/22 process area progressed smoothly, and pre-trial operation work such as instrumentation operation testing and pipeline leak testing began.

2023/08

Entered the second phase of the restoration project. The process piping project and instrumentation and electrical engineering in the 23/24/25 process area have completed the bidding and contracting process, and the project implementation planning and pipe welding operations have begun.

2023/09

Conducted self-inspection and testing of various equipment and continued to promote the restoration and production preparation work in each process area.

Looking Ahead to the Guanyin Pharmaceutical Base

In January 2021, SCI Pharmtech collaborated with the French Veolia Group to re-plan the development of the Guanyin land, aiming to integrate modern pharmaceutical manufacturing with a circular economy, allowing this century-old pharmaceutical company to keep pace with the sustainable trend of ESG (Environment, Social, Governance).

To address the company's long-term development needs and enhance overall production capacity, SCI Pharmtech plans to build the Guanyin plant and diversify production locations to ensure supply chain stability. The expansion plan for the Guanyin plant includes four high-standard semi-automated production lines and collaborates with France on solvent treatment to create a high-performance and internationally competitive modern production base, significantly increasing the existing mature process capacity to meet customer demand.

However, in 2023, due to limited production capacity, SCI Pharmtech conducted production and reconstruction work simultaneously within the plant. Although this increased production to meet demand, it also led to an increase in the probability of foreign matter in products, which in turn triggered some customer complaints and returns. To avoid similar problems and potential occupational safety risks in the future, the Board of Directors decided in July 2023 to complete the construction of the Guanyin plant in one go and increase the budget to NT$2.44 billion. To ensure financial stability, the company therefore conducted a cash capital increase of NT$960 million.

The Guanyin plant will introduce an automated warehousing system and packaging equipment to create a smart factory. It is expected to apply for a use license and complete acceptance by the end of 2023, complete air conditioning, electromechanical, pure water, and wastewater system engineering in 2024, and have the main production equipment enter the site and undergo verification by the end of 2024. In 2025, product trial production verification and GMP inspections will be conducted, and the company plans to obtain GMP certification in 2025. Through these measures, SCI Pharmtech expects to improve resource utilization efficiency, create a high-value-added green pharmaceutical base, and promote the company's operational and environmental sustainability.

AI Integrated Factory. New Plant Ready to Soar

Introducing the automated storage system at our new Guanyin Plant

Improve Production Efficiency

Swift and accurate warehousing operations reducing errors and delays, and improving operational accuracy and reliability.

Optimize Space Utilization

Automatic storage and stacking according to the characteristics of the goods, and optimize storage and arrangement of goods to fully utilize warehouse space.

Enhanced Safety

Automation reduces safety risks caused by human operation, and is equipped with safety features and monitoring systems to ensure operational safety.

Reduce Labor Costs

Continuous system operation without interruption, saving work hours and human resources.

04 Employee-Friendly Workplace

Labor Relations

SCI Pharmtech 2023 Material Topic "Labor Relations" Response and Management Approach Elements and Evaluation

Material Topic	Labor Relations
Corresponding GRI Indicators	GRI 401-1 New and departing employees
Policies and Commitments	SCI Pharmtech upholds the employee care policy of respect, diversity, communication, equality, and compliance. Based on internationally recognized human rights standards such as the International Bill of Human Rights and the International Labor Organization Declaration on Fundamental Principles and Rights at Work, the company makes every effort to treat and respect all employees with kindness.
Goals and Targets	Short term goals • Strengthen employee communication channels and encourage employees to put forward constructive suggestions. • Reduce employee turnover rate. Medium term goals • Increase the retention rate of key technical personnel. • Optimize the work environment. long term goals • Develop a succession plan for middle and senior management.
Responsibilities and Resources	SCI Pharmtech has core production technology and market advantages, and can provide a working environment where professionals can apply what they have learned and demonstrate their talents. The company entrusts the human resources department to formulate sound training and welfare systems to stabilize labor-management relations.
Evaluation Mechanisms and Results	In 2023, SCI Pharmtech had 71 new employees, with an overall new employee rate of 27.95%; 19 departing employees, with an overall turnover rate of 7.48%; and 39 non-national employees, accounting for 15.35%.

Human Resources Structure

To protect employees' employment rights and maintain a stable and healthy labor-management relationship, SCI Pharmtech actively creates an equal, diverse, safe, and non-discriminatory work environment, hoping that colleagues can care for each other and thrive here, and attract outstanding talents to join, adding impetus to the company's sustainable development.

In 2023, SCI Pharmtech had a total of 254 employees, all of whom were full-time employees. Among them, there were 71 new employees, with an overall new employee rate of 27.95%; 19 departing employees, with an overall turnover rate of 7.48%; and 39 non-national employees, accounting for 15.35%.

SCI Pharmtech Employee Structure in 2023



/ Statistics on New Hires and Departing Employees in 2023



New Hires	24	Percentage 9.45%
Departing Employees	3	Percentage 1.18%



New Hires	44	Percentage 17.32%
Departing Employees	14	Percentage 5.51%



New Hires	3	Percentage 1.18%
Departing Employees	2	Percentage 0.79%

Note:

1. New employee ratio = number of new employees in the category / total number of employees at the end of the period in the category
2. Turnover rate = number of departing employees in the category / total number of employees at the end of the period in the category

Employee Rights Protection

Standards Compliance	Employee Communication	Diversity and Inclusion	Prohibition of Child Labor	Prohibition of Discrimination	Human Rights Protection	Zero Tolerance for Harassment
SCI Pharmtech adheres to international human rights standards, including those from the International Labour Organization, the Universal Declaration of Human Rights, and the UN Guiding Principles on Business and Human Rights. We also comply with local labor laws to ensure the rights and obligations of all employees are protected.	SCI Pharmtech uses multiple channels for communication, such as labor-management meetings, manager meetings, and an employee suggestion box. We actively seek employee feedback, understand their needs and expectations, and respond to their concerns.	We are committed to equal opportunity employment. Hiring and treatment of employees are based on qualifications and experience, without regard to nationality, political affiliation, race, religion, gender, age, or disability.	SCI Pharmtech strictly adheres to child labor laws, prohibiting the employment of anyone under 16 years of age, with robust recruitment and screening processes to verify age and prevent child labor. We have no history of employing underage workers or related labor disputes.	We recruit through public channels like recruitment agencies and our company website, ensuring job postings are detailed and transparent. We are committed to equal opportunity employment and comply with laws regarding the employment of people with disabilities and older workers.	SCI Pharmtech follows labor laws and regulations to protect human rights, employee property rights, and privacy, and provide annual human rights training to all employees once a year.	SCI Pharmtech has formulated the "Regulations for the Prevention, Complaint and Punishment of Sexual Harassment" to ensure workplace safety and prevent sexual harassment, and to maintain gender equality in employment and personal dignity. A Sexual Harassment Complaint Committee is established.

Minimum Notice Period for Operational Changes

SCI Pharmtech completed reconstruction work at the beginning of 2024, and production lines are being expanded one by one and the company's operations are growing quarter by quarter. During this period, we have continuously and gradually added new partners in production, but we still cannot alleviate the shortage of frontline manpower scheduling. After several applications to the Workforce Development Agency for the hiring of foreign workers, and many exchanges of documents, we finally obtained the hiring permits issued by the Agency. We have rehired one by one the foreign colleagues who worked with us in the past. This strong logistical support will inject a stable force into the production front.

Employee Benefits

Compensation

Our compensation policy aims to provide competitive salaries to attract and retain the talent necessary to support our operational needs and achieve sustainable growth. Employee compensation consists of fixed and variable components. Fixed salaries are paid monthly and are determined based on industry benchmarks and labor market statistics, and takes into account position responsibilities, nature of the job, professional skills, and market supply and demand. Variable compensation includes year-end bonuses and employee profit-sharing, linking a portion of employee earnings to our overall performance.

SCI Pharmtech has established a Salary Management Policy and a Performance Appraisal Policy. These policies are communicated to employees through new employee training and our internal email communication system, ensuring transparency and understanding of our compensation structure. Additionally, we have a policy outlining performance goals, compensation policies, systems, standards, and structures for managerial positions. Compensation and benefits for managerial roles require the approval of the Remuneration Committee and the Board of Directors, further enhancing corporate governance and transparency.

Average Employee Salary Over the Past Four Years (Unit: 10 Thousand)



Employee Welfare

At SCI Pharmtech, we believe our employees are our most valuable asset. In addition to providing a competitive compensation structure, we are committed to offering a comprehensive and diverse range of benefits. These benefits allow our employees to relax and recharge, while also promoting camaraderie and a harmonious workplace through various activities and initiatives.

2022~2023
Employee Benefits Cost

526 Million NTD

SCI Pharmtech Employee Welfare Programs

Retirement Security	• A Supervisory Committee of Business Entities' Labor Retirement Reserve as required by law oversees the monthly allocation of 5% of salaries into a dedicated retirement reserve fund held in a special account with the Bank of Taiwan. Since July 1, 2005, we have complied with the Labor Pension Act and contributed to the pension plan. Employees who choose this new system have 6% of their monthly salary contributed by the company to their individual pension accounts with the Bureau of Labor Insurance. • To further enhance retirement security, we have provided an employee annuity insurance plan since 2016. • An employee self-formed stock ownership association allows employees to contribute a portion of their monthly salary to a trust managed by CTBC Bank, helping them accumulate wealth over time.
Benefits	• Financial Incentives: Perfect attendance bonuses, year-end bonuses, employee profit-sharing, and holiday bonuses. • Insurance Coverage: In addition to mandatory labor and health insurance, we offer group insurance covering life insurance, hospitalization, accident insurance, cancer insurance, occupational accident insurance, and maternity benefits. • Meals: Free meals are provided to employees. • Accommodation: Employee dormitories are available. • Transportation: On-site parking is provided for employees. • Facilities: Employees have access to an employee cafeteria. • Social Activities: Employee gatherings and year-end parties. • Other Benefits: Employee uniforms and on-the-job training are provided. • Seniority Recognition: Employees receive seniority bonuses for their dedicated service at 5, 10, 15, 20, and 25 years of service. • Gender-Friendly Benefits: We offer a breastfeeding room, maternity check-up leave, paternity leave, and childcare leave to support employees emotional needs. • Employee Welfare Committee: This committee organizes employee travel, provides subsidies for employee weddings, funerals, and other life events, and arranges holiday bonuses and year-end parties.
Work-Life Balance	• A 45-minute lunch break and a 5:15 PM end of workday allow employees to avoid peak traffic hours. • Regular health check-ups are provided to all employees. • Specific health check-up items and health-level management programs are implemented. • Occupational health physicians conduct bi-monthly on-site visits, and nurses provide health consultation services six times per month. • The facility includes recreational areas and sports equipment, such as a basketball court, badminton court, fitness center, table tennis room, and billiards room. Various competitions are organized periodically.

Education and Training

SCI Pharmtech has established employee education and training methods, each department formulates an annual education and training plan and implements it after approval, and updates records and evaluates training results in a timely manner. Tailor-made courses are designed for employees in different positions and professional fields. Through internal and external education and training, colleagues can continue to learn professional knowledge, new industry knowledge and innovative thinking.

- Supervisor training: From time to time, supervisors will be educated and trained in professional fields, industry trends and management methods.
- New recruit training: New recruits will receive training courses on the personnel system, welfare measures, industrial safety and health requirements, and good manufacturing practices (GMP) within one week.
- External professional training: Heads of each department can assign colleagues to participate in external professional training according to work requirements, so as to improve the professional functions of employees and their work efficiency and quality.
- Security education and training: SCI Pharmtech's security is entrusted to Bowchen Security, which has completed all internal professional trainings. SCI Pharmtech's administrative department also conducts additional training on company introduction, responsibilities, personnel system, employee rights, fire safety and other items for new security personnel.
- General staff: The company conducts fire safety and disaster relief training, emergency response training, and SOP document issuance education training annually.
- Production workers: Production workers are given additional pre-production professional training before each production.
- Professional technical personnel training: Technical personnel are given training on the operation and handling of anoxic procedures, organic solvents, specialty chemicals, forklift driving, boiler operation, high-pressure gas specific equipment, stationary crane, and the procedures of various testing and analysis instruments. The company also provides professional certificate training on energy management and environmental protection related operations.
- Quality management training: The company also conducts annual training for GMP quality, ISO 9001, ISO 14001, ISO 45001 and other international standard management system certification training.

SCI Pharmtech is committed to enhancing the quality and capabilities of our workforce through ongoing employee training and development programs. These initiatives form the foundation for our sustainable business operations and growth. We have established an Employee Training and Development Policy that encompasses internal training, external training, and overseas study opportunities. Each department implements annual training plans, which are accessible to all employees on the company intranet and regularly updated.

In 2023, a total of 37,941 instances of internal training were recorded. This includes 13,343 instances within the Production Department, 1,695 within the Quality Assurance Department, 15,662 within the Quality Control Department, and 141 within the Occupational Safety Department. Additionally, 189 instances of external training were conducted, demonstrating positive learning outcomes. Total expenditure on external training in 2023 amounted to NT$669,547.

Performance Evaluation

According to SCI Pharmtech's Performance Appraisal and Human Resource Management Regulations, all employees are required to conduct regular performance and career development inspections. Evaluation results will reflect on the employee's career advancement and compensation growth, and encourage colleagues to cultivate their professional abilities. Through the communication and interaction between supervisors and employees, we hope to guide the direction of personal efforts in line with the company's development goals, thereby enhancing the company's overall competitiveness and organization efficiency.

2022～2023 External Training

Participants	Expenditure
313 Participants	947,000 NTD

05
Occupational Safety and Health

Occupational Hazards and Hazard Reporting Process

When the on-site alarm system is activated, the guard room will confirm the situation with the area supervisor and report back. If it is confirmed that there is no hazard, the guard room will deactivate the alarm. However, if a hazard is confirmed, a plant-wide announcement will be made, the emergency response mechanism will be activated, and an emergency response center will be established.



Occupational Accident Investigation and Improvement Measures

In 2022, SCI Pharmtech experienced two occupational accidents. The specific incidents are as follows:

1. February 24 Incident: An employee in the production department was injured when an angle iron fell from above during a barrel-filling operation.
2. December 29 Incident: A contractor accidentally fell at an opening.

Regarding the February 24 incident, the investigation revealed that the primary cause was residual materials left at the site by a contractor, which were not properly collected, bundled, and organized. As the production area was in the construction restoration stage with a higher number of contractors present, occupational safety and area supervisors needed to strengthen work area management and helmet supervision.

Regarding the December 29 incident, the investigation showed that the contractor entered a non-construction area where control and signage were inadequate. To prevent recurrence, SCI Pharmtech implemented the following corrective actions:

1. A comprehensive inspection of all openings with potential fall hazards was conducted, and protective covers were installed.
2. Access to construction areas was restricted to authorized personnel only, and safety signage was enhanced for clarity.

Following each incident, SCI Pharmtech followed established procedures to complete a "Workplace Safety Accident Investigation Report" to ensure thorough investigation and the implementation of appropriate corrective actions. These measures aim to strengthen workplace safety management, prevent similar incidents, and enhance the company's overall occupational safety performance.

Emergency Response Drills

To strengthen employee awareness of occupational safety and health, SCI Pharmtech has been collaborating with the Taoyuan City Fire Department's Third Emergency and Rescue Brigade to conduct annual disaster prevention and response drills since 2016. These drills simulate complex disaster scenarios, such as earthquakes and fires, incorporating real-life operations to practice activating emergency response mechanisms, guiding employee evacuation, providing emergency medical care to the injured, and conducting safe and efficient evacuations. By partnering with the fire department, we aim to reinforce our disaster response capabilities and implement effective preparedness measures to ensure appropriate handling of emergencies. In compliance with fire safety regulations, we conduct two fire drills annually and one large-scale fire and chemical disaster drill involving all employees. These exercises enhance employee awareness and preparedness, and respond effectively during emergencies and minimize casualties.

Fire Drill


Protective Equipment Demonstration


Chemical Spill Response Drill


Emergency First Aid Training


Public utilities natural gas drill; boiler natural gas leak emergency shutdown of the natural gas main station and fire drill




Refresher Training for Emergency Responders

To ensure the emergency response capabilities and quality of our first aid personnel, SCI Pharmtech has implemented annual 3-hour refresher training courses for first aid responders since 2018. Based on the specific needs of each department, additional personnel are sent to participate in initial first aid training. This training is also coordinated with the annual site-wide emergency drills to ensure that a team of first aiders is available to assist with emergency treatment, safeguarding the health and safety of all employees.

To ensure the effective implementation of our occupational safety and health management processes, we regularly verify the environmental and safety certifications of our personnel, and arrange for refresher trainings. We also provide safety awareness training to contract workers, temporary employees, and vendors. Additionally, a gate entry application process is in place for delivery and supply vendors accessing our facility.

Number of First Aid Certifications in the Past 5 Years

Year	2019	2020	2021	2022	2023
Number of Employees Trained	36	-	27	26	27

Employee Health Promotion

SCI Pharmtech prioritizes the health and well-being of its employees. We provide annual health check-ups for all employees, which include comprehensive examinations beyond the basic requirements. These additional tests cover liver function, gallbladder function, bone density, ultrasound (pelvic, prostate, abdominal, thyroid), and lung cancer screening. In 2022 and 2023, 214 employees underwent these enhanced health checks. In accordance with the " Regulations Governing the Labor Health Protection," we also provide specialized health examinations for employees working in specific job categories that involve exposure to certain elements. These include noise, dimethylformamide, benzidine and its salts, n-hexane, chromic acid and its salts, benzene, nickel and its compounds, and formaldehyde. We also arrange for on-site consultations with a physician who provides personalized health guidance, reinforces health education related to specific diseases, and conducts follow-up examinations, demonstrating our commitment to employee well-being.

Number of Health Check-ups Conducted in the Past 5 Years

Year		2019	2020	2021	2022	2023
General Health Check-ups		195	214	191	188	199
Special Hazard Health Check-ups	Dimethylformamide	22	21	22	20	25
	Noise	17	21	20	13	13
	Benzidine and its Salts(Note 1)	5	6	4	6	5
	n-Hexane(Note 2)				15	29
	Chromic Acid and its Salts(Note 2)				5	5
	Nickel and its Compounds(Note 3)					3
	Benzene(Note 2)				5	
	Formaldehyde(Note 3)					3

Note 1: "Benzidine and its salts" was added as a special health check-up item in 2019.

Note 2: "N-hexane, chromic acid and its salts, benzene" were added as special health check-up items in 2022.

Note 3: "Nickel and its compounds, formaldehyde" were added as special health check-up items in 2023.

Occupational Safety and Health Improvement Measures

To eliminate unsafe factors within our facilities, supervisors conduct regular walk-through inspections to ensure employees are using personal protective equipment (PPE) correctly, we also routinely review safety operation standards and conduct hazard identification and risk assessments. Whenever possible, we prioritize purchasing equipment and instruments with inherently safe designs, and select comfortable PPE to encourage greater usage and provide ongoing training to reinforce a strong safety culture. By combining these proactive measures, we aim to cultivate safe working habits for all employees.

Occupational Safety and Health Initiatives

Initiative	Target	Performance Indicator	Management Plan
Mandatory Safety Training	Specialized personnel initial and refresher training (including Class 1 pressure vessel operators)	Establish SOPs for equipment certification and training for legal compliance across all areas.	Implementation Period: 12/21/2021 - 12/30/2022 Ongoing initial and refresher training for Class 1 pressure vessel operation and forklift operation.
Static Electricity Control in Production Areas	Measure static voltage of reaction vessels and pipelines in production areas. Improve grounding and jumper cabling.	Static voltage measurements below 4KV.	Implementation Period: 12/21/2021 - 12/30/2022 Procure static electricity meters to measure static voltage in production areas and improve grounding and jumper cabling.
Pedestrian and Vehicle Control During Demolition/ Reconstruction and Transportation	Control the movement of large machinery and vehicles within the facility to prevent accidents.	Zero accidents per month due to pedestrian and vehicle collisions during the restoration period of Plant A and Plant B.	Implementation Period: 7/5/2021 - 12/30/2022 Promote a zero-accident safety culture.
Chemical Incompatibility Assessment for New Product Production	Pre-evaluate and identify hazard characteristics of new products.	Revise SOP SA-025 for pre-production safety risk assessment procedures. Include data on thermal and chemical stability and material compatibility.	Implementation Period: 7/5/2021 - 12/30/2022 Promote Process Safety Management (PSM) and process safety assessments.
Leakage Alarm System	Establish an alarm system to detect VOCs, oxygen, hydrogen, and natural gas leaks.	100% inspection and re-establishment of detectors.	Implementation Period: 12/21/2021 - 12/30/2022 Establish a leak detection and alarm system.

Occupational Safety and Health

Our occupational safety and health practices include implementing mandatory safety training, controlling static electricity in production areas, managing pedestrian and vehicle traffic during demolition/reconstruction and transportation, assessing chemical incompatibility for new products, and implementing a leakage alarm system. We also conduct regular inspections of hazardous machinery and equipment, including boilers, high-pressure gas-specific equipment, Class 1 pressure vessels, and elevators. From 2022 to 2023, we completed model confirmation, construction completion, periodic welding, and structural inspections for all relevant equipment.

/ Periodic Inspection of Hazardous Machinery and Equipment

Equipment Category	Equipment Name/Model	Inspection Certificate Number	Expiration Date
Boiler	Horizontal smoke tube boiler (2 tons) Horizontal smoke tube steam boiler (6 tons) Horizontal once-through oil boile	11B3314160002 11B33C1070001 11B33C1070002	2024/04/07 2024/07/27 2024/07/27
High-Pressure Gas Equipment	Vertical liquid nitrogen storage tank Vertical jacketed hydrogenation reactor (R3102)	211108S0709 211111S0313	2024/9/8 2024/5/16
Class 1 Pressure Vessel	Vertical jacketed 4000L hydrogenation reactor (R501A) Vertical jacketed 4000L hydrogenation reactor (R501B) Vertical jacketed hydrogenation reactor (R501C) Vertical jacketed hydrogenation reactor (R1609)	211111P0740 211111P0741 211111P0739 211111P0488	2024/8/11 2024/8/11 2024/8/11 2024/5/8
Elevator	High-rise warehouse elevator Office building elevator R&D building elevator (passenger and freight) R&D building elevator (passenger)	036B032651 040126563 036B048062 040211796	2024/9/29 2024/7/09 2024/9/29 2024/8/04

Occupational Injury Statistics

In 2022, one serious occupational injury occurred due to a fall accident involving a contractor at an opening. This resulted in a serious injury rate of 0.499 and a recordable injury rate of 0.998. Historically, "contact with harmful substances" has been the most frequent category of occupational injury.

Occupational Injury Statistics at SCI Pharmtech in the Past Two Years

Year	Hours Worked	Minor Injuries	Minor Injury Rate	Serious Injuries	Serious Injury Rate	Fatalities	Fatality Rate	RecordableInjuries	RecordableInjury Rate
2022	400768	1	0.499	1	0.499	0	0	2	0.998
2023	508024	0	0	0	0	0	0	0	0

Note:

1. Occupational injury statistics do not include "commuting accidents" that occur during travel to and from work.
2. Minor Injury Rate = (Number of Minor Injuries x 200,000) / Total Hours Worked
3. Serious Injury Rate = (Number of Serious Injuries x 200,000) / Total Hours Worked
4. Fatality Rate = (Number of Fatalities / Total Hours Worked) x 200,000
5. Recordable Injury Rate = (Number of Recordable Injuries x 200,000) / Total Hours Worked

Disability Injury Statistics at SCI Pharmtech in the Past Two Years

Year	Days Lost Due to Disability Injury	Disability Injury Frequency (FR)	Disability Injury Severity Rate (SR)	Comprehensive Injury Index (FSI)	Injury Category
2022	64	4.99	159.69	0.89	Crush injuries, fall injuries
2023	0	0	0	0	-

06
Social Engagement

Community Engagement

A. Sponsored local temple events and contributed to temple funds.
B. Sponsored athletic events at Haihu Elementary School.
C. Sponsored Mid-Autumn Festival celebrations in Haihu and Binhai villages.
D. Provided location support for national military training exercises.
E. Participated in community activities and maintained positive relationships with residents.
F. Conducted joint fire drills with the Shanjiao Fire Brigade.

Social Services and Public Welfare

A. Joined the Republic of China Criminal Investigation and Prevention Association to support the development of public welfare initiatives in law enforcement.
B. Donated NT$150,000 to the Chang Chao-Ting Memorial Foundation to sponsor research and publications in science, culture, and talent development.
C. Contributed NT$30,000 to the BIO Asia-Taiwan Conference to showcase Taiwan's biotechnology industry and attract global talent and research resources.

Appendix

Independent Auditor's Report

附件9：最近年度經會計師查核簽證之公司個體財務報告

KPMG 安侯建業聯合會計師事務所
KPMG
台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)
電 話 Tel + 886 2 8101 6666
傳 真 Fax + 886 2 8101 6667
網 址 Web kpmg.com/tw

會 計 師 查 核 報 告

旭富製藥科技股份有限公司董事會　公鑒：

查核意見

旭富製藥科技股份有限公司民國一一一年及一一〇年十二月三十一日之資產負債表，暨民國一一一年及一一〇年一月一日至十二月三十一日之綜合損益表、權益變動表及現金流量表，以及個體財務報告附註(包括重大會計政策彙總)，業經本會計師查核竣事。

依本會計師之意見，上開個體財務報告在所有重大方面係依照證券發行人財務報告編製準則編製，足以允當表達旭富製藥科技股份有限公司民國一一一年及一一〇年十二月三十一日之財務狀況，暨民國一一一年及一一〇年一月一日至十二月三十一日之財務績效與現金流量。

查核意見之基礎

本會計師係依照會計師查核簽證財務報表規則及審計準則執行查核工作。本會計師於該等準則下之責任將於會計師查核個體財務報告之責任段進一步說明。本會計師所隸屬事務所受獨立性規範之人員已依會計師職業道德規範，與旭富製藥科技股份有限公司保持超然獨立，並履行該規範之其他責任。本會計師相信已取得足夠及適切之查核證據，以作為表示查核意見之基礎。

關鍵查核事項

關鍵查核事項係指依本會計師之專業判斷，對旭富製藥科技股份有限公司民國一一一年度個體財務報告之查核最為重要之事項。該等事項已於查核個體財務報告整體及形成查核意見之過程中予以因應，本會計師並不對該等事項單獨表示意見。本會計師判斷應溝通在查核報告上之關鍵查核事項如下：

一、存貨評價

有關存貨評價之會計政策請詳個體財務報告附註四(七)存貨；存貨評價之會計估計，請詳個體財務報告附註五；存貨及相關費損之附註說明請詳個體財務報告附註六(五)存貨。

KPMG

關鍵查核事項之說明：

旭富製藥科技股份有限公司因製藥產業特性，產品係為特定客戶製造，並依客戶需求提供各批次規格差異化服務，因此旭富製藥科技股份有限公司於估計存貨淨變現價值時，若無客觀之近期銷售價格資訊可供參考時，須個別評估該品項市場需求變化等諸多不同因素後，判斷該批產品淨變現價值。因其估計之允當合理有可能影響存貨之評價，故本會計師認為旭富製藥科技股份有限公司存貨備抵跌價損失之評估測試為本年度查核最重要事項之一。

因應之查核程序：

本會計師對上述關鍵查核事項之主要查核程序包括：

- 評估旭富製藥科技股份有限公司存貨跌價或呆滯提列政策之合理性，包括評估市場變化、考量客戶需求及存貨去化狀況以判斷存貨呆滯項目之合理性。
- 執行存貨回溯性測試，檢視存貨報廢情形與呆滯損失提列政策以驗證本期存貨呆滯損失提列是否允當。
- 執行抽核程序以檢查旭富製藥科技股份有限公司所採用之銷售價格，以評估存貨淨變現價值之合理性。

二、收入認列

有關營業收入認列之會計政策請詳個體財務報告附註四(十五)收入認列。

關鍵查核事項之說明：

旭富製藥科技股份有限公司主要產品為原料藥及中間體等。惟主要交易對象多為國外藥廠，由於交易條件不盡然相同，且因收入認列涉及人工作業調整，可能存在收入認列時點不適當之風險，故本會計師認為旭富製藥科技股份有限公司收入認列為本年度查核最為重要的評估事項之一。

因應之查核程序：

本會計師對上述關鍵查核事項之主要查核程序包括：

- 測試銷貨及收款作業循環之相關控制。
- 執行銷貨收入細部測試。
- 選取資產負債表日前後一段期間之銷售交易，測試銷貨是否認列於正確期間，以評估旭富製藥科技股份有限公司營業收入認列時點之正確性。

管理階層與治理單位對個體財務報告之責任

管理階層之責任係依照證券發行人財務報告編製準則編製允當表達之個體財務報告，且維持與個體財務報告編製有關之必要內部控制，以確保個體財務報告未存有導因於舞弊或錯誤之重大不實表達。

於編製個體財務報告時，管理階層之責任亦包括評估旭富製藥科技股份有限公司繼續經營之能力、相關事項之揭露，以及繼續經營會計基礎之採用，除非管理階層意圖清算旭富製藥科技股份有限公司或停止營業，或除清算或停業外別無實際可行之其他方案。

旭富製藥科技股份有限公司之治理單位(含審計委員會)負有監督財務報導流程之責任。

會計師查核個體財務報告之責任

本會計師查核個體財務報告之目的，係對個體財務報告整體是否存有導因於舞弊或錯誤之重大不實表達取得合理確信，並出具查核報告。合理確信係高度確信，惟依照審計準則執行之查核工作無法保證必能偵出個體財務報告存有之重大不實表達。不實表達可能導因於舞弊或錯誤。如不實表達之個別金額或彙總數可合理預期將影響個體財務報告使用者所作之經濟決策，則被認為具有重大性。

本會計師依照審計準則查核時，運用專業判斷及專業懷疑。本會計師亦執行下列工作：

1.辨認並評估個體財務報告導因於舞弊或錯誤之重大不實表達風險；對所評估之風險設計及執行適當之因應對策；並取得足夠及適切之查核證據以作為查核意見之基礎。因舞弊可能涉及共謀、偽造、故意遺漏、不實聲明或踰越內部控制，故未偵出導因於舞弊之重大不實表達之風險高於導因於錯誤者。

2.對與查核攸關之內部控制取得必要之瞭解，以設計當時情況下適當之查核程序，惟其目的非對旭富製藥科技股份有限公司內部控制之有效性表示意見。

3.評估管理階層所採用會計政策之適當性，及其所作會計估計與相關揭露之合理性。

4.依據所取得之查核證據，對管理階層採用繼續經營會計基礎之適當性，以及使旭富製藥科技股份有限公司繼續經營之能力可能產生重大疑慮之事件或情況是否存在重大不確定性，作出結論。本會計師若認為該等事件或情況存在重大不確定性，則須於查核報告中提醒個體財務報告使用者注意個體財務報告之相關揭露，或於該等揭露係屬不適當時修正查核意見。本會計師之結論係以截至查核報告日所取得之查核證據為基礎。惟未來事件或情況可能導致旭富製藥科技股份有限公司不再具有繼續經營之能力。

5.評估個體財務報告(包括相關附註)之整體表達、結構及內容，以及個體財務報告是否允當表達相關交易及事件。

6.對於採用權益法之被投資公司之財務資訊取得足夠及適切之查核證據，以對個體財務報告表示意見。本會計師負責查核案件之指導、監督及執行，並負責形成旭富製藥科技股份有限公司之查核意見。

本會計師與治理單位溝通之事項，包括所規劃之查核範圍及時間，以及重大查核發現(包括於查核過程中所辨認之內部控制顯著缺失)。

本會計師亦向治理單位提供本會計師所隸屬事務所受獨立性規範之人員已遵循會計師職業道德規範中有關獨立性之聲明，並與治理單位溝通所有可能被認為會影響會計師獨立性之關係及其他事項(包括相關防護措施)。

本會計師從與治理單位溝通之事項中，決定對旭富製藥科技股份有限公司民國一一一年度個體財務報告查核之關鍵查核事項。本會計師於查核報告中敘明該等事項，除非法令不允許公開揭露特定事項，或在極罕見情況下，本會計師決定不於查核報告中溝通特定事項，因可合理預期此溝通所產生之負面影響大於所增進之公眾利益。

安侯建業聯合會計師事務所

會計師：郭芸綾 許永敏

證券主管機關：金管證審字第1010004977號
核准簽證文號：金管證六字第0940100754號
民國 一一二 年 三 月 十四 日

KPMG 安侯建業聯合會計師事務所
KPMG
台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)
電 話 Tel + 886 2 8101 6666
傳 真 Fax + 886 2 8101 6667
網 址 Web kpmg.com/tw

會 計 師 查 核 報 告

旭富製藥科技股份有限公司董事會 公鑒：

查核意見

旭富製藥科技股份有限公司及其子公司民國一一二年及一一一年十二月三十一日之合併資產負債表，暨民國一一二年及一一一年一月一日至十二月三十一日之合併綜合損益表、合併權益變動表及合併現金流量表，以及合併財務報告附註(包括重大會計政策彙總)，業經本會計師查核竣事。

依本會計師之意見，上開合併財務報告在所有重大方面係依照證券發行人財務報告編製準則暨經金融監督管理委員會認可並發布生效之國際財務報導準則、國際會計準則、解釋及解釋公告編製，足以允當表達旭富製藥科技股份有限公司及其子公司民國一一二年及一一一年十二月三十一日之合併財務狀況，暨民國一一二年及一一一年一月一日至十二月三十一日之合併財務績效與合併現金流量。

查核意見之基礎

本會計師係依照會計師受託查核簽證財務報表規則及審計準則執行查核工作。本會計師於該等準則下之責任將於會計師查核合併財務報告之責任段進一步說明。本會計師所隸屬事務所受獨立性規範之人員已依會計師職業道德規範，與旭富製藥科技股份有限公司及其子公司保持超然獨立，並履行該規範之其他責任。本會計師相信已取得足夠及適切之查核證據，以作為表示查核意見之基礎。

關鍵查核事項

關鍵查核事項係指依本會計師之專業判斷，對旭富製藥科技股份有限公司及其子公司民國一一二年度合併財務報告之查核最為重要之事項。該等事項已於查核合併財務報告整體及形成查核意見之過程中予以因應，本會計師並不對該等事項單獨表示意見。本會計師判斷應溝通在查核報告上之關鍵查核事項如下：

一、存貨評價

有關存貨評價之會計政策請詳合併財務報告附註四(八)存貨；存貨評價之會計估計，請詳合併財務報告附註五；存貨及相關費損之附註說明請詳合併財務報告附註六(五)存貨。

KPMG

關鍵查核事項之說明：

旭富製藥科技股份有限公司及其子公司因製藥產業特性，產品係為特定客戶製造，並依客戶需求提供各批次規格差異化服務，因此旭富製藥科技股份有限公司及其子公司於估計存貨淨變現價值時，若無客觀之近期銷售價格資訊可供參考時，須個別評估該品項市場需求變化等諸多不同因素後，判斷該批產品淨變現價值。因其估計之允當合理有可能影響存貨之評價，故本會計師認為旭富製藥科技股份有限公司及其子公司存貨備抵跌價損失之評估測試為本年度查核最重要事項之一。

因應之查核程序：

本會計師對上述關鍵查核事項之主要查核程序包括：

- 評估旭富製藥科技股份有限公司及其子公司存貨跌價或呆滯提列政策之合理性，包括評估市場變化、考量客戶需求及存貨去化狀況以判斷存貨呆滯項目之合理性。
- 執行存貨回溯性測試，檢視存貨報廢情形與呆滯損失提列政策以驗證本期存貨呆滯損失提列是否允當。
- 執行抽核程序以檢查旭富製藥科技股份有限公司及其子公司所採用之銷售價格，以評估存貨淨變現價值之合理性。

二、收入認列

有關營業收入認列之會計政策請詳合併財務報告附註四(十七)收入認列。

關鍵查核事項之說明：

旭富製藥科技股份有限公司及其子公司主要產品為原料藥及中間體等。惟主要交易對象多為國外藥廠，由於交易條件不盡然相同，且因收入認列涉及人工作業調整，可能存在收入認列時點不適當之風險，故本會計師認為旭富製藥科技股份有限公司及其子公司收入認列為本年度查核最為重要的評估事項之一。

因應之查核程序：

本會計師對上述關鍵查核事項之主要查核程序包括：

- 測試銷貨及收款作業循環之相關控制。
- 核對銷貨收入相關憑證。
- 選取資產負債表日前後一段時間之銷售交易，測試銷售是否認列於正確期間，以評估旭富製藥科技股份有限公司及其子公司營業收入認列時點之正確性。

其他事項

旭富製藥科技股份有限公司及其子公司已編製民國一一二年度及一一一年度之個體財務報告，並經本會計師出具無保留意見之查核報告在案，備供參考。

管理階層與治理單位對合併財務報告之責任

管理階層之責任係依照證券發行人財務報告編製準則暨經金融監督管理委員會認可並發布生效之國際財務報導準則、國際會計準則、解釋及解釋公告編製允當表達之合併財務報告，且維持與合併財務報告編製有關之必要內部控制，以確保合併財務報告未存有導因於舞弊或錯誤之重大不實表達。

於編製合併財務報告時，管理階層之責任亦包括評估旭富製藥科技股份有限公司及其子公司繼續經營之能力、相關事項之揭露，以及繼續經營會計基礎之採用，除非管理階層意圖清算旭富製藥科技股份有限公司及其子公司或停止營業，或除清算或停業外別無實際可行之其他方案。

旭富製藥科技股份有限公司及其子公司之治理單位(含審計委員會)負有監督財務報導流程之責任。

會計師查核合併財務報告之責任

本會計師查核合併財務報告之目的，係對合併財務報告整體是否存有導因於舞弊或錯誤之重大不實表達取得合理確信，並出具查核報告。合理確信係高度確信，惟依照審計準則執行之查核工作無法保證必能偵出合併財務報告存有之重大不實表達。不實表達可能導因於舞弊或錯誤。如不實表達之個別金額或彙總數可合理預期將影響合併財務報告使用者所作之經濟決策，則被認為具有重大性。

本會計師依照審計準則查核時，運用專業判斷及專業懷疑。本會計師亦執行下列工作：

1.辨認並評估合併財務報告導因於舞弊或錯誤之重大不實表達風險；對所評估之風險設計及執行適當之因應對策；並取得足夠及適切之查核證據以作為查核意見之基礎。因舞弊可能涉及共謀、偽造、故意遺漏、不實聲明或踰越內部控制，故未偵出導因於舞弊之重大不實表達之風險高於導因於錯誤者。

2.對與查核攸關之內部控制取得必要之瞭解，以設計當時情況下適當之查核程序，惟其目的非對旭富製藥科技股份有限公司及其子公司內部控制之有效性表示意見。

3.評估管理階層所採用會計政策之適當性，及其所作會計估計與相關揭露之合理性。

4.依據所取得之查核證據，對管理階層採用繼續經營會計基礎之適當性，以及使旭富製藥科技股份有限公司及其子公司繼續經營之能力可能產生重大疑慮之事件或情況是否存在重大不確定性，作出結論。本會計師若認為該等事件或情況存在重大不確定性，則須於查核報告中提醒合併財務報告使用者注意合併財務報告之相關揭露，或於該等揭露係屬不適當時修正查核意見。本會計師之結論係以截至查核報告日所取得之查核證據為基礎。惟未來事件或情況可能導致旭富製藥科技股份有限公司及其子公司不再具有繼續經營之能力。

5.評估合併財務報告(包括相關附註)之整體表達、結構及內容，以及合併財務報告是否允當表達相關交易及事件。

6.對於集團內組成個體之財務資訊取得足夠及適切之查核證據，以對合併財務報告表示意見。本會計師負責集團查核案件之指導、監督及執行，並負責形成集團查核意見。

本會計師與治理單位溝通之事項，包括所規劃之查核範圍及時間，以及重大查核發現(包括於查核過程中所辨認之內部控制顯著缺失)。

本會計師亦向治理單位提供本會計師所隸屬事務所受獨立性規範之人員已遵循會計師職業道德規範中有關獨立性之聲明，並與治理單位溝通所有可能被認為會影響會計師獨立性之關係及其他事項(包括相關防護措施)。

本會計師從與治理單位溝通之事項中，決定對旭富製藥科技股份有限公司及其子公司民國一一二年度合併財務報告查核之關鍵查核事項。本會計師於查核報告中敘明該等事項，除非法令不允許公開揭露特定事項，或在極罕見情況下，本會計師決定不於查核報告中溝通特定事項，因可合理預期此溝通所產生之負面影響大於所增進之公眾利益。

安侯建業聯合會計師事務所

會計師：

證券主管機關核准簽證文號：金管證審字第1120333238號
金管證六字第0940100754號

民國 一一三 年 三 月 十五 日

GRI Content Index

Statement of Use	SCI Pharmtech has prepared this report in accordance with the GRI
GRI 1	GRI 1：Foundation 2021
Applicable GRI Sector Standard	None

GRI Standard/ Other Frameworks	Disclosure	Chapter	Corresponding Pages
General Disclosures			
GRI 2: General Disclosures 2021	2-1 Organizational details	About the Report	1
		Chapter 1 About SCI	17
	2-2 Entities included in the organization's sustainability reporting	Chapter 1 About SCI	17
	2-3 Reporting period, frequency and contact point	Reporting Scope and Boundaries and Reporting Guidelines	1
	2-4 Restatements of information	Reporting Scope and Boundaries and Reporting Guidelines	1
	2-5 External assurance	**Appendix-Independent Auditors' Report**	89-92
	2-6 Activities, value chain and other business relationships	Chapter 1 About SCI	17-22
		Chapter 2 Corporate Governance：Corporate Governance Structure	40-43
	2-7 Employees	Chapter 4 Employee-Friendly Workplace： Human Resources Structure	75-76
	2-8 Workers who are not employees	Chapter 4 Employee-Friendly Workplace： Human Resources Structure	75-76
	2-9 Governance structure and composition	Chapter 2 Corporate Governance：Corporate Governance Structure	23
	2-10 Nomination and selection of the highest governance body	Chapter 2 Corporate Governance：Corporate Governance Structure	23
	2-11 Chair of the highest governance body	Chapter 2 Corporate Governance：Corporate Governance Structure	24
	2-12 Role of the highest governance body in overseeing the management of impacts	ESG Implementation Structure	5
	2-13 Delegation of responsibility for managing impacts	ESG Implementation Structure	5
	2-14 Role of the highest governance body in sustainability reporting	ESG Implementation Structure	5
	2-15 Conflicts of interest	Chapter 2 Corporate Governance：Corporate Governance Structure	23-24
	2-16 Communication of critical concerns	**Stakeholder Identification and Materiality Assessment**	7-9
	2-17 Collective knowledge of the highest governance body	Chapter 2 Corporate Governance：Corporate Governance Structure	24
	2-18 Evaluation of the performance of the highest governance body	Chapter 2 Corporate Governance：Corporate Governance Structure	23
	2-19 Remuneration policies	Chapter 4 Employee-Friendly Workplace： Employee Benefits	78-79
	2-23 Process to determine remuneration	Chapter 4 Employee-Friendly Workplace： Employee Benefits	78
	2-21 Annual total compensation ratio	Chapter 2 Corporate Governance：Remuneration Policy	28
	2-22 Statement on sustainable development strategy	Message from the Chairman, Message from the Persident	2-3
	2-23 Policy commitments	Chapter 4 Employee-Friendly Workplace： Labor Relations, Employee Rights Protection	75,77
	2-24 Embedding policy commitments	Chapter 4 Employee-Friendly Workplace： Labor Relations, Employee Rights Protection	75,77
	2-25 Processes to remediate negative impacts	**Stakeholder Identification and Materiality Assessment**	8-10

GRI Standard/ Other Frameworks	Disclosure	Chapter	Corresponding Pages
	2-26 Mechanisms for seeking advice and raising concerns	**Stakeholder Identification and Materiality Assessment**	8-10
		Chapter 2 Corporate Governance：Policy and Complaint Channels	28
	2-27 Compliance with laws and regulations	Chapter 2 Corporate Governance：Legal Compliance	29
	2-28 Membership associations	Chapter 1 About SCI	18
	2-29 Approach to stakeholder engagement	**Stakeholder Identification and Materiality Assessment**	8-10
	2-30 Collective bargaining agreements	Chapter 4 Employee-Friendly Workplace： Labor Relations, Employee Rights Protection	75,77
Material Topics			
GRI 3: Material Topics 2021	3-1 Process to determine material topics	**Stakeholder Identification and Materiality Assessment**	11
	3-2 List of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
1. Energy Management and GHG Emissions			
GRI 3: Material Topics 2021	3-3 Management of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
GRI 305: Emissions 2016	305-1 Direct (Scope 1) GHG emissions	Chapter 3 Green Operations and Circular Innovation：Greenhouse Gas and Energy Management	59-61
	305-2 Energy indirect (Scope 2) GHG emissions	Chapter 3 Green Operations and Circular Innovation：Greenhouse Gas and Energy Management	59-61
	305-3 Other indirect (Scope 3) GHG emissions	Disclosure of this information is planned for future reporting periods	-
	305-4 GHG emissions intensity	Chapter 3 Green Operations and Circular Innovation：Greenhouse Gas and Energy Management	59-61
	305-5 Reduction of GHG emissions	Chapter 3 Green Operations and Circular Innovation：Greenhouse Gas and Energy Management	59-61
	305-6 Emissions of Ozone-Depleting Substances (ODS)	Chapter 3 Green Operations and Circular Innovation：Air Pollution	62
	305-7 Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air	Chapter 3 Green Operations and Circular Innovation：Air Pollution	62
2. Wastewater and Waste Management			
GRI 3: Material Topics 2021	3-3 Management of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
GRI 303: Water and Effluents 2018	303-1 Interactions with water as a shared resource	Chapter 3 Green Operations and Circular Innovation：Water Resource Management	64
	303-2 Management of water discharge-related impacts	Chapter 3 Green Operations and Circular Innovation：Water Resource Management	64
	303-3 Water withdrawal	Chapter 3 Green Operations and Circular Innovation：Water Resource Management	64
	303-4 Water discharge	Chapter 3 Green Operations and Circular Innovation：Water Resource Management	64
	303-5 Water consumption	Chapter 3 Green Operations and Circular Innovation：Water Resource Management	64

GRI Standard/ Other Frameworks	Disclosure	Chapter	Corresponding Pages
GRI 306: Waste 2020	306-1 Waste generation and significant waste-related impacts	Chapter 3 Green Operations and Circular Innovation：Water and Waste Management	63-69
	306-2 Management of significant waste-related impacts	Chapter 3 Green Operations and Circular Innovation：Water and Waste Management	63-69
	306-3 Waste generated	Chapter 3 Green Operations and Circular Innovation：Water and Waste Management	63-69
	306-4 Waste diverted from disposal	Chapter 3 Green Operations and Circular Innovation：Water and Waste Management	63-69
	306-5 Waste directed to disposal	Chapter 3 Green Operations and Circular Innovation：Water and Waste Management	63-69
3. Self-defined topic: Disaster Recovery			
GRI 3: Material Topics 2021	3-3 Management of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
4.Economic Performance			
GRI 3: Material Topics 2021	3-3 Management of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
GRI 201: Economic Performance 2016	GRI 201-1	Chapter 1 About SCI	17
5.Occupational Safety and Health			
GRI 3: Material Topics 2021	3-3 Management of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
	403-1 Occupational health and safety management system	Chapter 5 Occupational Safety and Health：Occupational Hazards and Hazard Reporting Process	81
GRI 403: Occupational Health and Safety 2018	403-2 Hazard identification, risk assessment, and incident investigation	Chapter 5 Occupational Safety and Health：Occupational Accident Investigation and Improvement Measures	82
	403-3 Occupational Health Services	Chapter 5 Occupational Safety and Health：Employee Health Promotion	84
	403-4 Worker participation, consultation, and communication on occupational health and safety	Chapter 5 Occupational Safety and Health：Refresher Training for Emergency Responders	84
	403-5 Worker training on occupational health and safety	Chapter 5 Occupational Safety and Health：Refresher Training for Emergency Responders	84
	403-6 Promotion of worker health	Chapter 5 Occupational Safety and Health：Employee Health Promotion	84
	403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	Chapter 5 Occupational Safety and Health：Occupational Safety and Health Improvement Measures	85
	403-8 Workers covered by an occupational health and safety management system	Chapter 5 Occupational Safety and Health：Occupational Hazards and Hazard Reporting Process	81
	403-09 Work-related injuries	Chapter 5 Occupational Safety and Health：Occupational Injury Statistics	87
	403-10 Work-related ill health	Chapter 5 Occupational Safety and Health：Employee Health Promotion	84

GRI Standard/ Other Frameworks	Disclosure	Chapter	Corresponding Pages
6.Customer Health and Safety			
GRI 3: Material Topics 2021	3-3 Management of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
GRI 416: Customer Health and Safety 2016	416-1 Assessment of the health and safety impacts of product and service categories	Chapter 3 Green Operations and Circular Innovation： Responsible Chemical Management, Toxic Substance Control	46-48
	416-2 Incidents of non-compliance concerning the health and safety impacts of products and services	No such incidents occurred	NA
7.Labor Relations			
GRI 3: Material Topics 2021	3-3 Management of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
GRI 401: Employment 2016	401-1 New employee hires and employee turnover	Chapter 4 Employee-Friendly Workplace： Human Resources Structure	75-76
	401-2 Benefits provided to full-time employees that are not provided to temporary or parttime employees	Chapter 4 Employee-Friendly Workplace： Employee Benefits	72-73
	401-3 Parental leave	Chapter 4 Employee-Friendly Workplace： Employee Benefits	78
8.Integrity Management			
GRI 3: Material Topics 2021	3-3 Management of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
GRI 205: Anti-corruption 2016	205-1 Operations assessed for risks related to corruption	Chapter 2 Corporate Governance：Integrity Management	12-16
	205-2 Communication and training about anti-corruption policies and procedures	Chapter 2 Corporate Governance：Policy and Complaint Channels, Education and Training	27-28
	205-3 Confirmed incidents of corruption and actions taken	No such incidents occurred	26
9.Self-defined topic: Legal Compliance			
GRI 3: Material Topics 2021	3-3 Management of material topics	**Stakeholder Identification and Materiality Assessment**	12-16
Other Topic Disclosures			
GRI 204: Procurement Practice 2016	GRI 204-1	Chapter 2 Corporate Governance：Supply Chain Management	41
GRI 308: Supplier Environmental Assessment 2016	GRI 308-2 Negative environmental impacts in the supply chain and actions taken	Chapter 2 Corporate Governance：Supply Chain Management	42
GRI 308: Supplier Environmental Assessment 2016	GRI 414-2 Negative social impacts in the supply chain and actions taken	Chapter 2 Corporate Governance：Supply Chain Management	42

Appendix

SASB Index

SASB Code	Accounting Metric	Report Disclosure
GHG Emissions		
RT-CH-110a.1	Gross global Scope 1 emissions, percentage covered under emissions-limiting regulations	Direct (Scope 1) greenhouse gas emissions, energy indirect (Scope 2) greenhouse gas emissions indicator information.
RT-CH-110a.2	Discussion of long and short-term strategy or plan to manage Scope 1 emissions, emissions reduction targets, and an analysis of performance against those targets	Greenhouse gas inventory and energy use policies and commitments, management practices, management indicators, assessment mechanisms, and target values.
Air Quality		
RT-CH-120a.1	Air emissions of the following pollutants: (1) NOx (excluding N2O), (2) SOx, (3) volatile organic compounds (VOCs), and (4) hazardous air pollutants (HAPs)	Air pollutant emissions statistics.
Energy Management		
RT-CH-130a.1	(1) Total energy consumed, (2) percentage grid electricity, (3) percentage renewable and (4) total self-generated energy	Energy intensity (GJ/million NTD of production value) indicator information, total energy consumption information.
Water Management		
RT-CH-140a.1	(1) Total water withdrawn, (2) total water consumed, percentage of each in regions with high or extremely high baseline water stress	Total water intake, total water consumption indicator information.
RT-CH-140a.2	Number of incidents of non-compliance associated with water quality permits, standards, and regulations	Wastewater discharge treatment information, wastewater treatment compliance rate.
RT-CH-140a.3	Description of water management risks and discussion of strategies and practices to mitigate those risks	Water resource management and water pollution prevention policies and commitments, management practices, management indicators, and water intake management.
Hazardous Waste Management		
RT-CH-150a.1	Amount of hazardous waste generated, percentage recycled	From 2022 to 2023, the total amount of hazardous industrial waste was 1,760.345 tons, with 586.965 tons recycled.
Community Relations		
RT-CH-210a.1	Discussion of engagement processes to manage risks and opportunities associated with community interests	A summary of the environmental impact assessment on the local community and supply chain; community communication and maintenance, including the promotion of economic development, industrial safety, and community development.
Workforce Health & Safety		
RT-CH-320a.1	(1) Total recordable incident rate (TRIR) and (2) fatality rate for (a) direct employees and (b) contract employees	2022 Injury/accident rate: 0.998, fatality rate: 0. 2023 Injury/accident rate: 0, fatality rate: 0.
RT-CH-320a.2	Description of efforts to assess, monitor, and reduce exposure of employees and contract workers to long-term (chronic) health risks	Implementation of hazard identification and risk assessment, eliminating hazards, and reducing occupational safety and health risks.
Product Design for Use Phase Efficiency		
RT-CH-410a.1	Revenue from products designed for use-phase resource efficiency	Co-founded Fromosa Company with the French company Veolia, with a projected solvent recovery rate of approximately 85%, and an estimated annual solvent recovery volume of 23,000 tons in the future.
Safety & Environmental Stewardship of Chemicals		
RT-CH-410a.1	(1) Percentage of products that contain Globally Harmonized System of Classification and Labeling of Chemicals (GHS) Category 1 and 2 Health and Environmental Hazardous Substances, (2) percentage of such products that have undergone a hazard assessment	Implemented responsible chemical management and control of toxic substances.
RT-CH-410a.2	Discussion of strategy to (1) manage chemicals of concern and (2) develop alternatives with reduced human and/or environmental impact	
Genetically Modified Organisms		
RT-CH-410a.1	Percentage of products by revenue that contain genetically modified organisms (GMOs)	The company does not produce such products.
Management of the Legal & Regulatory Environment		
RT-CH-530a.1	Discussion of corporate positions related to government regulations and/or policy proposals that address environmental and social factors affecting the industry	Analyzed factors such as increasingly stringent regulations and policies, the risks of extreme weather events, and supply chain stability to assess the financial impact of changes in production, compliance, and market demand, as well as the feasibility of transition actions.
Operational Safety, Emergency Preparedness & Response		
RT-CH-540a.1	Process Safety Incidents Count (PSIC), Process Safety Total Incident Rate (PSTIR), and Process Safety Incident Severity Rate (PSISR)	Engaged professional institutions to provide technical guidance on process safety assessment, improving the safety of new product development. From 2022 to 2023, there were no production process safety accidents.
RT-CH-540a.2	Number of transport incidents	From 2022 to 2023, there were 0 transportation accidents.

1.Sustainability Disclosure Index – Chemical Industry

No.	Metric	Metric Type	Annual Disclosure	Unit	Remarks (Relevant Chapters)
1	Total energy consumed, percentage of externally purchased electricity, renewable energy usage rate, and total amount of self-generated energy	Quantitative	・Total energy consumed 57,391.39 GJ(2022)；100,985.75 GJ (2023) ・Percentage of externally purchased electricity：100% ・renewable energy usage rate and total amount of self-generated energy：0	Gigajoules, Percentage (%)	Chapter 3 Green Operations and Circular Innovation ・Greenhouse Gas and Energy Management
2	Total water intake, total water consumption, and wastewater discharge according to regulatory requirements or voluntary disclosure	Quantitative	・Total water intake：104ML(2022)；259ML (2023) ・Wastewater discharge：47.036ML(2022)；82.943ML (2023)	Million liters (ML), Percentage (%)	Chapter 3 Green Operations and Circular Innovation ・Water Resource Management ・Wastewater Treatment System Reconstruction and Innovatio
3	Total hazardous waste generated and recycling percentage in the product production process according to regulatory requirements or voluntary disclosure	Quantitative	Total hazardous waste generated from 2022 to 2023 was 1,760.345 metric tons, 586.965 tons of waste were recycled	Metric tons (t), Ratio (%)	Chapter 3 Green Operations and Circular Innovation ・ Waste Management
4	Illustrate the number and percentage of occupational accidents	Qualitative Description	2022 Injury/Accident Rate: 0.998, Fatality Rate: 0 2023 Injury/Accident Rate: 0, Fatality Rate: 0	Ratio (%), Count	Chapter 5 Occupational Safety an Health ・ Occupational Injury Statistics
5	Operational activities with significant actual or potential negative impacts on the local community	Qualitative Description	The following operational activities have an impact on the local community: ・Water consumption ・Pollutant discharge management ・Waste management ・Responsible chemical management	Not Applicable	Chapter 3 Green Operations and Circular Innovation ・Responsible Chemical Management ・Water Resource Management ・Wastewater Treatment System Reconstruction and Innovation ・Waste Management
6	Specific and effective mechanisms and actions taken by the company and its suppliers to reduce negative impacts on the environment or society	Qualitative Description	・ Supply Chain Management ・ Water consumption ・ Pollutant discharge management ・ Waste management ・ Responsible chemical management	Not Applicable	Chapter 2 Corporate Governance Supply Chain Management Chapter 3 Green Operations and Circular Innovation ・Responsible Chemical Management ・Water Resource Management ・Wastewater Treatment System Reconstruction and Innovation ・Waste Management
7	Production volume by product category	Quantitative	API：216.94 tons/order (2022)；267.47 tons/oder (2023) Intermediates：173.88 tons/order (2022)；190.64 tons/order (2023)	tons/order	Chapter 1 About SCI

2. Climate Change Risks and Opportunities and Relevant Response Measures by SCI Pharmtech

No.	Item	Implementation Status	Description	Remarks (Relevant Chapters)
1	Board and management oversight and governance of climate related risks and opportunities	Implemented	SCI Pharmtech places high importance on the oversight and governance of climate related risks and opportunities. The President's Office is the dedicated unit for promoting sustainable development. We have established a Sustainability Development Committee, chaired by Chairperson Dr. Wei-Chyun Wong, with President Dr. Wen-Chih Chou, serving as Vice Chairman. The Sustainability Development Committee has six subgroups that regularly review and improve implementation. At the board level, President Dr. Chou, and Deputy General Manager report to the Board of Directors at least once a year on the current status of sustainable development implementation. This allows the Board to assess the company's climate change impacts and provide relevant recommendations.	ESG Implementation Structure
2	How identified climate risks and opportunities impact the company’ s business, strategy, and finances (Short, medium, and long term)	In Progress	SCI Pharmtech has preliminarily identified climate risks and opportunities: ・Short-term impacts: Extreme weather events or supply chain disruptions could lead to production interruptions, logistics delays, and increased costs. SCI Pharmtech mitigates potential impacts by establishing contingency plans. ・Medium-term impacts: Unstable climate conditions in certain regions could affect the supply of specific raw materials. Therefore, SCI Pharmtech will strengthen supply chain management to ensure the stability of raw material supply. ・Long-term impacts: Climate change could have long-term impacts on the company's sustainability and financial stability. SCI Pharmtech plans to introduce a risk assessment mechanism recommended by the TCFD to assess specific climate change issues and understand the potential financial impacts. This will inform adjustments to long-term strategies to ensure future development aligns with climate challenges.	Chapter 3 Green Operations and Circular Innovation ・Climate Change Response and Adaptation
3	Financial impact of extreme climate events and transition actions	Implemented/In Progress	Extreme climate events could lead to production interruptions, requiring remedial measures such as temporary adjustments to production plans or stockpiling raw materials, which could put short-term pressure on financial performance. Implementing climate transition actions in the future will require increased sustainability-related investments, such as purchasing more environmentally friendly equipment and adopting green energy. Such investment costs could impact the company's cash flow in the short term. However, taking climate transition actions could also enhance the company's brand value and maintain its competitiveness in an increasingly sustainability-conscious market, positively impacting financial performance.	Chapter 3 Green Operations and Circular Innovation ・Climate Change Response and Adaptation
4	Integration of climate risk identification, assessment, and management processes into the overall risk management system	Implemented/In Progress	To strengthen corporate governance and effectively implement a sound risk management mechanism to mitigate potential operational risks, SCI Pharmtech has formulated a "Risk Management Policy and Procedures" mechanism. We will gradually incorporate climate risks into our overall risk management system, closely integrated with the company's governance structure, to ensure comprehensive and effective management of climate-related risks.	Chapter 3 Green Operations and Circular Innovation ・Climate Change Response and Adaptation ・List of Climate Risk and Opportunity Issues and Financial Impacts
5	Scenario analysis to assess resilience to climate change risks. If applicable, describe the scenarios, parameters, assumptions, analysis factors and main financial impacts.	Implemented/In Progress	SCI Pharmtech plans to implement the TCFD-recommended risk assessment mechanism. In the future, we will assess the financial impact of increasingly stringent regulations and policies, extreme weather event risks, and supply chain stability. We will also evaluate the feasibility of transition actions in response to changes in production, legal compliance, and market demand.	Chapter 3 Green Operations and Circular Innovation ・Financial Impact of Opportunity Issues
6	Transition plan to manage climate related risks. If applicable, describe the content of the plan, and the indicators and targets used to identify and manage physical and transition risks.	Implemented	To mitigate the impact of climate change risks, SCI Pharmtech's Board of Directors has approved the planning and timeline for greenhouse gas inventory and third-party verification, with the goal of completing third-party verification by 2026.	Chapter 3 Green Operations and Circular Innovation ・Financial Impact of Opportunity Issues ・Greenhouse Gas and Energy Management
7	Internal carbon pricing as a planning tool. If applicable, describe the basis for pricing.	Implemented	SCI Pharmtech completed a carbon footprint assessment for one product in 2023 and plans to complete an organizational greenhouse gas inventory in 2024. After understanding the greenhouse gas emissions of each business category and process, we will refer to domestic and international carbon pricing trends and complete internal carbon pricing based on objective and concrete data.	Chapter 3 Green Operations and Circular Innovation ・Financial Impact of Opportunity Issues ・Greenhouse Gas and Energy Management
8	Climate related targets. If applicable, describe the activities covered, the scope of greenhouse gas emissions, the planning period, annual achievement progress and other information. If carbon offsets or renewable energy certificates (RECs) are used to achieve relevant goals, describe the source and quantity of offset carbon reduction credits or quantity of RECs.	Implemented	Preliminary target of an annual carbon reduction of 1%.	Chapter 3 Green Operations and Circular Innovation ・Greenhouse Gas and Energy Management

3. Greenhouse Gas Emissions Inventory and Assurance

1	Describe the greenhouse gas emissions for the most recent two years, including emissions amount (in metric tons of CO_2 equivalent), emissions intensity (in metric tons of CO_2 equivalent per million NT dollars of revenue), and the scope of the data (e.g., which facilities or operations are included)	In 2022 and 2023, with the resumption of operations in some production areas, our greenhouse gas emissions and intensity were: -2022: Total emissions 6,289 tCO_2e; intensity 7.0 tCO_2e per million NT$. (Scope 1: 1,352 tCO_2e; Scope 2: 4,937 tCO_2e) -2023: Total emissions 10,570 tCO_2e; intensity 8.8 tCO_2e per million NT$. (Scope 1: 2,416 tCO_2e; Scope 2: 8,154 tCO_2e) Emissions in 2023, with the resumption of production, were approximately 63% of the pre-fire emissions in 2020 (2020 emissions were 16,805 tCO_2e).
2	Describe the assurance status of the most recent two years as of the date of publication of the annual report, including the scope of assurance, the assurance provider, the assurance standards used, and the assurance opinion.	In 2023, SCI Pharmtech obtained ISO 14067:2018 verification for one product from SGS Taiwan Ltd.

旭富製藥科技股份有限公司

SCI PHARMTECH, INC.
旭富製藥科技股份有限公司